Bicyclic heteroaromatics and methods of use thereof

The inhibition of the toxicity of TDP-43 and C9orf72 by specific compounds has solved the problem of poor efficacy in treating neurological diseases in the prior art, and effective treatment of these diseases has been achieved, significantly improving the quality of life of patients.

CN118946360APending Publication Date: 2024-11-12KINETA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280091012.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-08
Filing Date
2022-12-08
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat neurological disorders such as ALS and FTD, especially due to incomplete understanding of the molecular perturbations that cause these disorders and limitations on the model system library, resulting in limited efficacy of current therapies.

Method used

A compound, including a specific compound of formula (I) or a pharmaceutically acceptable salt thereof, is provided for inhibiting TDP-43 and C9orf72-associated cytotoxicity, by acting with PIKfyve enzymes, to treat related neurological disorders.

Benefits of technology

This compound significantly improves patient condition by inhibiting the toxicity of TDP-43 and C9orf72, reducing its aggregation in cells, improving patient condition, and delaying or preventing disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946360A_ABST
    Figure CN118946360A_ABST
Patent Text Reader

Abstract

Compounds useful in the treatment of neurological disorders are disclosed. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used to treat or prevent neurological diseases, including frontotemporal dementia, chronic traumatic encephalopathy, Alzheimer's disease, edge system dominated age-related TDP-43 encephalopathy (LATE), or frontotemporal lobe degeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to bicyclic heteroaromatic hydrocarbons and their use for therapeutic treatment of neurological disorders in patients, such as human patients. Background Art

[0002] An incomplete understanding of the molecular perturbations that cause the disease and a limited library of robust model systems have prevented the generation of successful disease-modifying therapies for common and progressive neurological disorders such as ALS and FTD. Many advances have been made in the search for agents that can halt the progression of these disorders. However, current therapies for most, if not all, of these diseases have had limited success. Therefore, there is a need to develop therapies that can alter the course of neurodegenerative diseases. More generally, there is a need for better methods and compositions to treat neurodegenerative diseases to improve the quality of life of people afflicted with such diseases. Summary of the invention

[0003] TDP-43 is a nuclear DNA / RNA binding protein involved in RNA splicing. Under pathological cellular stress, TDP-43 translocates to the cytoplasm and aggregates into stress granules and associated protein inclusions. These phenotypes are hallmarks of degenerating motor neurons and are found in 97% of all ALS cases. The high permeability of this pathology suggests that TDP-43 is widely involved in familial and sporadic ALS. In addition, TDP-43 mutations that promote aggregation are associated with a higher risk of developing ALS, indicating that protein misfolding and aggregation are drivers of toxicity. TDP-43 toxicity can be reproduced in a yeast model, in which the protein induces viability defects and localizes to stress granules.

[0004] In one aspect, the present invention provides a compound of formula (I):

[0005]

[0006] or a pharmaceutically acceptable salt thereof,

[0007] in

[0008] is a single bond, X 1 (C(R A )2) m or –OC(R A )2–R X , and X 2 C(R A )2 or CO; or is a double bond, and X 1 and X 2 Each of the CR A or N, where RX For X 2 Keys;

[0009] R 1 for – (L) n –R B ; halogen, cyano, hydrogen, optionally substituted C 1-6 Alkoxy, optionally substituted C 1-9 heterocyclyl, optionally substituted C1-C6 alkyl, optionally substituted piperazin-1-yl, optionally substituted pyrrolidin-3-yl, pyrimidinyl optionally substituted by cyclopropyl, or optionally substituted C6-C 10 aryl, optionally substituted pyridazinyl, optionally substituted oxazolyl, pyridin-2-on-1-yl, optionally substituted isoindolinyl, unsubstituted pyridin-4-yl, unsubstituted pyridin-2-yl, optionally substituted furan-3-yl, unsubstituted pyridin-3-yl or optionally substituted pyrazol-1-yl;

[0010] R 2 is an optionally substituted C1-C6 alkyl, an optionally substituted C 6- C 10 aryl, optionally substituted piperidin-4-yl, optionally substituted tetrahydropyran-4-yl, optionally substituted pyrimidin-5-yl, optionally substituted pyrimidin-4-yl, optionally substituted pyridin-3-yl, optionally substituted pyridazin-4-yl, optionally substituted pyrazol-1-yl, optionally substituted pyrazol-4-yl, optionally substituted pyrazol-3-yl, optionally substituted pyridin-2-yl, optionally substituted triazolyl, optionally substituted benzodioxol-2-yl, optionally substituted benzodioxol-2-yl, optionally substituted C6-C 10 Aryl C1-C 10 alkyl or optionally substituted acyl;

[0011] R 3 A group of the following structure:

[0012]

[0013]

[0014] Each R A are independently H, optionally substituted C 1-6 Alkyl or optionally substituted C 6- C 10 Aryl, or two R A Together with the atoms to which they are attached, they form an oxo group; A When combined with the atoms to which they are attached to form an oxo group, is a single bond;

[0015] R B is an optionally substituted C 6-10 aryl, optionally substituted C1-C9 heteroaryl, optionally substituted C 3-8 Cycloalkyl, -N=CH-R D , or optionally substituted C1-C9 heterocyclyl, optionally substituted C2-C9 heteroarylC1-C6 alkyl, optionally substituted C2-C9 heterocyclylC1-C6 alkyl;

[0016] R C is H or optionally substituted C 1- C6 alkyl;

[0017] R D is an optionally substituted C 6- C 10 aryl; or

[0018] Each L is independently an optionally substituted C 1-6 alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C3-C8 cycloalkylene, optionally substituted C2-C6 alkynylene, O or NR C ;

[0019] n is 1, 2 or 3; and

[0020] m is 0, 1 or 2.

[0021] In some embodiments, In some embodiments, X 1 (C(R A )2) m In some embodiments, m is 1. In some embodiments, X 2 C(R A )2. In some embodiments, each R A For hydrogen.

[0022] In some embodiments, the compound has Formula (Ia):

[0023]

[0024] or a pharmaceutically acceptable salt thereof.

[0025] Preferably, the compound of formula Ia has the following structure:

[0026]

[0027] or a pharmaceutically acceptable salt thereof.

[0028] In some embodiments, the compound has formula (1a'):

[0029]

[0030] or a pharmaceutically acceptable salt thereof.

[0031] Preferably, the compound of formula Ia' has the following structure:

[0032]

[0033] or a pharmaceutically acceptable salt thereof.

[0034] In some embodiments, the compound has formula (1b):

[0035]

[0036]

[0037] or a pharmaceutically acceptable salt thereof.

[0038] In some embodiments, the compound has formula (1c):

[0039]

[0040] or a pharmaceutically acceptable salt thereof.

[0041] In some embodiments, the compound has formula (1d):

[0042]

[0043] or a pharmaceutically acceptable salt thereof.

[0044] In some embodiments, the compound has formula (1e):

[0045]

[0046] or a pharmaceutically acceptable salt thereof.

[0047] In some embodiments, R 1 for –O–(L) (n-1) –R B In some embodiments, n is 2. In some embodiments, n is 1. In some embodiments, at least one L is an optionally substituted C 1-6 In some embodiments, L is methylene. In some embodiments, L is ethylene. In some embodiments, R B is an optionally substituted C 1-9 In some embodiments, R Bis an optionally substituted C 1-9 In some embodiments, R B is an optionally substituted C 1-6 alkyl.

[0048] In some embodiments, R A is an optionally substituted C 1-6 In some embodiments, R A In some embodiments, R 1 is an optionally substituted C 1-6 In some embodiments, R 1 is an optionally substituted C4 alkyl. 1 In some embodiments, R 1 is an optionally substituted piperazin-1-yl. 1 In some embodiments, R 2 is an optionally substituted C6-C 10 In some embodiments, R 2 is an optionally substituted C6-C 10 In some embodiments, R 2 In some embodiments, R 2 is an optionally substituted C1-C6 alkyl. 2 is an optionally substituted C4 alkyl. 2 In some embodiments, R 2 is an optionally substituted C6-C 10 In some embodiments, R 2 is an optionally substituted phenyl. 2 Substituted with fluorine, cyano or methoxy.

[0049] In some embodiments, R 1 for:

[0050]

[0051]

[0052] Methyl or methoxy.

[0053] In some embodiments, R 1 for

[0054]

[0055]

[0056] In some embodiments, R 2 for:

[0057]

[0058] In some embodiments, R 2 for:

[0059]

[0060] In some embodiments, R 3 for:

[0061]

[0062] In some embodiments, the compound has the structure:

[0063]

[0064] or a pharmaceutically acceptable salt thereof,

[0065] Where R 2 is optionally substituted pyrimidin-3-yl or optionally substituted pyrimidin-4-yl; and

[0066] R 4 is hydrogen or optionally substituted C 6- C 10 Aryl.

[0067] In some embodiments, R 4 In some embodiments, R 4 is an optionally substituted C6-C 10 In some embodiments, R 4 C6-C 10 Aryl is phenyl. In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is an optionally substituted pyridin-3-yl. 4 It is pyridin-4-yl.

[0068] In some embodiments, the compound has the structure:

[0069]

[0070] or a pharmaceutically acceptable salt thereof,

[0071] Where R 5 is hydrogen or optionally substituted C 6- C 10 aryl; and

[0072] R 2 is optionally substituted triazolyl, optionally substituted pyrazol-4-yl, optionally substituted pyrazol-3-yl, optionally substituted pyrimidin-4-yl or optionally substituted C6-C 10 Aryl C1-C6 alkyl.

[0073] In some embodiments, R 5 In some embodiments, R 5 In some embodiments, R 2 In some embodiments, R 2 for

[0074] In some embodiments, R 2 for

[0075] In some embodiments, the compound has the structure:

[0076]

[0077] or a pharmaceutically acceptable salt thereof,

[0078] Where R 2 is optionally substituted pyridin-3-yl.

[0079] In some embodiments, the compound has the structure:

[0080]

[0081] or a pharmaceutically acceptable salt thereof,

[0082] Where R 2 is an optionally substituted C6-C 10 aryl; or optionally substituted pyridazin-4-yl.

[0083] In some embodiments, R 2 In some embodiments, R 2 It is pyridazin-4-yl.

[0084] In some embodiments, the compound has the structure:

[0085]

[0086] or a pharmaceutically acceptable salt thereof,

[0087] Where R 2 is optionally substituted pyridin-3-yl.

[0088] In some embodiments, the compound has the structure:

[0089]

[0090] or a pharmaceutically acceptable salt thereof,

[0091] wherein L is an optionally substituted C3-C8 cycloalkylene or C2-C6 alkynylene; and

[0092] R B is an optionally substituted C 6- C 10 Aryl.

[0093] In some embodiments, L is In some embodiments, L is In some embodiments, R B is 3-methoxy-phenyl.

[0094] In some embodiments, the compound has the structure:

[0095]

[0096] or a pharmaceutically acceptable salt thereof,

[0097] Among them LR B -NHN=CHR D ;

[0098] R 2 is optionally substituted pyridin-3-yl; and

[0099] R D is an optionally substituted C 6- C 10 Aryl.

[0100] In some embodiments, R D is 3-methyl-phenyl. 2 In some embodiments, the compound has the structure or a pharmaceutically acceptable salt thereof.

[0101] In some embodiments, the compound has the structure:

[0102]

[0103] or a pharmaceutically acceptable salt thereof,

[0104] Where R 2 is optionally substituted pyridin-3-yl; and

[0105] R 6 is an optionally substituted C 6- C 10 Aryl.

[0106] In some embodiments, R 7 is 3-methyl-phenyl or phenyl.

[0107] In one aspect, the present invention provides a compound of formula (12):

[0108]

[0109] or a pharmaceutically acceptable salt thereof,

[0110] Where X 3 N or CH;

[0111] R 8 is an optionally substituted C2-C9 heteroaryl; or an optionally substituted C6-C 10 Aryl;

[0112] R 9 is an optionally substituted C2-C9 heteroaryl or -OR 11 ;

[0113] R 10 is hydrogen or optionally substituted C 1- C6 alkyl; and

[0114] R 11 It is an optionally substituted C2-C9 heteroarylC1-C6 alkyl.

[0115] In some embodiments, the compound has the structure:

[0116]

[0117] or a pharmaceutically acceptable salt thereof.

[0118] In some embodiments, R 2 In some embodiments, R 2 For hydrogen.

[0119] In some embodiments, the compound has the structure:

[0120]

[0121] or a pharmaceutically acceptable salt thereof.

[0122] In some embodiments, the compound has the structure:

[0123]

[0124] or a pharmaceutically acceptable salt thereof.

[0125] In some embodiments, R A is an optionally substituted phenyl. A is optionally substituted pyridin-2-yl, optionally substituted pyrimidin-4-yl, optionally substituted pyrimidin-2-yl, optionally substituted pyrazol-4-yl, optionally substituted pyridin-3-yl, optionally substituted pyrazol-4-yl, optionally substituted 7-aza-5,6,7,8-tetrahydroindolizin-1-yl, optionally substituted pyridazin-3-yl or optionally substituted pyridin-4-yl. In some embodiments, R A is an optionally substituted C2-C9 heteroaryl group or a C6-C9 heteroaryl group substituted by an optionally substituted C2-C9 heteroaryl group 10 In some embodiments, R A Cyclopropyl, methyl, methoxy or In some embodiments, R A is phenyl substituted with pyrazol-1-yl. A for

[0126] In some embodiments, R 1 is pyridin-3-yl, pyridin-4-yl or

[0127] In some embodiments, the compound has the structure or a pharmaceutically acceptable salt thereof.

[0128] In some embodiments, the compound has the structure: or a pharmaceutically acceptable salt thereof.

[0129] In some embodiments, the compound has the structure:

[0130]

[0131]

[0132]

[0133]

[0134]

[0135]

[0136]

[0137]

[0138]

[0139]

[0140] or a pharmaceutically acceptable salt thereof.

[0141] In some embodiments, the compound has the structure:

[0142]

[0143]

[0144]

[0145]

[0146]

[0147] or a pharmaceutically acceptable salt thereof.

[0148] In one aspect, the invention features a pharmaceutical composition comprising any of the aforementioned compounds and a pharmaceutically acceptable excipient.

[0149] In one aspect, the invention features a method of treating a neurological disorder (e.g., frontotemporal dementia (FTLD-TDP), chronic traumatic encephalopathy, ALS, Alzheimer's disease, limbic-dominant age-related TDP-43 encephalopathy (LATE), or frontotemporal lobar degeneration) in a subject in need thereof. The method comprises administering an effective amount of any of the foregoing compounds or pharmaceutical compositions.

[0150] In one aspect, the invention features a method of inhibiting toxicity in a cell (e.g., a mammalian neural cell) associated with a protein (e.g., TDP-43 or C9orf72). The method comprises administering an effective amount of any of the foregoing compounds or pharmaceutical compositions.

[0151] In one aspect, the invention features a method of treating a TDP-43-related disorder or a C9orf72-related disorder (e.g., FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration) in a subject in need thereof. The method comprises administering to the subject an effective amount of a compound described herein or a pharmaceutical composition containing one or more compounds described herein. In some embodiments, the method comprises administering to the subject in need thereof an effective amount of a compound of formula (14):

[0152]

[0153] or a pharmaceutically acceptable salt thereof,

[0154] in

[0155] is a single bond, X 1 (C(R A )2) m or –OC(R A )2–R X , and X 2 C(R A )2 or CO; or is a double bond, and X 1 and X 2 Each of the CR A or N, where R X For X 2 Keys;

[0156] R 1 for – (L) n –R B , hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 1-6 Alkoxy, optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heterocyclic or optionally substituted C 1-9 heteroaryl;

[0157] R 2 is hydrogen optionally substituted by C 1-6 Alkyl, optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heterocyclic group, optionally substituted C 1-9 heteroaryl or optionally substituted C6-C 10 Aryl C1-C6 alkyl;

[0158] R 3A group of the following structure:

[0159]

[0160] Each R A are independently H, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl, or two twin R A The groups, together with the atoms to which they are attached, combine to form an oxo group;

[0161] R B is an optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heteroaryl, optionally substituted C 3-8 Cycloalkyl, -N=CH-R D or optionally substituted C 1-9 Heterocyclyl, optionally substituted C2-C9 heteroarylC1-C6 alkyl, optionally substituted C2-C9 heterocyclylC1-C6 alkyl;

[0162] R C is H or optionally substituted C 1- C6 alkyl;

[0163] R D is an optionally substituted C 6- C 10 Aryl;

[0164] Each L is independently optionally substituted alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C3-C8 cycloalkylene, optionally substituted C2-C6 alkynylene, O or NR C ;and

[0165] n is 1, 2 or 3; and

[0166] m is 0, 1 or 2.

[0167] In some embodiments, In some embodiments, X 1 (C(R A )2) m In some embodiments, m is 1. In some embodiments, X 2 C(R A )2. In some embodiments, each R A For hydrogen.

[0168] In one aspect, the invention features a method of inhibiting PIKfyve. The method comprises contacting a cell with an effective amount of any of the foregoing compounds or pharmaceutical compositions.

[0169] In another aspect, the invention features a method of treating a neurological disorder in a patient, such as a human patient, who is determined to be likely to benefit from treatment with a compound of the invention based on TDP-43 toxicity. In this regard, the method may include (i) determining that the patient exhibits or is susceptible to TDP-43 toxicity, and (ii) providing the patient with a therapeutically effective amount of a compound of the invention. In some embodiments, the patient has previously been determined to exhibit or be susceptible to TDP-43 toxicity, and the method includes providing the patient with a therapeutically effective amount of a compound of the invention. The patient's susceptibility to TDP-43 aggregation can be determined, for example, by determining whether the patient expresses a TDP-43 mutant isoform containing a mutation associated with TDP-43 aggregation and toxicity (e.g., a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D). This can be performed, for example, by determining the amino acid sequence of a TDP-43 isoform isolated from a sample obtained from the patient or by determining the nucleic acid sequence of a TDP-43 gene isolated from a sample obtained from the patient. In some embodiments, the methods include the step of obtaining a sample from a patient.

[0170] In an additional aspect, the invention features a method of treating a neurological disorder in a patient, such as a human patient, who has been identified as likely to benefit from treatment with a compound of the invention based on TDP-43 expression. In this aspect, the method includes (i) determining that the patient expresses a mutant form of TDP-43 having a mutation associated with TDP-43 aggregation (e.g., a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D), and (ii) providing the patient with a therapeutically effective amount of a compound of the invention. In some embodiments, the patient has previously been identified as expressing a mutant form of TDP-43 having a mutation associated with TDP-43 aggregation (e.g., Q331K, M337V, Q343R, N345K, R361S, and N390D mutations), and the method includes providing the patient with a therapeutically effective amount of a compound of the invention.

[0171] In another aspect, the invention features a method of determining whether a patient (e.g., a human patient) has a neurological disorder that may benefit from treatment with a compound of the invention by (i) determining whether the patient exhibits or is susceptible to TDP-43 aggregation, and (ii) if the patient exhibits or is susceptible to TDP-43 aggregation, determining that the patient may benefit from treatment with a compound of the invention. In some embodiments, the method further comprises the step of (iii) informing the patient whether he or she may benefit from treatment with a compound of the invention. The patient's susceptibility to TDP-43 aggregation can be determined, for example, by determining whether the patient expresses a TDP-43 mutant isoform containing a mutation associated with TDP-43 aggregation and toxicity (e.g., a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D). This can be performed, for example, by determining the amino acid sequence of a TDP-43 isoform isolated from a sample obtained from the patient or by determining the nucleic acid sequence of a TDP-43 gene isolated from a sample obtained from the patient. In some embodiments, the methods include the step of obtaining a sample from a patient.

[0172] In another aspect, the invention features a method of determining whether a patient (e.g., a human patient) has a neurological disorder that may benefit from treatment with a compound of the invention by (i) determining whether the patient expresses a TDP-43 mutant having a mutation associated with TDP-43 aggregation (e.g., a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D), and (ii) if the patient expresses the TDP-43 mutant, determining that the patient may benefit from treatment with a compound of the invention. In some embodiments, the method further comprises the step of (iii) informing the patient whether he or she may benefit from treatment with a compound of the invention. The TDP-43 isoform expressed by the patient can be assessed, for example, by isolating TDP-43 protein from a sample obtained from the patient and sequencing the protein using molecular biology techniques described herein or known in the art. In some embodiments, the TDP-43 isoform expressed by the patient is determined by analyzing the patient's genotype at the TDP-43 locus, for example, by sequencing the TDP-43 gene in a sample obtained from the patient. In some embodiments, the method includes the step of obtaining a sample from the patient.

[0173] In some embodiments of any of the above aspects, the compounds of the invention are provided to a patient by administering a compound of the invention to the patient. In some embodiments, the compounds of the invention are provided to a patient by administering a prodrug that is converted in vivo to a compound of the invention.

[0174] In some embodiments of any of the aforementioned aspects, the nervous system disorder is a neuromuscular disorder, such as a neuromuscular disorder selected from amyotrophic lateral sclerosis, congenital myasthenic syndrome, congenital myopathy, spasticity-fasciculation syndrome, Duchenne muscular dystrophy, glycogen storage disease type II, hereditary spastic paraplegia, inclusion body myositis, Isaac's syndrome, Kearns-Sayre syndrome, Lambert-Eaton myasthenic syndrome, mitochondrial myopathy, muscular dystrophy, myasthenia gravis, myotonic dystrophy, peripheral neuropathy, spinal and bulbar muscular atrophy, spinal muscular atrophy, stiff-person syndrome, Troyer syndrome, and Guillain–Barré syndrome. In some embodiments, the nervous system disorder is amyotrophic lateral sclerosis.

[0175] In some embodiments of any of the aforementioned aspects, the nervous system disorder is selected from frontotemporal degeneration (also known as frontotemporal lobar degeneration and frontotemporal dementia), Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, dementia of Guam Parkinson's disease ALS complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibromyopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy.

[0176] In some embodiments, the neurological disorder is amyotrophic lateral sclerosis, and after administering a compound of the invention to a patient, the patient exhibits one or more or all of the following reactions:

[0177] (i) improvement in disease condition, as assessed using the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the Revised ALSFRS (ALSFRS-R), such as an improvement in the patient's ALSFRS or ALSFRS-R score within one or more days, one or more weeks, or one or more months after administration of a compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of a compound of the invention to the patient, such as an improvement in the patient's ALSFRS or ALSFRS-R score within one or more days, one or more weeks, or one or more months after administration of a compound of the invention to the patient 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer after the first administration of a compound of the present invention;

[0178] (ii) an increase in slow lung capacity, such as an increase in the patient's slow lung capacity after one or more days, one or more weeks, or one or more months after administration of the compound of the invention (e.g., an increase in the patient's slow lung capacity within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the compound of the invention to the patient, such as an increase in the patient's slow lung capacity within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, 53 weeks, 54 weeks, 56 weeks, 57 weeks, 58 weeks, 59 weeks, 60 weeks, 61 weeks, 62 weeks, 63 weeks, 64 weeks, 65 weeks, 66 weeks, 67 weeks, 68 weeks, 69 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer);

[0179] (iii) the patient exhibits a decrease in the decremental response after repeated nerve stimulation, such as a decrease observed one or more days, one or more weeks, or one or more months after administration of the compound of the invention (e.g., a decrease observed within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the compound of the invention to the patient, such as a decrease observed within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 ​​days, 49 days, 50 days, 51 days, 52 days, 53 days, 54 days, 55 days, 56 days, 57 days, 58 days, 59 days, 60 days, 61 days, 62 days, 63 days, 64 days, 65 days, 66 days, 67 days, 68 days, 69 days, 70 days, 71 days, 72 days, 73 days, 74 days, 75 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer);

[0180] (iv) improvement in muscle strength, as assessed, for example, by the Medical Research Council Muscle Testing Scale (as described, for example, in Jagtap et al., Ann. Indian. Acad. Neurol. 17:336-339 (2014), the disclosure of which is incorporated herein by reference as it relates to measuring a patient's response to treatment for a neurological disease), as observed one or more days, one or more weeks, or one or more months after administration of a compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) after the first administration of a compound of the invention to a patient or more weeks after the first administration of a compound of the invention to a patient);

[0181] (v) improvement in quality of life, as assessed, for example, using an amyotrophic lateral sclerosis-specific quality of life (ALS-specific QOL) questionnaire, such as an improvement in the patient's quality of life observed within one or more days, one or more weeks, or one or more months after administration of a compound of the invention (e.g., an improvement in the subject's quality of life observed within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of a compound of the invention to the patient, such as an improvement in the subject's quality of life observed within 1 day after the first administration of a compound of the invention to the patient , 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer);

[0182] (vi) a decrease in the frequency and / or severity of muscle spasms, such as a decrease in the frequency and / or severity of spasms within one or more days, one or more weeks, or one or more months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the compound of the invention to the patient, such as a decrease in the frequency and / or severity of spasms within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days after the first administration of the compound of the invention to the patient , 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or more); and / or

[0183] (vii) TDP-43 aggregation is reduced, such as TDP-43 aggregation is reduced within one or more days, one or more weeks, or one or more months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the compound of the invention to the patient, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 ​​days, 49 days, 50 days, 51 days, 52 days, 53 days, 54 days, 55 days, 56 days, 57 days, 58 days, 59 days, 60 days, 61 days, 62 days, 63 days, 64 days, 65 days, 66 days, 67 days, 68 days, 69 days, 70 days, 71 days, 72 days, 73 days, 74 days, 75 days, 76 days, 7 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer).

[0184] Chemical terms

[0185] It is to be understood that the terminology used herein is for the purpose of describing particular embodiments and is not intended to be limiting.

[0186] It will be appreciated by those skilled in the art that certain compounds described herein may exist in one or more different isomeric (e.g., stereoisomers, geometric isomers, tautomers and / or isotopic (e.g., wherein one or more atoms have been substituted with a different isotope of that atom, such as hydrogen with deuterium) forms. Unless otherwise indicated or clear from the context, drawn structures may be understood to represent any such isomeric or isotopic forms, alone or in combination.

[0187] In some embodiments, one or more compounds depicted herein may exist in different tautomeric forms. As is clear from the context, unless explicitly excluded, reference to such compounds encompasses all such tautomeric forms. In some embodiments, tautomeric forms are produced by the exchange of a single bond with an adjacent double bond and the accompanying proton migration. In certain embodiments, the tautomeric form may be a proton transfer tautomer, which is an isomeric protonation state with the same empirical formula and total charge as the reference form. Examples of parts with proton transfer tautomeric forms include keto-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-imine pairs, and cyclic forms, wherein protons can occupy two or more positions of a heterocyclic system, such as 1H- and 3H-imidazoles, 1H-, 2H- and 4H-1,2,4-triazoles, 1H- and 2H-isoindoles, and 1H- and 2H-pyrazoles. In some embodiments, the tautomeric form may be in equilibrium or locked into one form spatially by appropriate substitution. In certain embodiments, tautomeric forms arise from acetal interconversions, for example, as illustrated in the following schemes:

[0188]

[0189] It will be appreciated by those skilled in the art that in some embodiments, isotopes of the compounds described herein may be prepared and / or used according to the present invention. "Isotopes" refer to atoms having the same atomic number but different mass numbers, which are caused by the different number of neutrons in the nucleus. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, isotopic substitution (e.g., substitution of hydrogen with deuterium) may alter the physicochemical properties of the molecule, such as the rate of racemization of metabolism and / or chiral centers.

[0190] As is known in the art, many chemical entities (particularly many organic molecules and / or many small molecules) can take a variety of different solid forms, such as amorphous forms and / or crystalline forms (e.g., polymorphs, hydrates, solvates, etc.). In some embodiments, such entities can be used in any form, including in any solid form. In some embodiments, such entities are used in a specific form, such as in a specific solid form.

[0191] In some embodiments, the compounds described and / or depicted herein may be provided and / or used in the form of a salt.

[0192] In certain embodiments, the compounds described and / or illustrated herein may be provided and / or used in the form of a hydrate or a solvate.

[0193] In various places of this specification, substituents of compounds of the present disclosure are disclosed in groups or in ranges. It is specifically intended that the present disclosure includes each individual subcombination of members of such groups and ranges. For example, the term "C1-C6 alkyl" is specifically intended to disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl individually. In addition, when a compound includes multiple positions where substituents are disclosed in groups or in ranges, unless otherwise stated, the present disclosure is intended to cover individual compounds and groups of compounds (e.g., genera and subgenera) containing each individual subcombination of members at each position.

[0194] As used herein, a statement of the form "optionally substituted X" (e.g., optionally substituted alkyl) is intended to be equivalent to "X, wherein X is optionally substituted" (e.g., "alkyl, wherein the alkyl is optionally substituted"). It is not intended to mean that the feature "X" (e.g., alkyl) itself is optional.

[0195] As used herein, the term "acyl" means hydrogen, alkyl, aryl or heteroaryl as defined herein, attached to the parent molecular group through a carbonyl group, and is exemplified by formyl (i.e., carboxaldehyde group), acetyl, trifluoroacetyl, propionyl, butyryl, benzoyl. Exemplary unsubstituted acyl groups include 1 to 6, 1 to 11 or 1 to 21 carbons. Optionally substituted acyl is

[0196] As used herein, the term "alkyl" refers to a branched or straight chain monovalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms (e.g., 1 to 16 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms). Alkylene is a divalent alkyl group.

[0197] As used herein, the term "alkenyl", alone or in combination with other groups, refers to a straight or branched hydrocarbon residue having a carbon-carbon double bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms).

[0198] As used herein, the term "alkynyl", alone or in combination with other groups, refers to a straight or branched hydrocarbon residue having a carbon-carbon triple bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms). Alkynylene is a divalent alkynyl group.

[0199] As used herein, the term "amino" refers to -N(R N1 )2, where each R N1 are independently H, OH, NO2, N(R N2 2. SO2OR N2 、SO2R N2 、SOR N2, N-protecting group, alkyl, alkoxy, aryl, arylalkyl, cycloalkyl, acyl (e.g., acetyl, trifluoroacetyl, or other acyl described herein), wherein these described R N1 Each of the groups may be optionally substituted, or both R N1 are combined to form an alkylene group or a heteroalkylene group, and wherein each R N2 The amino groups of the present invention can be unsubstituted amino (ie, -NH2) or substituted amino (ie, -N(R N1 )2).

[0200] As used herein, the term "aryl" refers to an aromatic monocyclic or polycyclic group of 6 to 12 carbon atoms having at least one aromatic ring. Examples of such groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, indanyl, and 1H-indenyl.

[0201] As used herein, the term "arylalkyl" represents an alkyl group substituted with an aryl group. Exemplary unsubstituted arylalkyl groups have 7 to 30 carbon atoms (e.g., 7 to 16 or 7 to 20 carbon atoms, such as C 6-10 Aryl C1-C6 alkyl, C 6-10 Aryl C1-C 10 Alkyl or C 6-10 Aryl C1-C 20 In some embodiments, the alkyl and aryl groups may each be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the corresponding groups.

[0202] As used herein, the term "azido" represents a -N3 group.

[0203] As used herein, the term "cyano" represents a CN group.

[0204] As used herein, the term "carbocyclyl" refers to a non-aromatic C3-C4 ring formed by carbon atoms. 12 Monocyclic, bicyclic or tricyclic structures.Carbocyclic structures include cycloalkyl groups and unsaturated carbocyclic groups.

[0205] As used herein, the term "cycloalkyl" refers to a saturated, non-aromatic, monovalent mono- or poly-carbocyclic radical having three to ten, preferably three to six carbon atoms. The term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl. Cycloalkylene is a divalent cycloalkyl radical.

[0206] As used herein, the term "halo" refers to a fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo) group.

[0207] As used herein, the term "heteroalkyl" refers to an alkyl group as defined herein in which one or more of the constituent carbon atoms have been replaced with nitrogen, oxygen or sulfur. In some embodiments, the heteroalkyl group may be further substituted with 1, 2, 3 or 4 substituent groups as described herein for the alkyl group. Examples of heteroalkyl groups include "alkoxy", which, as used herein, refers to alkyl-O- (e.g., methoxy and ethoxy). Heteroalkylene is a divalent heteroalkyl group.

[0208] As used herein, the term "heteroalkenyl" refers to an alkenyl group as defined herein in which one or more of the constituent carbon atoms have been replaced with nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl group may be further substituted with 1, 2, 3, or 4 substituent groups as described herein for the alkenyl group. Examples of heteroalkenyl groups include "alkenyloxy," which, as used herein, refers to alkenyl-O-. Heteroalkenylene is a divalent heteroalkenyl group.

[0209] As used herein, the term "heteroalkynyl" refers to an alkynyl group as defined herein in which one or more of the constituent carbon atoms have been replaced with nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkynyl group may be further substituted with 1, 2, 3, or 4 substituent groups as described herein for the alkynyl group. Examples of heteroalkynyl groups include "alkynyloxy," which, as used herein, refers to alkynyl-O-. Heteroalkynylene is a divalent heteroalkynyl group.

[0210] As used herein, the term "heteroaryl" refers to an aromatic monocyclic or polycyclic group of 5 to 12 atoms having at least one aromatic ring and containing one, two, three or four ring heteroatoms selected from N, O and S, the remaining ring atoms being C. One or two ring carbon atoms of the heteroaryl group may be replaced by a carbonyl group. Examples of heteroaryl groups include pyridyl, pyrazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, imidazolyl, oxaxolyl and thiazolyl.

[0211] As used herein, the term "heteroarylalkyl" represents an alkyl group substituted with a heteroaryl group. Exemplary unsubstituted heteroarylalkyl groups have 7 to 30 carbon atoms (e.g., 7 to 16 or 7 to 20 carbon atoms, such as C2-C9 heteroarylC1-C6 alkyl, ... 10 Alkyl or C2-C9 heteroaryl C1-C 20 In some embodiments, alkyl and heteroaryl can each be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the corresponding groups.

[0212] As used herein, the term "heterocyclyl" refers to a monocyclic or polycyclic group having 3 to 12 atoms, wherein at least one ring contains one, two, three or four ring heteroatoms selected from N, O or S, and wherein no ring is aromatic. Examples of heterocyclyl groups include, but are not limited to, morpholinyl, thiomorpholinyl, furanyl, piperazinyl, piperidinyl, pyranyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl and 1,3-dioxanyl.

[0213] As used herein, the term "heterocyclylalkyl" represents an alkyl group substituted by a heterocyclyl group. Exemplary unsubstituted heterocyclylalkyl groups have 7 to 30 carbon atoms (e.g., 7 to 16 or 7 to 20 carbon atoms, such as C2-C9 heterocyclylC1-C6 alkyl, ... 10 Alkyl or C2-C9 heterocyclic C1-C 20 In some embodiments, alkyl and heterocyclyl can each be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the corresponding groups.

[0214] As used herein, the term "hydroxy" represents an -OH group.

[0215] As used herein, the term "N-protecting group" represents those groups intended to protect amino groups from undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis," 3rd Edition (John Wiley & Sons, New York, 1999). N-protecting groups include acyl, aroyl or carbamoyl groups, such as formyl, acetyl, propionyl, pivaloyl, tert-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and chiral auxiliaries such as protected or unprotected D,L or D,L-amino acids such as alanine, leucine and phenylalanine; sulfonyl-containing groups such as benzenesulfonyl and p-toluenesulfonyl; carbamate-forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 4 ...bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, alkyl groups such as benzyl, triphenylmethyl and benzyloxymethyl; and silyl groups such as trimethylsilyl. Preferred N-protecting groups are alloc, formyl, acetyl, benzoyl, pivaloyl, tert-butylacetyl, alanyl, phenylsulfonyl, benzyl, tert-butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).

[0216] As used herein, the term "nitro" represents a NO2 group.

[0217] As used herein, the term "oxyheteroaryl" represents a heteroaryl group having at least one endocyclic oxygen atom.

[0218] As used herein, the term "oxyheterocyclyl" represents a heterocyclyl group having at least one endocyclic oxygen atom.

[0219] As used herein, the term "thiol" represents a -SH group.

[0220] Alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclic radical (for example, cycloalkyl), aryl, heteroaryl and heterocyclic radical groups can be substituted or unsubstituted. When substituted, unless otherwise indicated, there will usually be 1 to 4 substituents. Substituents include, for example, aryl (for example, substituted and unsubstituted phenyl), carbocyclic radical (for example, substituted and unsubstituted cycloalkyl), halogen (for example, fluorine), hydroxyl, oxo, heteroalkyl (for example, substituted and unsubstituted methoxy, ethoxy or thioalkoxy), heteroaryl, heterocyclic radical, amino (for example, NH2 or monoalkylamino or dialkylamino), azido, cyano, nitro or thiol. Aryl, carbocyclic radical (for example, cycloalkyl), heteroaryl and heterocyclic radical groups can also be substituted by alkyl (unsubstituted and substituted, such as arylalkyl (for example, substituted and unsubstituted benzyl)).

[0221] The compounds of the present invention may have one or more asymmetric carbon atoms and may exist in the form of optically pure enantiomers, mixtures of enantiomers (e.g., racemates, optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates, or mixtures of diastereomeric racemates). Optically active forms may be obtained, for example, by resolution of racemates, by asymmetric synthesis, or by asymmetric chromatography (chromatography using a chiral adsorbent or eluent). That is, certain disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are non-superimposable, most commonly because they contain asymmetrically substituted carbon atoms as chiral centers. "Enantiomers" refer to one of a pair of molecules that are mirror images of each other and non-superimposable. Diastereoisomers are stereoisomers that are not associated in mirror image form, most commonly because they contain two or more asymmetrically substituted carbon atoms and represent the configuration of substituents around one or more chiral carbon atoms. The enantiomers of a compound can be prepared, for example, by separating enantiomers from a racemate using one or more well-known techniques and methods (e.g., chiral chromatography and separation methods based thereon). One skilled in the art can easily determine the appropriate techniques and / or methods for separating the enantiomers of a compound described herein from a racemic mixture. "Racemate" or "racemic mixture" refers to a compound containing two enantiomers, wherein such a mixture does not exhibit optical activity; that is, they do not rotate the plane of polarized light. "Geometric isomers" refers to isomers with different orientations of substituent atoms relative to a carbon-carbon double bond, a cycloalkyl ring, or a bridged bicyclic system. The atoms (except H) on each side of a carbon-carbon double bond can be in an E configuration (substituents on opposite sides of a carbon-carbon double bond) or a Z configuration (substituents oriented on the same side). "R", "S", "S*", "R*", "E", "Z", "cis" and "trans" indicate configurations relative to a core molecule. Certain disclosed compounds may exist in atropisomeric forms. Atropisomers are stereoisomers resulting from hindered rotation about a single bond, where the steric tension barrier to rotation is high enough to allow separation of the conformers. The compounds of the invention may be prepared as single isomers by isomer-specific synthesis or resolution from a mixture of isomers. Conventional resolution techniques include formation of salts of the free bases of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base); formation of salts of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid); formation of esters or amides of each isomer of an isomeric pair using an optically pure acid, amine, or alcohol (followed by chromatographic separation and removal of the chiral auxiliary); or resolution of isomeric mixtures of the starting material or final product using various well-known chromatographic methods.When the stereochemistry of a disclosed compound is named or depicted by structure, the stereoisomer named or depicted is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the enantiomer depicted or named is at least 60%, 70%, 80%, 90%, 99%, or 99.9% optically pure by weight. When a single diastereomer is named or depicted by structure, the diastereomer depicted or named is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by weight. Percent optical purity is the ratio of the weight of the enantiomer to the weight of the enantiomer plus the weight of its optical isomer. Diastereomeric weight purity is the ratio of the weight of one diastereomer to the weight of all diastereomers. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by mole fraction relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the enantiomer depicted or named is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by mole fraction. When a single diastereomer is named or depicted by structure, the diastereomer depicted or named is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by mole fraction. Percent purity is the ratio of the number of moles of an enantiomer to the number of moles of an enantiomer plus the number of moles of its optical isomers. Similarly, mole fraction percent purity is the ratio of the number of moles of a diastereomer to the number of moles of a diastereomer plus the number of moles of its isomers. When a disclosed compound is named or depicted by structure without specifying stereochemistry and the compound has at least one chiral center, it is understood that the name or structure encompasses either enantiomer of the compound free of the corresponding optical isomer, a racemic mixture of the compound, or a mixture enriched in one enantiomer relative to its corresponding optical isomer. When a disclosed compound is named or depicted by structure without specifying stereochemistry and has two or more chiral centers, it is understood that the name or structure encompasses a diastereomer free of other diastereomers, a plurality of diastereomers free of other pairs of diastereomers, a mixture of diastereomers, a mixture of pairs of diastereomers, a mixture of diastereomers in which one diastereomer is enriched relative to the other diastereomers, or a mixture of diastereomers in which one or more diastereomers are enriched relative to the other diastereomers. The present invention includes all of these forms.

[0222] definition

[0223] In this application, unless the context clearly indicates otherwise, (i) the term "a" or "an" may be understood to mean "at least one"; (ii) the term "or" may be understood to mean "and / or"; (iii) the terms "comprising" and "including" may be understood to cover the components or steps listed individually, whether presented alone or together with one or more additional components or steps; and (iv) the terms "about" and "approximately" may be understood to allow for standard variations understood by those of ordinary skill in the art; and (v) where a range is provided, the endpoints are included.

[0224] As used herein, the term "administering" refers to administering a composition (e.g., a compound, complex, or formulation comprising a compound or complex as described herein) to a subject or system. Administration to an animal subject (e.g., to a human) can be by any appropriate route. For example, in some embodiments, administration can be bronchial (including by bronchial instillation), buccal, enteral, intradermal, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal, and vitreous administration.

[0225] As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to humans at any stage of development. In some embodiments, "animal" refers to non-human animals at any stage of development. In some embodiments, non-human animals are mammals (e.g., rodents, mice, rats, rabbits, monkeys, dogs, cats, sheep, cattle, primates and / or pigs). In some embodiments, animals include but are not limited to mammals, birds, reptiles, amphibians, fish and / or worms. In some embodiments, animals can be transgenic animals, genetically engineered animals and / or clones.

[0226] As used herein, the terms "approximately" and "about" are each intended to encompass normal statistical variation, as will be understood by those of ordinary skill in the art based on the relevant context. In certain embodiments, the terms "approximately" or "about" each refer to a series of values ​​falling within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of a range in either direction (greater than or less than) of the stated value, unless otherwise noted or apparent from the context (e.g., when such a numeral exceeds 100% of the possible value).

[0227] As the term is used herein, two events or entities are "associated with" one another if the presence, level, and / or form of one event or entity is related to the presence, level, and / or form of the other event or entity. For example, a particular entity (e.g., a polypeptide) is considered to be associated with a particular disease, disorder, or condition if the presence, level, and / or form of the entity (e.g., a polypeptide) is associated with the incidence and / or susceptibility of the disease, disorder, or condition (e.g., in a related population).

[0228] As used herein, the terms "benefit" and "response" are used interchangeably in the context of a subject, such as a human subject, who is receiving therapy for treatment of a neurological disorder, such as amyotrophic lateral sclerosis, frontotemporal degeneration (also known as frontotemporal lobar degeneration and frontotemporal dementia), Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia Parkinson's disease ALS complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibromyopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy. The terms "benefit" and "response" refer to any clinical improvement in a subject's condition. In the context of a subject being treated for a neurological disorder using the compositions and methods described herein (e.g., in the context of a human subject being treated for a neurological disorder described herein such as amyotrophic lateral sclerosis with a FYVE-type zinc finger-containing phosphoinositide kinase (PIKfyve) inhibitor such as an inhibitory small molecule, antibody, antigen-binding fragment thereof, or interfering RNA molecule described herein), exemplary benefits include slowing and halting disease progression and inhibiting one or more symptoms associated with the disease. In particular, in the context of patients (e.g., human patients) who are being treated with a compound of the invention for amyotrophic lateral sclerosis, examples of clinical "benefits" and "responses" are (i) an improvement in the subject's condition as assessed using the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the Revised ALSFRS (ALSFRS-R) following administration of a compound of the invention, such as an improvement in the subject's ALSFRS or ALSFRS-R score within one or more days, one or more weeks, or one or more months following administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) following the first administration of the compound of the invention to the subject; an improvement in the subject's ALSFRS or ALSFRS-R score within 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer after the first administration of a compound of the invention to the subject;(ii) the slow lung capacity of the subject increases after administration of the compound of the invention, such as the slow lung capacity of the subject increases one or more days, one or more weeks, or one or more months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the compound of the invention to the subject, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 ​​days, 49 days, 50 days, 51 days, 52 days, 53 days, 54 days, 55 days, 56 days, 57 days, 58 days, 59 days, 60 days, 61 days, 62 days, 63 days, 64 days, 65 days, 66 days, 67 days, 68 days, 70 days, 71 days, 72 days, 73 days, 74 days, 75 days, 76 days, 77 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer (iii) a decrease in the decremental response exhibited by the subject following repeated neural stimulation, such as a decrease observed one or more days, one or more weeks, or one or more months after administration of the compound of the invention (e.g., a decrease observed within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the compound of the invention to the subject, such as a decrease observed within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days after the first administration of the compound of the invention to the subject , 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer);(iv) an improvement in the subject's muscle strength, as assessed, for example, by the Medical Research Council Muscle Testing Scale (as described, for example, in Jagtap et al., Ann. Indian. Acad. Neurol. 17:336-339 (2014), the disclosure of which is incorporated herein by reference as it relates to measuring a patient's response to treatment for a neurological disorder), as observed one or more days, one or more weeks, or one or more months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 1 month) after the first administration of the compound of the invention to the subject 20 weeks, or about 12 weeks to about 16 weeks) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, 53 weeks, 54 weeks, 55 weeks, 56 weeks, 57 weeks, 58 weeks, 59 weeks, 60 weeks, 61 weeks, 62 weeks, 63 weeks, 64 weeks, 65 weeks (v) an improvement in the subject's quality of life, as assessed, for example, using an amyotrophic lateral sclerosis-specific quality of life (ALS-specific QOL) questionnaire, such as an improvement in the subject's quality of life observed within one or more days, one or more weeks, or one or more months after administration of a compound of the invention (e.g., an improvement in the subject's quality of life observed within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of a compound of the invention to the subject, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer after the first administration of a compound of the invention to a subject;and (vi) the subject exhibits a decrease in the frequency and / or severity of muscle spasms, such as a decrease in the frequency and / or severity of spasms within one or more days, one or more weeks, or one or more months after administration of the compound of the invention (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the compound of the invention to the subject, such as a decrease in the frequency and / or severity of spasms within 1 day, 2 days, 3 days, 4 days, or more after the first administration of the compound of the invention to the subject , 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer).

[0229] As used herein, the term "dosage form" refers to a physical discrete unit of an active compound (e.g., a therapeutic agent or a diagnostic agent) for administration to a subject. Each unit contains a predetermined amount of an active agent. In some embodiments, such an amount is a unit dosage amount (or its entire portion) suitable for administration according to a dosage regimen that has been determined to be associated with a desired or beneficial result when administered to a relevant population (i.e., using a therapeutic dosage regimen). It will be understood by those of ordinary skill in the art that the total amount of a therapeutic composition or compound administered to a particular subject is determined by one or more attending physicians and may involve the administration of multiple dosage forms.

[0230] As used herein, the term "dosage regimen" refers to a group of unit doses (usually more than one) that are usually administered separately to a subject at intervals of time. In some embodiments, a given therapeutic compound has a recommended dosing regimen that may involve one or more doses. In some embodiments, the dosing regimen includes multiple doses, each separated by a time period of the same length; in some embodiments, the dosing regimen includes multiple doses and at least two different time periods separating each dose. In some embodiments, all doses within the dosing regimen have the same unit dose amount. In some embodiments, different doses within the dosing regimen have different amounts. In some embodiments, the dosing regimen includes a first dose of a first dose amount, followed by one or more additional doses of a second dose amount different from the first dose amount. In some embodiments, the dosing regimen includes a first dose of a first dose amount, followed by one or more additional doses of a second dose amount identical to the first dose amount. In some embodiments, the dosing regimen is associated with a desired or beneficial outcome when administered within a related population (i.e., a therapeutic dosing regimen).

[0231] In practicing the methods of the present invention, an "effective amount" of any one of the compounds of the present invention or a combination of any one of the compounds of the present invention or a pharmaceutically acceptable salt thereof is administered alone or in combination via any common and acceptable method known in the art.

[0232] As used herein, the term "pharmaceutical composition" means a composition containing a compound described herein, formulated with a pharmaceutically acceptable excipient, and manufactured or sold as part of a therapeutic regimen for treating a disease in a mammal approved by a governmental regulatory agency. The pharmaceutical composition can be formulated, for example, in unit dosage forms for oral administration (e.g., tablets, capsules, caplets, caplets, or syrups); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or formulated into any other pharmaceutically acceptable formulation.

[0233] As used herein, "pharmaceutically acceptable excipient" refers to any ingredient other than the compounds described herein and having the property of being substantially non-toxic and non-inflammatory in a patient (e.g., a vehicle capable of suspending or dissolving the active compound). Excipients may include, for example, antiadherents, antioxidants, binders, coating agents, compression aids, disintegrants, dyes (colorants), emollients, emulsifiers, fillers (diluents), film formers or coating agents, flavoring agents, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and water of hydration. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dicalcium phosphate), calcium stearate, cross-linked carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

[0234] As used herein, the term "pharmaceutically acceptable salt" refers to any pharmaceutically acceptable salt of a compound of formula (I). For example, pharmaceutically acceptable salts of any of the compounds described herein include those salts that are suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reaction and commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66: 1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. PHStahl and CGWermuth), Wiley-VCH, 2008. These salts can be prepared in situ during the final isolation and purification of the compounds described herein, or prepared separately by reacting the free base group with a suitable organic acid.

[0235] The compounds of the present invention may have ionizable groups that enable preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids, or in the case of acidic forms of the compounds of the present invention, these salts may be prepared from inorganic or organic bases. Typically, the compounds are prepared or used as pharmaceutically acceptable salts, which are prepared from addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases and methods for preparing appropriate salts are well known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases (including inorganic and organic acids and bases).

[0236] The terms "PIKfyve" and "phosphoinositide kinase containing a FYVE-type zinc finger" are used interchangeably herein and refer to an enzyme that catalyzes the phosphorylation of phosphatidylinositol 3-phosphate to produce phosphatidylinositol 3,5-bisphosphate, for example in a human subject. The terms "PIKfyve" and "phosphoinositide kinase containing a FYVE-type zinc finger" refer not only to the wild-type form of PIKfyve, but also to variants of the wild-type PIKfyve protein and nucleic acids encoding the same. The gene encoding PIKfyve can be obtained under NCBI reference sequence number NG_021188.1. Exemplary transcript sequences of the wild-type form of human PIKfyve can be obtained under NCBI reference sequence numbers NM_015040.4, NM_152671.3, and NM_001178000.1. Exemplary protein sequences of wild-type forms of human PIKfyve are available under NCBI reference sequence numbers NP_055855.2, NP_689884.1 and NP_001171471.1.

[0237] As used herein, the term "PIKfyve inhibitor" refers to substances such as compounds of Formula I. This type of inhibitor can competitively inhibit PIKfyve activity, for example, by specifically binding to the PIKfyve enzyme (e.g., by virtue of the inhibitor's affinity for the PIKfyve active site), thereby preventing, hindering or stopping one or more endogenous substrates of PIKfyve from entering the active site of the enzyme. Other examples of PIKfyve inhibitors that inhibit PIKfyve enzyme activity include substances that can bind to PIKfyve at a site away from the active site and weaken the binding of endogenous substrates to the PIKfyve active site by changing the spatial conformation of the enzyme when the inhibitor is bound. In addition to covering substances that modulate PIKfyve activity, the term "PIKfyve inhibitor" also refers to substances that reduce the concentration and / or stability of PIKfyve mRNA transcripts in vivo, as well as substances that inhibit the translation of functional PIKfyve enzymes.

[0238] The term "pure" means substantially pure or free from unwanted components (eg, other compounds and / or other components of a cell lysate), material contamination, adulteration, or defects.

[0239] Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, dodecylsulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and valerate. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.

[0240] A variety of clinical indicators can be used to identify patients as being “at risk” for developing a particular neurological disease. Examples of patients (e.g., human patients) who are "at risk" for developing a neurological disease such as amyotrophic lateral sclerosis, frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia-Parkinson's disease ALS complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibromyopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy include (i) subjects who exhibit or are susceptible to exhibiting aggregation of TAR-DNA binding protein (TDP)-43, and (ii) subjects who express a mutant form of TDP-43 containing a mutation associated with TDP-43 aggregation and toxicity, such as a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D. A subject "at risk" for developing ALS may exhibit one or both of these characteristics, for example, prior to the first administration of a PIKfyve inhibitor according to the compositions and methods described herein.

[0241] As used herein, the terms "TAR-DNA binding protein-43" and "TDP-43" are used interchangeably and refer to transcriptional repressors involved in regulating the selective splicing of HIV-1 transcription and cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA transcripts, for example in human subjects. The terms "TAR-DNA binding protein-43" and "TDP-43" refer not only to wild-type forms of TDP-43, but also to variants of wild-type TDP-43 proteins and nucleic acids encoding them. The amino acid sequence and corresponding mRNA sequence of the wild-type form of human TDP-43 are provided under NCBI reference sequence numbers NM_007375.3 and NP_031401.1, respectively.

[0242] As used herein, the terms "TAR-DNA binding protein-43" and "TDP-43" include, for example, a form of a human TDP-43 protein having an amino acid sequence that is at least 85% identical to the amino acid sequence of NCBI Reference Sequence No. NP_031401.1 (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9% or 100% identical to the amino acid sequence of NCBI Reference Sequence No. NP_031401.1) and / or a form of a human TDP-43 protein that contains one or more substitutions, insertions and / or deletions (e.g., one or more conservative and / or non-conservative amino acid substitutions, such as up to 5, 10, 15, 20, 25 or more conservative or non-conservative amino acid substitutions) relative to a wild-type TDP-43 protein. For example, patients who can be treated for a neurological disorder as described herein, such as amyotrophic lateral sclerosis, frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia-Parkinson's disease ALS complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibromyopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy include human patients expressing a form of TDP-43 with a mutation associated with increased TDP-43 aggregation and toxicity, such as a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D. Similarly, as used herein, the terms "TAR-DNA binding protein-43" and "TDP-43" include, for example, forms of the human TDP-43 gene that encode an mRNA transcript having a nucleic acid sequence that is at least 85% identical to the nucleic acid sequence of NCBI Reference Sequence No. NM_007375.3 (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9% or 100% identical to the amino acid sequence of NCBI Reference Sequence No. NM_007375.3).

[0243] As used herein, the term "subject" refers to any organism to which a composition according to the invention may be administered, for example, for experimental, diagnostic, preventive and / or therapeutic purposes. Typical subjects include any animal (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans). A subject may be seeking treatment or have a need for treatment, need treatment, be receiving treatment, be about to receive treatment, or be a person or animal receiving care from a trained professional for a particular disease or illness.

[0244] A "therapeutic regimen" refers to a regimen of dosages that is administered in a relevant population and is associated with desired or beneficial therapeutic outcomes.

[0245] The term "therapeutically effective amount" refers to an amount sufficient to treat the disease, disorder and / or patient when administered to a group suffering from or susceptible to a disease, disorder and / or illness according to a therapeutic dosing regimen. In some embodiments, a therapeutically effective amount is an amount that reduces the incidence and / or severity of one or more symptoms of a disease, disorder and / or patient and / or delays its onset. It should be understood by those of ordinary skill in the art that the term "therapeutically effective amount" does not actually require successful treatment in a particular individual. On the contrary, a therapeutically effective amount can be an amount that provides a specific desired pharmacological response in a large number of subjects when administered to a patient in need of such treatment. Specifically, it should be understood that a particular subject may actually be "refractory" to a "therapeutically effective amount". To cite only one example, a refractory subject may have a low bioavailability, making it impossible to obtain clinical efficacy. In some embodiments, reference to a therapeutically effective amount may refer to an amount measured in one or more specific tissues (e.g., tissues affected by a disease, disorder or patient) or body fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc.). Those of ordinary skill in the art will appreciate that in some embodiments, a therapeutically effective amount may be formulated and / or administered in a single dose. In some embodiments, a therapeutically effective amount may be formulated and / or administered in multiple doses, for example, as part of a dosing regimen. BRIEF DESCRIPTION OF THE DRAWINGS

[0246] Figure 1 Scheme showing the method of generating a control TDP-43 yeast model (FAB1 TDP-43). The control yeast TDP-43 model was generated by integrating the human TDP-43 gene and the GAL1 promoter into the yeast genome. The yeast ortholog of human PIKFYVE is FAB1.

[0247] Figure 2 The schematic diagram shows the method of generating the humanized PIKFYVE TDP-43 yeast model (PIKFYVE TDP-43). The FAB1 gene was homologously recombined with the G418 resistance cassette (fab1::G418 R )( Figure 2 ). PIKFYVE was cloned downstream of the GPD promoter carried on a plasmid containing URA3 and introduced into the fab1::G418R ura3 strain. The pGAL1-TDP-43 construct was then introduced into the "humanized" yeast strain and cytotoxicity was assessed.

[0248] Figure 3 Histogram generated for flow cytometry-based viability assay of TDP-43 from Fab1.

[0249] Figure 4 Histograms generated from a flow cytometry-based viability assay of PIKFYVE TDP-43. Nonviable cells (rightmost population) increased significantly following induction of TDP-43, with the effect being more pronounced in the PIKFYVE TDP-43 than in the FAB1 TDP-43 strain (see Figure 3 ).

[0250] Figure 5 Overlay of histograms generated from a flow cytometry-based viability assay of FAB1 TDP-43 in the presence of APY0201.

[0251] Figure 6 Overlay of histograms generated from a flow cytometry-based viability assay of PIKFYVE TDP-43 in the presence of APY0201.

[0252] Figure 7 Figure 3 is a scatter plot comparing the PIKFYVE TDP-43 cell protection efficacy with the PIKfyve inhibitory activity of the test compounds. DETAILED DESCRIPTION

[0253] The present invention relates to compositions and methods for treating neurological disorders such as amyotrophic lateral sclerosis and other neuromuscular disorders as well as frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia Parkinson's disease ALS complex, Huntington's disease, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia (IBMPFD), sporadic inclusion body myositis, myofibromyopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease and hereditary inclusion body myopathy, etc. In particular, the present invention provides inhibitors of phosphoinositide kinases containing FYVE-type zinc fingers (PIKfyve), which can be administered to a patient (e.g., a human patient) to treat or prevent a neurological disorder, such as one or more of the aforementioned conditions. In the context of therapeutic treatment, a PIKfyve inhibitor may be administered to a patient to alleviate one or more symptoms of a disorder and / or to correct the underlying molecular pathology associated with the disease, such as inhibiting or preventing aggregation of TAR-DNA binding protein (TDP)-43.

[0254] The disclosure herein is based in part on the discovery that PIKfyve inhibition regulates TDP-43 aggregation in cells. Inhibition of TDP-43 aggregation plays a beneficial role in patients suffering from neurological disorders. Many pathological conditions are associated with TDP-43-promoted aggregation and toxicity, such as amyotrophic lateral sclerosis, frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, Lewy body dementia, corticobasal degeneration, progressive supranuclear palsy, Guam dementia Parkinson's disease ALS complex, Huntington's disease, IBMPFD, sporadic inclusion body myositis, myofibromyopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy. Without being limited by mechanism, by administering an inhibitor of PIKfyve, patients suffering from diseases associated with TDP-43 aggregation and toxicity can be treated, for example, due to inhibition of TDP-43 aggregation induced by a PIKfyve inhibitor.

[0255] Patients who may respond to PIKfyve inhibition as described herein include patients who have or are at risk for TDP-43 aggregation, such as patients who express mutant forms of TDP-43 that are associated with TDP-43 aggregation and toxicity in vivo. Examples of such mutations in TDP-43 associated with elevated TDP-43 aggregation and toxicity include Q331K, M337V, Q343R, N345K, R361S, and N390D, among others. Thus, the compositions and methods described herein provide additional clinical benefits of being able to identify patients who may respond to PIKfyve inhibitor therapy, and methods of treating these patients accordingly.

[0256] The following sections provide descriptions of exemplary PIKfyve inhibitors that can be used in conjunction with the compositions and methods disclosed herein. The following sections also provide descriptions of various exemplary routes of administration and pharmaceutical compositions that can be used to deliver these substances to treat neurological disorders.

[0257] PIKfyve inhibitors

[0258] Exemplary PIKfyve inhibitors described herein include compounds of Formula (I):

[0259]

[0260] or a pharmaceutically acceptable salt thereof,

[0261] in

[0262] is a single bond, X 1 (C(R A )2) m or –OC(R A )2–R X , and X 2C(R A )2 or CO; or is a double bond, and X 1 and X 2 Each of the CR A or N, where R X For X 2 Keys;

[0263] R 1 for – (L) n –R B ; halogen, cyano, hydrogen, optionally substituted C 1-6 Alkoxy, optionally substituted C 1-9 heterocyclyl, optionally substituted C1-C6 alkyl, optionally substituted piperazin-1-yl, optionally substituted pyrrolidin-3-yl, pyrimidinyl optionally substituted by cyclopropyl, or optionally substituted C6-C 10 aryl, optionally substituted pyridazinyl, optionally substituted oxazolyl, pyridin-2-on-1-yl, optionally substituted isoindolinyl, unsubstituted pyridin-4-yl, unsubstituted pyridin-2-yl, optionally substituted furan-3-yl, unsubstituted pyridin-3-yl or optionally substituted pyrazol-1-yl;

[0264] R 2 is an optionally substituted C1-C6 alkyl, an optionally substituted C 6- C 10 aryl, optionally substituted piperidin-4-yl, optionally substituted tetrahydropyran-4-yl, optionally substituted pyrimidin-5-yl, optionally substituted pyrimidin-4-yl, optionally substituted pyridin-3-yl, optionally substituted pyridazin-4-yl, optionally substituted pyrazol-1-yl, optionally substituted pyrazol-4-yl, optionally substituted pyrazol-3-yl, optionally substituted pyridin-2-yl, optionally substituted triazolyl, optionally substituted benzodioxol-2-yl, optionally substituted benzodioxol-2-yl, optionally substituted C6-C 10 Aryl C1-C 10 alkyl or optionally substituted acyl;

[0265] R 3 A group of the following structure:

[0266]

[0267] Each R A are independently H, optionally substituted C 1-6 Alkyl or optionally substituted C 6- C 10 Aryl, or two R ATogether with the atoms to which they are attached, they form an oxo group; A When combined with the atoms to which they are attached to form an oxo group, is a single bond;

[0268] R B is an optionally substituted C 6-10 aryl, optionally substituted C1-C9 heteroaryl, optionally substituted C 3-8 Cycloalkyl, -N=CH-R D , or optionally substituted C1-C9 heterocyclyl, optionally substituted C2-C9 heteroarylC1-C6 alkyl, optionally substituted C2-C9 heterocyclylC1-C6 alkyl;

[0269] R C is H or optionally substituted C 1- C6 alkyl;

[0270] R D is an optionally substituted C 6- C 10 aryl; or

[0271] Each L is independently an optionally substituted C 1-6 alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C3-C8 cycloalkylene, optionally substituted C2-C6 alkynylene, O or NR C ;

[0272] n is 1, 2 or 3; and

[0273] m is 0, 1 or 2.

[0274] In some embodiments, R 1 for – (L) n –R B ; optionally substituted C 1-6 Alkoxy; optionally substituted C 1-9 heterocyclyl; unsubstituted pyrimidinyl; optionally substituted pyridazinyl; optionally substituted oxazolyl, or pyridin-2-one-1-yl. In some embodiments, R 2 is an optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heterocyclic or optionally substituted C 1-9 Heteroaryl.

[0275] Exemplary PIKfyve inhibitors described herein include compounds of Formula 1a:

[0276]

[0277]

[0278] and pharmaceutically acceptable salts thereof.

[0279] Exemplary PIKfyve inhibitors described herein include compounds of Formula 1a':

[0280]

[0281] and pharmaceutically acceptable salts thereof.

[0282] Exemplary PIKfyve inhibitors described herein include compounds of Formula 1b:

[0283]

[0284] and pharmaceutically acceptable salts thereof.

[0285] Exemplary PIKfyve inhibitors described herein include compounds of Formula 1c:

[0286]

[0287] and pharmaceutically acceptable salts thereof.

[0288] Exemplary PIKfyve inhibitors described herein include compounds of Formula 1d:

[0289]

[0290] and pharmaceutically acceptable salts thereof.

[0291] Exemplary PIKfyve inhibitors described herein include compounds of Formula 1e:

[0292]

[0293] and pharmaceutically acceptable salts thereof.

[0294] Exemplary PIKfyve inhibitors described herein include compounds of Formula 2:

[0295]

[0296] and pharmaceutically acceptable salts thereof,

[0297] Where R 2 is optionally substituted pyrimidin-3-yl or optionally substituted pyrimidin-4-yl; and R 4 is hydrogen or optionally substituted C 6- C 10 Aryl.

[0298] Exemplary PIKfyve inhibitors described herein include compounds of Formula 3:

[0299]

[0300] and pharmaceutically acceptable salts thereof,

[0301] Where R 5 is hydrogen or optionally substituted C 6- C 10 aryl; and

[0302] R 2 is optionally substituted triazolyl, optionally substituted pyrazol-4-yl, optionally substituted pyrazol-3-yl, optionally substituted pyrimidin-4-yl or optionally substituted C6-C 10 Aryl C1-C6 alkyl.

[0303] Exemplary PIKfyve inhibitors described herein include compounds of Formula 4:

[0304]

[0305] and pharmaceutically acceptable salts thereof,

[0306] Where R 2 is optionally substituted pyridin-3-yl.

[0307] Exemplary PIKfyve inhibitors described herein include compounds of Formula 5:

[0308]

[0309] and pharmaceutically acceptable salts thereof,

[0310] Where R 2 is an optionally substituted C6-C 10 aryl; or optionally substituted pyridazin-4-yl.

[0311] Exemplary PIKfyve inhibitors described herein include compounds of Formula 6:

[0312]

[0313] and pharmaceutically acceptable salts thereof,

[0314] Where R 2 is optionally substituted pyridin-3-yl.

[0315] Exemplary PIKfyve inhibitors described herein include compounds of Formula 7:

[0316]

[0317] and pharmaceutically acceptable salts thereof,

[0318] wherein L is an optionally substituted C3-C8 cycloalkylene or C2-C6 alkynylene; and R B is an optionally substituted C 6- C 10 Aryl.

[0319] Exemplary PIKfyve inhibitors described herein include compounds of Formula 8:

[0320]

[0321] and pharmaceutically acceptable salts thereof,

[0322] Among them LR B -NHN=CHR D ;

[0323] R 2 is optionally substituted pyridin-3-yl; and

[0324] R D is an optionally substituted C 6- C 10 Aryl.

[0325] Exemplary PIKfyve inhibitors described herein include compounds of Formula 9:

[0326]

[0327] and pharmaceutically acceptable salts thereof,

[0328] Where R 2 is optionally substituted pyridin-3-yl; and

[0329] R 7 is an optionally substituted C 6- C 10 Aryl.

[0330] Exemplary PIKfyve inhibitors described herein include compounds of Formula 10:

[0331]

[0332] and pharmaceutically acceptable salts thereof,

[0333] Where X 2 N or CH;

[0334] R A is an optionally substituted C2-C9 heteroaryl; or an optionally substituted C6-C 10 Aryl;

[0335] R 1 is an optionally substituted C2-C9 heteroaryl or -OR 7 ;

[0336] R 2 is hydrogen or optionally substituted C 1- C6 alkyl; and

[0337] R 7 It is an optionally substituted C2-C9 heteroarylC1-C6 alkyl.

[0338] Additional exemplary PIKfyve inhibitors include compounds of Formula 11:

[0339]

[0340] and pharmaceutically acceptable salts thereof.

[0341] Exemplary PIKfyve inhibitors described herein include compounds of Formula 12:

[0342]

[0343] and pharmaceutically acceptable salts thereof.

[0344] Exemplary PIKfyve inhibitors described herein include compounds of Formula 13:

[0345]

[0346] and pharmaceutically acceptable salts thereof.

[0347] Exemplary PIKfyve inhibitors described herein include compounds of Formula 14:

[0348]

[0349] or a pharmaceutically acceptable salt thereof,

[0350] in

[0351] is a single bond, X 1 (C(R A )2) m or –OC(R A )2–R X , and X 2 C(R A )2 or CO; or is a double bond, and X 1 and X 2 Each of the CR A or N, where RX For X 2 Keys;

[0352] R 1 for – (L) n –R B , hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 1-6 Alkoxy, optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heterocyclic or optionally substituted C 1-9 heteroaryl;

[0353] R 2 is hydrogen optionally substituted by C 1-6 Alkyl, optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heterocyclic group, optionally substituted C 1-9 heteroaryl or optionally substituted C6-C 10 Aryl C1-C6 alkyl;

[0354] R 3 A group of the following structure:

[0355]

[0356]

[0357] Each R A are independently H, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl, or two twin R A The groups, together with the atoms to which they are attached, combine to form an oxo group;

[0358] R B is an optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heteroaryl, optionally substituted C 3-8 Cycloalkyl, -N=CH-R D or optionally substituted C 1-9 Heterocyclyl, optionally substituted C2-C9 heteroarylC1-C6 alkyl, optionally substituted C2-C9 heterocyclylC1-C6 alkyl;

[0359] R C is H or optionally substituted C 1- C6 alkyl;

[0360] R D is an optionally substituted C6- C 10 Aryl;

[0361] Each L is independently optionally substituted alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C3-C8 cycloalkylene, optionally substituted C2-C6 alkynylene, O or NR C ;and

[0362] n is 1, 2 or 3; and

[0363] m is 0, 1 or 2.

[0364] Non-limiting examples of compounds of the present invention include:

[0365]

[0366]

[0367]

[0368]

[0369]

[0370]

[0371]

[0372]

[0373]

[0374]

[0375]

[0376]

[0377]

[0378] and pharmaceutically acceptable salts thereof.

[0379] Treatment

[0380] Inhibition of PIKfyve activity and TDP-43 aggregation for the treatment of neurological disorders

[0381] Using the compositions and methods described herein, a PIKfyve inhibitor, such as a small molecule described herein, can be administered to a patient suffering from a neurological disorder to treat the disorder and / or inhibit one or more symptoms associated with the disorder. Exemplary neurological disorders that can be treated using the compositions and methods described herein are, but are not limited to, amyotrophic lateral sclerosis, frontotemporal degeneration, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy, Guam dementia Parkinson's disease ALS complex, Huntington's disease, IBMPFD, sporadic inclusion body myositis, myofibromyopathy, dementia pugilistica, chronic traumatic encephalopathy, Alexander disease, and hereditary inclusion body myopathy, as well as neuromuscular diseases such as congenital myasthenic syndrome, congenital myasthenic syndrome, myopathy, spasticity-fasciculation syndrome, Duchenne muscular dystrophy, glycogen storage disease type II, hereditary spastic paraplegia, inclusion body myositis, Isaac's syndrome, Kearns-Sayre syndrome, Lambert-Eaton myasthenic syndrome, mitochondrial myopathy, muscular dystrophy, myasthenia gravis, myotonic dystrophy, peripheral neuropathy, spinal and bulbar muscular atrophy, spinal muscular atrophy, stiff-person syndrome, Troyer syndrome, and Guillain–Barré syndrome.

[0382] The present disclosure is based in part on the discovery that PIKfyve inhibitors, such as the agents described herein, can mitigate TDP-43 toxicity. TDP-43-promoted toxicity is associated with various neurological diseases. The discovery that PIKfyve inhibitors modulate TDP-43 aggregation provides important therapeutic benefits. Using PIKfyve inhibitors, such as the PIKfyve inhibitors described herein, patients suffering from neurological disorders or at risk of suffering from such disorders can be treated in a manner that corrects the underlying molecular cause of the disease. Without being limited by mechanism, the compositions and methods described herein can be used to treat or prevent such neurological disorders, for example by inhibiting TDP-43 aggregation that promotes pathology.

[0383] In addition, the compositions and methods described herein provide the beneficial feature of being able to identify and treat patients who may respond to PIKfyve inhibitor therapy. For example, in some embodiments, if a patient (e.g., a human patient suffering from or at risk of developing a neurological disease described herein such as amyotrophic lateral sclerosis) is identified as likely to respond to this form of treatment, a PIKfyve inhibitor is administered to the patient. Patients may be identified as such based on, for example, susceptibility to TDP-43 aggregation. In some embodiments, patients are identified as likely to respond to PIKfyve inhibitor treatment based on the isoform of TDP-43 expressed by the patient. For example, patients expressing TDP-43 isoforms with mutations selected from Q331K, M337V, Q343R, N345K, R361S, and N390D, etc., are more likely to experience TDP-43-promoted aggregation and toxicity relative to patients who do not express such TDP-43 isoforms. Using the compositions and methods described herein, patients can be identified as likely to respond to PIKfyve inhibitor therapy based on expression of such TDP-43 isoforms, and PIKfyve inhibitors can then be administered to treat or prevent one or more neurological disorders, such as one or more neurological disorders described herein.

[0384] Assessing patient response

[0385] A variety of methods known in the art and described herein can be used to determine whether a patient with a neurological disorder (e.g., a patient at risk for TDP-43 aggregation, such as a patient expressing a mutant form of TDP-43 with a mutation associated with increased TDP-43 aggregation and toxicity, such as a mutation selected from Q331K, M337V, Q343R, N345K, R361S, and N390D) responds positively to PIKfyve inhibition. For example, successful treatment of a patient with a neurological disorder such as amyotrophic lateral sclerosis using a PIKfyve inhibitor described herein can be signaled by:

[0386] (i) improvement in disease, as assessed using the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the Revised ALSFRS (ALSFRS-R), such as an improvement in the patient's ALSFRS or ALSFRS-R score within one or more days, one or more weeks, or one or more months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the PIKfyve inhibitor to the patient, such as an improvement in the patient's ALSFRS or ALSFRS-R score within one or more days, one or more weeks, or one or more months after administration of the PIKfyve inhibitor to the patient 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or more after the first administration of a PIKfyve inhibitor;

[0387] (ii) an increase in slow lung capacity, such as an increase in the patient's slow lung capacity after one or more days, one or more weeks, or one or more months after administration of the PIKfyve inhibitor (e.g., an increase in the patient's slow lung capacity within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the PIKfyve inhibitor to the patient, such as an increase in the patient's slow lung capacity within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or more after the first administration of the PIKfyve inhibitor to the patient , 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer);

[0388] (iii) the patient exhibits a decrease in the decremental response to repeated nerve stimulation, such as a decrease observed one or more days, one or more weeks, or one or more months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the PIKfyve inhibitor to the patient, such as a decrease observed within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or more after the first administration of the PIKfyve inhibitor to the patient 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer);

[0389] (iv) improvement in muscle strength, as assessed, for example, by the Medical Research Council Muscle Testing Scale (as described, for example, in Jagtap et al., Ann. Indian. Acad. Neurol. 17:336-339 (2014), the disclosure of which is incorporated herein by reference as it relates to measuring a patient's response to a treatment for a neurological disease), as observed one or more days, one or more weeks, or one or more months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) after the first administration of the PIKfyve inhibitor to the patient ) or longer, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer after the first administration of the PIKfyve inhibitor to the patient;

[0390] (v) an improvement in quality of life, as assessed, for example, using an amyotrophic lateral sclerosis-specific quality of life (ALS-specific QOL) questionnaire, such as an improvement in the subject's quality of life observed within one or more days, one or more weeks, or one or more months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the PIKfyve inhibitor to the patient, such as an improvement in the subject's quality of life observed within one or more days, one or more weeks, or one or more months after the first administration of the PIKfyve inhibitor to the patient 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or more after the preparation);

[0391] (vi) a decrease in the frequency and / or severity of muscle spasms, such as a decrease in the frequency and / or severity of spasms within one or more days, one or more weeks, or one or more months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the PIKfyve inhibitor to the patient, such as a decrease in the frequency and / or severity of spasms within one day, two days, three days, four days, or one month after the first administration of the PIKfyve inhibitor to the patient. 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or more); and / or

[0392] (vii) TDP-43 aggregation is reduced, such as TDP-43 aggregation is reduced within one or more days, one or more weeks, or one or more months after administration of the PIKfyve inhibitor (e.g., within about 1 day to about 48 weeks (e.g., within about 2 days to about 36 weeks, within about 4 weeks to about 24 weeks, within about 8 weeks to about 20 weeks, or within about 12 weeks to about 16 weeks) or longer after the first administration of the PIKfyve inhibitor to the patient, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days after the first administration of the PIKfyve inhibitor to the patient , 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks or longer).

[0393] Combination preparations and their uses

[0394] The compounds of the invention may be combined with one or more therapeutic agents. In particular, the therapeutic agent may be a therapeutic agent for the treatment or prophylactic treatment of any of the neurological disorders described herein.

[0395] Combination therapy

[0396] The compounds of the present invention can be used alone or in combination with other agents for treating a nervous system disorder or symptoms associated therewith, or in combination with other types of treatments to treat, prevent any nervous system disorder and / or reduce the risk of any nervous system disorder. In a combined therapy, the dosage of one or more therapeutic compounds can be reduced from the standard dosage when administered alone. For example, the dosage can be determined empirically from drug combinations and permutations or can be derived by isobolometric analysis (e.g., Black et al., Neurology 65: S3-S6, 2005). In this case, the dosage of the compound should provide a therapeutic effect when used in combination.

[0397] Pharmaceutical composition

[0398] The compounds of the invention are preferably formulated into pharmaceutical compositions for administration to human subjects in a biocompatible form suitable for in vivo administration. Thus, in another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention admixed with a suitable diluent, carrier or excipient.

[0399] The compound of the present invention can be used in the form of free alkali, in the form of salt, solvate and as a prodrug. All forms are within the scope of the present invention. According to the method of the present invention, the described compound or its salt, solvate or prodrug can be applied to the patient in various forms, specifically depending on the selected route of administration, as will be understood by those skilled in the art. The compound of the present invention can be applied, for example, by oral, parenteral, oral, sublingual, nasal, rectal, patch, pump or transdermal administration, and the pharmaceutical composition is formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, epithelial, nasal, intrapulmonary, intrathecal, rectal and topical administration. Parenteral administration can be carried out by continuous infusion in a selected time period.

[0400] The compounds of the present invention can be administered orally, for example, with an inert diluent or with an assimilable edible carrier, or can be enclosed in a hard or soft shell gelatin capsule, or can be compressed into tablets, or can be directly mixed with the food of the diet. For oral therapeutic administration, the compounds of the present invention can be mixed with excipients and used in the form of ingestible tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups and wafers.

[0401] The compounds of the present invention may also be administered parenterally. Solutions of the compounds of the present invention may be prepared in water appropriately mixed with a surfactant. Dispersions may also be prepared in glycerol, liquid polyethylene glycol, DMSO and mixtures thereof with or without alcohol and in oil. Under general storage and use conditions, these preparations may contain preservatives to prevent the growth of microorganisms. Conventional procedures and ingredients for selecting and preparing suitable preparations are described in, for example, Remington's Pharmaceutical Sciences (2003, 20th edition) and The United States Pharmacopeia: The National Formulary (USP 24NF19) published in 1999.

[0402] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid in the sense of being easily administerable via syringe.

[0403] Compositions for nasal administration can be conveniently formulated as aerosols, drops, gels and powders. Aerosol preparations generally include solutions or fine suspensions of active substances in physiologically acceptable aqueous or non-aqueous solvents, and are generally present in a sealed container in a sterile form with a single dose or multiple doses, which can be in the form of a cartridge or a continuous medicine package used with an atomizing device. Alternatively, the sealed container can be a single dispensing device, such as a single dose nasal inhaler or an aerosol dispenser equipped with a metering valve, which is intended to be discarded after use. In the case where the dosage form includes an aerosol dispenser, it will contain a propellant, which can be a compressed gas such as compressed air or an organic propellant such as fluorochlorocarbons. Aerosol dosage forms can also be in the form of a pump-atomizer.

[0404] Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, in which the active ingredient is formulated with carriers such as sugar, acacia, tragacanth, gelatin and glycerol. Compositions for rectal administration are usually in the form of suppositories containing conventional suppository bases such as cocoa butter.

[0405] The compounds of the invention can be administered to animals, such as humans, alone or in combination with a pharmaceutically acceptable carrier as described herein, the proportion of the carrier being determined by the solubility and chemical properties of the compound, the chosen route of administration, and standard pharmaceutical practice.

[0406] dose

[0407] The dosage of the compound of the present invention and / or the composition comprising the compound of the present invention may vary with many factors, such as the pharmacodynamic properties of the compound; the mode of administration; the age, health status and weight of the recipient; the nature and extent of the symptoms; the frequency of treatment and the type of concurrent treatment (if any); and the clearance rate of the compound in the animal to be treated. Those skilled in the art can determine the appropriate dosage based on the above factors. The compound of the present invention may be initially administered at a suitable dose, which may be adjusted as needed according to the clinical response. In general, when the compound of the present invention is administered to a human at a daily dose of, for example, between 0.05 mg and 3000 mg (measured in solid form), satisfactory results may be obtained. The dosage range includes, for example, between 10-1000 mg.

[0408] Alternatively, the patient's body weight may be used to calculate the dosage amount.For example, the dosage of the compound or its pharmaceutical composition administered to the patient may be in the range of 0.1-50 mg / kg.

[0409] The following examples are intended to illustrate the present invention. They are not intended to limit the present invention in any way.

[0410] Example

[0411] List of abbreviations:

[0412]

[0413]

[0414]

[0415] Synthesis of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 1):

[0416]

[0417] Step 1: Synthesis of 5-allylpyrimidine-2,4,6(1H,3H,5H)-trione.

[0418] To a solution of 2-allylmalonate (40.0g, 200.0mmol) and urea (12.0g, 200.0mmol) in ethanol (150mL), sodium ethoxide (20%, in ethanol) (80mL) was added and the mixture was heated to 85°C for 3 hours. The resulting mixture was cooled to 20°C and acetone (150mL) was added. After stirring for 10 minutes, the resulting precipitate was collected by filtration, washed with petroleum ether (150mL) and then dissolved in water (150mL). The pH of the resulting solution was adjusted to between 3-4 with concentrated HCl to obtain a precipitate, which was stirred for 10 minutes. The solid was collected by filtration and dried under high vacuum to obtain 5-allylpyrimidine-2,4,6 (1H, 3H, 5H) -trione (17.0g, 51%) as a brown solid. 1 H NMR (400MHz, DMSO-d6) δ11.25 (s, 2H), 5.63-5.73 (m, 1H), 5.03 (dd, J=12.0Hz, J=3. 6Hz,2H),3.68(t,J=5.2Hz,1H),2.66(t,J=5.62Hz,2H); LCMS(ESI)m / z:169.1[M+H] + .

[0419] Step 2: Synthesis of 5-allyl-2,4,6-trichloropyrimidine.

[0420] N, N-dimethylaniline (8.5 mL) was added to a solution of 5-allyl pyrimidine-2,4,6 (1H, 3H, 5H)-trione (17.0 g, 101.2 mmol) in phosphorus oxychloride (60 mL) and the solution was heated to 110 ° C for 4 hours. The dark solution was then cooled to 20 ° C and concentrated. Ethyl acetate (300 mL) and ice water (200 mL) were added to the residue, the organic phase was separated and washed with brine (200 mL), dried, concentrated to give a crude product. It was purified by column chromatography (petroleum ether: ethyl acetate from 20: 1 to 10: 1) to give 5-allyl-2,4,6-trichloropyrimidine (16.0 g, 71%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ5.79-5.89 (m, 1H), 5.11-5.21 (m, 2H), 3.63 (dt, J = 6.0Hz, J = 1.6Hz, 2H); LCMS (ESI) m / z: 223.1 [M+H] + .

[0421] Step 3: Synthesis of 2-(2,4,6-trichloropyrimidin-5-yl)acetaldehyde.

[0422] To a solution of 5-allyl-2,4,6-trichloropyrimidine (10.0 g, 44.7 mmol), potassium osmate (VI) dihydrate (330 mg, 0.89 mmol) and 4-methylmorpholine N-oxide (20.96 g, 89.4 mmol) in acetone (150 mL) and water (150 mL) was added sodium periodate (38.3 g, 178.8 mmol) at 0 ° C and the mixture was stirred at 0-20 ° C for 17 hours. The resulting mixture was filtered, the filtrate was concentrated to remove acetone, and the aqueous phase was extracted with ethyl acetate (150 mL×2). The organic layers were combined, washed with brine (150 mL), dried, and concentrated to give a crude product. It was then purified by silica gel chromatography (petroleum ether: acetate from 10:1 to 3:1) to give 2-(2,4,6-trichloropyrimidin-5-yl) acetaldehyde (5.9 g, 59%) as a gray solid. 1 H NMR (400MHz, CDCl3) δ9.80 (s, 1H), 4.14 (s, 2H).

[0423] Step 4: Synthesis of 2,4-dichloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine.

[0424] To a solution of 2-(2,4,6-trichloropyrimidin-5-yl)acetaldehyde (2.2 g, 9.76 mmol) and aniline (1.09 g, 11.71 mmol) in methanol (60 mL) was added acetic acid (1.0 mL) and sodium cyanoborohydride (1.23 g, 19.52 mmol) at 0°C. The resulting mixture was stirred between 0 and 20°C for 17 hours. Water (60 mL) was added to the mixture and the resulting precipitate was collected by filtration after 10 minutes and dried in vacuo to give 2,4-dichloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (2.0 g, 77%) as a white solid. 1 H NMR (400MHz, CDCl3) δ7.69 (dd, J=8.8Hz, J=1.2Hz, 2H), 7.39-7.44 (m, 2H), 7.16 (t, J= 7.2Hz,1H),4.21(t,J=8.8Hz,2H),3.17(t,J=8.8Hz,2H); LCMS(ESI)m / z:266.1[M+H] + .

[0425] Step 5: Synthesis of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0426] A solution of 2,4-dichloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.376 mmol) and morpholine (164 mg, 1.88 mmol) in tetrahydrofuran (10 mL) was heated to 50 ° C for 17 hours. The mixture was concentrated to dryness, and acetonitrile (5 mL) and water (20 mL) were subsequently added to the residue. The resulting precipitate was collected by filtration and dried in vacuo to give 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (67 mg, 56%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ7.78(d,J=7.6Hz,2H),7.39(t,J=6.8Hz,J=2.0Hz,2H),7.06(t,J=7.2H z, 1H), 4.10 (t, J = 8.8Hz, 2H), 3.65 (s, 8H), 2.99 (t, J = 8.8Hz, 2H); LCMS (ESI) m / z: 317.1 [M+H]+.

[0427] Synthesis of 4-(7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 2):

[0428]

[0429] Step 1a: Synthesis of morpholine-4-carboximidamide hydrochloride.

[0430] To a solution of morpholine (1.74 g, 20.00 mmol) and 1H-pyrazole-1-carboximide amide hydrochloride (2.92 g, 20.00 mmol) in N,N-dimethylformamide (5 mL) was added N,N-diisopropylethylamine (2.58 g, 20.00 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 hours and ether (50 mL) was added to the mixture. The oily product at the bottom of the flask was solidified by repeated ultrasonic treatment and fresh ether. The solid was then collected by filtration and dried to give morpholine-4-carboximide amide hydrochloride (3 g, 91%) as a white solid. LCMS (ESI) m / z: 130.1 [M+H] + .

[0431] Step 1: Synthesis of methyl 2-oxotetrahydrofuran-3-carboxylate.

[0432] To lithium hexamethyldisilazide (1.0M in tetrahydrofuran, 80.0mL, 80.0mmol) was added dropwise a solution of dihydrofuran-2(3H)-one (3.36g, 39.02mmol) in tetrahydrofuran (5mL) at -78°C. After stirring at -78°C for 10 minutes, dimethyl carbonate (3.69g, 40.98mmol) was added at the same temperature. The reaction mixture was warmed and stirred at room temperature for 16 hours. It was then poured onto a mixture of concentrated hydrochloric acid (15mL) and ice (150mL), followed by extraction with ethyl acetate (200mLx 2). The organic layer was washed with brine, dried over sodium sulfate and concentrated to give methyl 2-oxotetrahydrofuran-3-carboxylate (4.9g, 87%). LCMS (ESI) m / z: 144.9 [M+H] + .

[0433] Step 2: Synthesis of 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine.

[0434] Morpholine-4-carboximidamide hydrochloride (575 mg, 3.47 mmol) was added to a solution of 2-oxotetrahydrofuran-3-formic acid methyl ester (500 mg, 3.47 mmol) and sodium methoxide (287 mg, 5.31 mmol) in methanol (5 mL) at room temperature. The reaction mixture was refluxed for 2 hours and concentrated. The resulting residue was dissolved in phosphorus oxychloride (5 mL) and heated at 100 ° C for 16 hours under stirring. The reaction mixture was then added dropwise to water (100 mL) and then neutralized with a 5M aqueous sodium hydroxide solution. It was extracted with ethyl acetate (50 mL x 2), the organic layers were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The resulting crude product was purified by silica gel column chromatography (n-hexane / ethyl acetate=10 / 1) to give 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (236 mg, 23%) as a white solid. LCMS (ESI) m / z: 298.0 [M+H] + .

[0435] Step 3: Synthesis of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0436] To a solution of sodium hydride (68 mg, 1.70 mmol) in tetrahydrofuran (2 mL) was added a solution of aniline (157 mg, 1.69 mmol) in tetrahydrofuran (3 mL) at 0°C. The reaction mixture was then refluxed for 2 hours and cooled. 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (100 mg, 0.34 mmol) was then added at room temperature and the resulting mixture was refluxed for 16 hours. It was cooled, then poured into ice water (30 mL) and extracted with ethyl acetate (20 mL x 2). The organic layer was washed with brine (20 mL), dried over sodium sulfate, and concentrated. The resulting crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 9 / 1) to give 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (90 mg, 82%). LCMS (ESI) m / z: 317.0 [M+H] + .

[0437] Step 4: Synthesis of 4-(7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0438] A suspension of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (80 mg, 0.25 mmol) and Pd / C (30 mg) in methanol (10 mL) and ethyl acetate (2 mL) was stirred at room temperature for 30 minutes under a hydrogen atmosphere. The reaction solution was filtered through celite and the filtrate was concentrated. The crude product was purified by PREP-HPLC (SunFire C18, 4.6*50 mm, 3.5 um column Xbridge C18 3.5 μm 4.6×50 mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2 ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (49.2 mg, 70%) as a light yellow solid. 1 HNMR(400MHz,DMSO-d6)δ7.85(s,1H),7.80(d,J=8Hz,2H),7.37(t,J=8Hz,2H),7 .02(t,J=7.6Hz,1H), 4.04(t,J=8.4Hz,2H), 3.64(s,8H), 2.99(t,J=8.4Hz,2H). LCMS(ESI)m / z:283.1[M+H] + .

[0439] Synthesis of 4-(7-(3-fluorophenyl)-4-(pyridin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 3):

[0440]

[0441] Step 1: Synthesis of 4-(4-chloro-7-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0442] NaH (130 mg, 3.25 mmol) was slowly added to a solution of 3-fluoroaniline (181 mg, 1.63 mmol) in THF (20 mL) at 0 ° C. The mixture was stirred at 60 ° C for 2 hours, and then 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (400 mg, 1.35 mmol) was added. The resulting mixture was stirred at 110 ° C for 16 hours and then quenched with saturated NH4Cl aqueous solution (20 mL). The mixture was extracted with EtOAc (50*3 mL), the organic matter was combined, washed with brine (100 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by SGC (PE / EA=1:1) to give 4-(4-chloro-7-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (270 mg, 59%) as a yellow solid. LCMS (ESI) m / z: 335.0 [M+H] + .

[0443] Step 2: Synthesis of 4-(7-(3-fluorophenyl)-4-(pyridin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0444] To a solution of pyridin-3-ylmethanol (86 mg, 0.79 mmol) in THF (20 mL) was added NaH (32 mg, 0.79 mmol) slowly at 0°C. The mixture was stirred at 0°C for 2 hours, and then 4-(4-chloro-7-(3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (220 mg, 0.66 mmol) was added. The resulting mixture was stirred at 110°C for 16 hours and concentrated. The crude product was purified by preparative HPLC (0.05% FA / H2O:CH3CN=5% to 95%) to give 4-(7-(3-fluorophenyl)-4-(pyridin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (47.2 mg, 18%,) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ8.67(s,1H),8.54(d,J=4.0Hz,1H),7.86(d,J=8.0Hz,1H),7.77(d,J=12.8Hz,1H),7.49(d,J=8.4Hz,1H),7.43 –7.33(m,2H),6.81-6.76(m,1H),5.45(s,2H),4.03(t,J=8.8Hz,2H),3.67(s,8H),2.90(t,J=8.8Hz,2H); LCMS(ESI)m / z:408.1[M+H]+.

[0445] Synthesis of 3-(2-morpholino-4-(pyridin-3-ylmethoxy)-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)benzonitrile (Compound 4):

[0446]

[0447] Step 1: Synthesis of 3-(4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)benzonitrile.

[0448] To a suspension of sodium hydride (40 mg, 1.0 mmol) in tetrahydrofuran (10 mL) was added 3-aminobenzonitrile (48 mg, 0.405 mmol) at 0°C. The reaction mixture was then refluxed for 1 hour and cooled to room temperature. A solution of 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (100 mg, 0.337 mmol) in THF was added to the mixture, which was then refluxed for another 16 hours. After cooling to room temperature, the reaction mixture was quenched with water (50 mL) and the formed precipitate was collected by filtration, washed with methanol and dried to give 3-(4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)benzonitrile (60 mg, 52%). The crude product was used in the next step without further purification. LCMS (ESI) m / z: 342.0 [M+H] + .

[0449] Step 2: Synthesis of 3-(2-morpholino-4-(pyridin-3-ylmethoxy)-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)benzonitrile.

[0450] To a suspension of sodium hydride (21 mg, 0.525 mmol) in tetrahydrofuran (10 mL) was added pyridin-3-ylmethanol (48 mg, 0.440 mmol) at room temperature and stirred for 10 minutes. Then 3-(4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)benzonitrile (60 mg, 0.176 mmol) was added. The resulting mixture was refluxed for 12 hours and cooled. Water (30 mL) was added to the mixture and the solid formed was collected by filtration to give a crude product. It was then purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 3-(2-morpholino-4-(pyridin-3-ylmethoxy)-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)benzonitrile (11.3mg, 16%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ8.67(s,1H),8.53(d,J=4.8Hz,1H),8.16(d,J=8Hz,1H),8.12(s,1H),7.85(d,J=8Hz, 1H),7.55(s,1H),7.43-7.39(m,2H),5.45(s,2H),4.06(t,J=8.6Hz,2H),3.67(s,8H),2.92(t,J=8.6Hz,2H). LCMS(ESI)m / z:415.0[M+H] + .

[0451] Synthesis of tert-butyl 4-(2-morpholino-4-(pyridin-3-ylmethoxy)-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)piperidine-1-carboxylate (Compound 5) and 4-(7-(piperidin-4-yl)-4-(pyridin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 6):

[0452]

[0453] Step 1: Synthesis of tert-butyl 4-(6-chloro-5-(2-chloroethyl)-2-morpholinopyrimidin-4-ylamino)piperidine-1-carboxylate.

[0454] To a stirred solution of 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (100 mg, 0.337 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate (135 mg, 0.674 mmol) in acetonitrile (5 mL) at room temperature was added DIPEA (109 mg, 0.843 mmol) and the resulting mixture was refluxed for 16 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (50 mL), washed with water (20 mL), brine (20 mL), dried over sodium sulfate, filtered and concentrated to give tert-butyl 4-(6-chloro-5-(2-chloroethyl)-2-morpholinopyrimidin-4-ylamino)piperidine-1-carboxylate (100 mg, 64%) as a white solid. The material was used in the next step without further purification. LCMS (ESI) m / z: 460.1 [M+H] + .

[0455] Step 2: Synthesis of tert-butyl 4-(4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)piperidine-1-carboxylate.

[0456] To a mixture of tert-butyl 4-(6-chloro-5-(2-chloroethyl)-2-morpholinopyrimidin-4-ylamino)piperidine-1-carboxylate (100 mg, 0.217 mmol) and sodium iodide (7 mg, 0.047 mmol) in acetonitrile (10 mL) was added cesium carbonate (177 mg, 0.543 mmol) at room temperature. The resulting mixture was refluxed under a nitrogen atmosphere for 4 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (80 mL), washed with water (30 mL) and brine (30 mL). The organics were dried over sodium sulfate, filtered and concentrated. The resulting crude product was purified by silica gel column chromatography, eluting with petroleum ether / ethyl acetate = 9 / 1 and then 3 / 1 to give tert-butyl 4-(4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)piperidine-1-carboxylate (20 mg, 22%) as a white solid. LCMS (ESI) m / z: 424.3 [M+H] + .

[0457] Step 3: Synthesis of tert-butyl 4-(2-morpholino-4-(pyridin-3-ylmethoxy)-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)piperidine-1-carboxylate.

[0458] A suspension of pyridine-3-ylmethanol (10 mg, 0.092 mmol) and sodium hydride (5 mg, 0.125 mmol) in tetrahydrofuran (3 mL) was stirred at room temperature for 10 minutes, followed by the addition of tert-butyl 4-(4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidine-7(6H)-yl)piperidine-1-carboxylate (20 mg, 0.047 mmol). The reaction mixture was then refluxed for 72 hours and cooled. It was then diluted with ethyl acetate (80 mL), washed with water (30 mL x 2) and brine (20 mL), dried over sodium sulfate, filtered and concentrated. The obtained crude product was purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C183.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, the flow rate was 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give tert-butyl 4-(2-morpholino-4-(pyridin-3-ylmethoxy)-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)piperidine-1-carboxylate (14.6mg, 62%) as a white solid. 1 H NMR (400MHz, MeOD) δ8.60(d,J=1.6Hz,1H),8.47(dd,J=5.2,1.6Hz,1H),7.90(dt,J=8.0,1.6Hz,1H),7.44(dd,J=8.0,0.8Hz,1H),5.42(s,2H ), 4.18 (d, J = 12.4Hz, 2H), 4.03 (pent, J = 7.6Hz, 1H), 3.68 (s, 8H), 3.54 (t, J = 8.4Hz, 2H), 2.82-2.78 (m, 4H), 1.73-1.68 (m, 4H), 1.48 (s, 9H). LCMS(ESI)m / z:497.1[M+H] + .

[0459] Step 4: Synthesis of 4-(7-(piperidin-4-yl)-4-(pyridin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0460] To a solution of tert-butyl 4-(2-morpholino-4-(pyridin-3-ylmethoxy)-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)piperidine-1-carboxylate (60 mg, 0.121 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) at room temperature. After stirring at room temperature for 2 hours, the reaction mixture was concentrated. The residue was subjected to preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(7-(piperidin-4-yl)-4-(pyridin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (9.5mg, 20%) as a white solid. 1 H NMR (400MHz, CD3OD) δ8.60(s,1H),8.48(d,J=4.4Hz,1H),7.90(d,J=8.0Hz,1H),7.44(dd,J=8.0,4.8Hz,1H),5.42(s, 2H), 4.08-4.03 (m, 1H), 3.69 (s, 8H), 3.58 (t, J = 8.0Hz, 2H), 3.32-3.30 (m, 2H), 2.91-2.80 (m, 4H), 1.90-1.81 (m, 4H). LCMS(ESI)m / z:397.1[M+H] + .

[0461] The following compounds were synthesized according to the scheme described above:

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469] Synthesis of 4-(7-(pyridin-3-yl)-4-((tetrahydrofuran-2-yl)methoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 23):

[0470]

[0471] Step 1: Synthesis of 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0472] To a suspension of sodium hydride (202 mg, 5.06 mmol) in tetrahydrofuran (10 mL) was added a solution of pyridine-3-amine (238 mg, 2.53 mmol) in tetrahydrofuran (15 mL) at 0 ° C. The reaction mixture was then refluxed for 1 hour. After cooling to room temperature, 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (500 mg, 1.69 mmol) was added and the mixture was refluxed for another 16 hours. The reaction mixture was then poured into ice water (50 mL) and extracted with ethyl acetate (50 mL x 2). The organic layer was washed with brine (40 mL), dried over sodium sulfate, filtered and concentrated. The obtained residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 3 to 0 / 100) to give 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (400 mg, 74%). LCMS (ESI) m / z: 318.1 [M+H] + .

[0473] Step 2: Synthesis of 4-(7-(pyridin-3-yl)-4-((tetrahydrofuran-2-yl)methoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0474] To a solution of sodium hydride (38 mg, 0.95 mmol) in tetrahydrofuran (5 mL) was added a solution of (tetrahydrofuran-2-yl)methanol (80 mg, 0.78 mmol) in THF (3 mL) at 0°C. After stirring at room temperature for 10 minutes, 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 0.31 mmol) was added. The resulting reaction mixture was refluxed for 12 hours. After cooling, the reaction mixture was diluted with ethyl acetate (80 mL), washed with water (30 mL x 2) and brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5umcolumn Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(7-(pyridin-3-yl)-4-((tetrahydrofuran-2-yl)methoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (28.8mg, 24%) as a white solid. 1 H NMR(400MHz,DMSO-d6)δ8.99(d,J=2.4hz,1H),8.18-8.15(m,2H),7.36(dd,J=8.4,4.4Hz,1H),4.30-4.22(m,2H),4.2 0-4.13(m,1H),4.04(t,J=8.6hz,2H),3.80-3.75(m,1H),2.90(t,J=8.6hz,2H),1.99-1.81(m,3H),1.70-1.64(m,1H). LCMS(ESI)m / z:384.1[M+H] + .

[0475] Synthesis of 4-(7-phenyl-4-(pyridin-2-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 24):

[0476]

[0477] To a solution of pyridin-2-ylmethanol (52 mg, 0.47 mmol) in dry THF (10 mL) was added NaH (28 mg, 0.71 mmol) and the mixture was stirred at 0 ° C for 15 minutes. Then a solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (150 mg, 0.47 mmol) in THF (5 mL) was added and the resulting mixture was stirred at 100 ° C for another 16 hours. The reaction was quenched with ice water (20 mL) and extracted with EtOAc (20 mL*3). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by preparative HPLC to give 4-(7-phenyl-4-(pyridin-2-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (28.4 mg, 16%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ8.54(dd,J=4.8,0.8Hz,1H),7.82-7.78(m,1H),7.76(s,1H),7.74(s,1H),7.42(d,J=8.0Hz,1H),7.36-7.2 9(m,3H),6.97(t,J=7.2Hz,1H),5.44(s,2H),4.04(t,J=8.8Hz,2H),3.59(s,8H),2.94(t,J=8.8Hz,2H); LCMS(ESI)m / z:390.3[M+H] + .

[0478] The following compounds were synthesized according to the scheme described above:

[0479]

[0480]

[0481]

[0482]

[0483] Synthesis of tert-butyl 3-(((2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)pyrrolidine-1-carboxylate (Compound 33), 4-(7-(pyridin-3-yl)-4-(pyrrolidin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 34), and 4-(4-((1-methylpyrrolidin-3-yl)methoxy)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 35):

[0484]

[0485] Step 1: Synthesis of tert-butyl 3-(((2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)pyrrolidine-1-carboxylate.

[0486] To a solution of tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (84 mg, 0.42 mmol) in THF (15 mL) was carefully added NaH (30 mg, 0.76 mmol) at 0°C. The mixture was stirred at room temperature for 15 minutes, and then 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (120 mg, 0.38 mmol) was added. The resulting mixture was stirred at 100°C for another 16 hours. It was quenched with water (10 mL) and extracted with EA (30*3 mL). The organic layer was washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by SGC (PE / EA=1:1 to 0:1) to give tert-butyl 3-(((2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)pyrrolidine-1-carboxylate (135 mg, 74%) as a white solid. 1 H NMR (400MHz, CDCl3) δ9.05(d,J=2.4Hz,1H),8.23(d,J=4.0Hz,1H),8.06(d,J=9 .2Hz,1H),7.28(s,1H),4.35-4.27(m,2H),4.04(t,J=8.4Hz,2H),3.62(s,8H), 3.60-3.34(m,3H),3.22-3.16(m,1H),3.03-2.97(m,2H),2.69-2.64(m,1H),2. 10-2.04(s,1H),1.82-1.74(m,1H),1.49(s,9H); LCMS(ESI)m / z:483.3[M+H]+.

[0487] Step 2: Synthesis of 4-(7-(pyridin-3-yl)-4-(pyrrolidin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0488] To a solution of tert-butyl 3-(((2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)pyrrolidine-1-carboxylate (120 mg, 0.25 mmol) in DCM (5 mL) was added TFA (1 mL) at 0°C. The mixture was stirred at room temperature for 2 hours and concentrated. The resulting residue was purified by preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5%~95%) to give 4-(7-(pyridin-3-yl)-4-(pyrrolidin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (16.8 mg, 63%,) as a white solid. 1 H NMR (400MHz, CDCl3) δ9.06 (d, J = 2.4Hz, 1H), 8.24 (d, J = 4.4Hz, 1H), 8.10 (d, J = 10.0Hz, 1H),7.28(s,1H),4.31(dd,J=10.8,6.0Hz,1H),4.23(dd,J=10.8,8.0Hz,1H),4.04(t, J=8.4Hz,2H),3.78(s,8H),3.13-3.10(m,1H),3.08-2.93(m,4H),2.82-2.77(m,1H),2 .60-2.53(m,1H),2.01-1.95(m,1H),1.60-1.53(m,1H); LCMS(ESI)m / z:383.1[M+H]+.

[0489] Step 3: Synthesis of 4-(4-((1-methylpyrrolidin-3-yl)methoxy)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0490] To a solution of 4-(7-(pyridin-3-yl)-4-(pyrrolidin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (30 mg, 0.076 mmol) in methanol (5 mL) was added formaldehyde (2.5 mg, 0.083 mmol). The mixture was stirred at room temperature for 2 hours, and then sodium cyanoborohydride (24 mg, 0.38 mmol) was added to the mixture. It was then stirred at room temperature for 12 hours. The reaction was then quenched with water (5 mL) and extracted with EA (20*3 mL). The organic layer was washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5%~95%) to give 4-(4-((1-methylpyrrolidin-3-yl)methoxy)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (8.7 mg, 28%) as a white solid. 1 H NMR(400MHz, CDCl3) δ9.06(d,J=2.4Hz,1H),8.25(d,J=3.6Hz,1H),8.09(d,J=9 .6Hz,1H),7.28(s,1H),4.33-4.23(m,2H),4.04(t,J=8.4Hz,2H),3.78(s,8H),3 .00(t,J=8.4Hz,2H),2.85-2.83(m,1H),2.75-2.64(m,3H),2.53-2.49(m,1H),2 .45(s,3H),2.13-2.03(m,1H),1.87-1.66(m,1H); LCMS(ESI)m / z:397.2[M+H]+.

[0491] The following compounds were synthesized according to the scheme described above:

[0492]

[0493]

[0494]

[0495] Synthesis of 2-methyl-1-(4-((1-methylpiperidin-3-yl)methoxy)-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)propan-2-ol (Compound 40):

[0496]

[0497] Step 1: Synthesis of 1-(6-chloro-5-(2-chloroethyl)-2-morpholinopyrimidin-4-ylamino)-2-methylpropan-2-ol.

[0498] To a stirred solution of 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (200 mg, 0.674 mmol) and 1-amino-2-methylpropane-2-ol (60 mg, 0.674 mmol) in acetonitrile (20 mL) was added N-ethyl-isopropylpropane-2-amine (218 mg, 1.687 mmol) at room temperature. The reaction mixture was then refluxed for 48 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (100 mL), washed with water (30 mL) and brine (30 mL). The organics were dried over sodium sulfate, filtered and concentrated to give 1-(6-chloro-5-(2-chloroethyl)-2-morpholinopyrimidin-4-ylamino)-2-methylpropane-2-ol (200 mg, 85%) as a brown solid. LCMS (ESI) m / z: 348.9 [M+H] + .

[0499] Step 2: Synthesis of 1-(4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)-2-methylpropan-2-ol.

[0500] To a solution of 1-(6-chloro-5-(2-chloroethyl)-2-morpholinopyrimidin-4-ylamino)-2-methylpropane-2-ol (200 mg, 0.573 mmol) and sodium iodide (17 mg, 0.113 mmol) in acetonitrile (20 mL) was added cesium carbonate (466 mg, 1.43 mmol) at room temperature. The reaction mixture was refluxed under a nitrogen atmosphere for 4 hours, cooled and then diluted with ethyl acetate (150 mL). The mixture was washed with water (50 mL), brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography, eluting with dichloromethane / methanol = 9 / 1 to give 1-(4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)-2-methylpropane-2-ol (100 mg, 55%) as a white solid. LCMS (ESI) m / z: 313.1 [M+H] + .

[0501] Step 3: Synthesis of 2-methyl-1-(4-((1-methylpiperidin-3-yl)methoxy)-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)propan-2-ol.

[0502] A suspension of (1-methylpiperidin-3-yl)methanol (83 mg, 0.64 mmol) and sodium hydride (32 mg, 0.8 mmol) in tetrahydrofuran (10 mL) was stirred at room temperature for 10 minutes, and then 1-(4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)-2-methylpropane-2-ol (100 mg, 0.32 mmol) was added. The resulting mixture was refluxed for 48 hours and cooled. It was then diluted with ethyl acetate (80 mL), washed with water (30 mL) and brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude product was purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 2-methyl-1-(4-((1-methylpiperidin-3-yl)methoxy)-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)propan-2-ol (14mg, 11%) as a light yellow solid. 1 H NMR(500MHz,MeOD)δ6.03(s,1H),4.17-4.07(m,2H),3.73-3.61(m,10),3.22(s,2H),2.93-2.77(m ,4H),2.27(s,3H),2.07(bs,1H),1.95-1.89(m,1H),1.76-1.57(m,4H),1.23(s,6H),1.00(m,1H). LCMS(ESI)m / z:406.2[M+H] + .

[0503] Synthesis of 4-(4-chloro-7-(3-methylbenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 41):

[0504]

[0505] A mixture of 2,4-dichloro-7-(3-methylbenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine (2.0 g, 6.80 mmol) and morpholine (2.96 g, 34.0 mmol) in tetrahydrofuran (40 mL) was heated to 35 °C for 17 hours and concentrated to dryness. MeOH (40 mL) and water (40 mL) were added to the residue and stirred. The resulting precipitate was collected by filtration and dried in vacuo to give 4-(4-chloro-7-(3-methylbenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (2.0 g, 85%). 1 H NMR(400MHz,DMSO-d6)δ7.23(t,J=8.0Hz,2H),7.05-7.10(m,3H),4.48(s,2H),3.61(s,8H) ), 3.48 (t, J = 8.4Hz, 2H), 2.85 (t, J = 8.4Hz, 2H), 2.29 (s, 3H); LCMS (ESI) m / z: 345.1 [M+H]+.

[0506] Synthesis of 4-(7-(1-methylpiperidin-4-yl)-4-(pyridin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 42):

[0507]

[0508] Step 1: Synthesis of 6-chloro-5-(2-chloroethyl)-N-(1-methylpiperidin-4-yl)-2-morpholinopyrimidin-4-amine.

[0509] To a stirred solution of 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (100 mg, 0.337 mmol) and 1-methylpiperidin-4-amine (38 mg, 0.333 mmol) in acetonitrile (10 mL) at room temperature was added N-ethyl-N-isopropylpropane-2-amine (109 mg, 0.843 mmol). The reaction mixture was then refluxed for 16 hours and cooled. It was diluted with ethyl acetate (80 mL), washed with water (20 mL), brine (20 mL), dried over sodium sulfate, filtered and concentrated to give 6-chloro-5-(2-chloroethyl)-N-(1-methylpiperidin-4-yl)-2-morpholinopyrimidin-4-amine (100 mg, 79%) as a white solid. LCMS (ESI) m / z: 374.0 [M+H] + .

[0510] Step 2: Synthesis of 4-(4-chloro-7-(1-methylpiperidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0511] To a solution of 6-chloro-5-(2-chloroethyl)-N-(1-methylpiperidin-4-yl)-2-morpholinopyrimidin-4-amine (100 mg, 0.267 mmol) and sodium iodide (8 mg, 0.053 mmol) in acetonitrile (20 mL) was added cesium carbonate (218 mg, 0.669 mmol) at room temperature. The resulting mixture was refluxed under a nitrogen atmosphere for 4 hours and cooled. It was diluted with ethyl acetate (150 mL), washed with water (50 mL) and brine (30 mL), dried over sodium sulfate, filtered and concentrated. The resulting crude product was purified by silica gel column chromatography, eluting with dichloromethane / methanol=9 / 1 to give 4-(4-chloro-7-(1-methylpiperidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (30 mg, 0.089 mmol, 33%) as a white solid. LCMS (ESI) m / z: 338.1 [M+H] + .

[0512] Step 3: Synthesis of 4-(7-(1-methylpiperidin-4-yl)-4-(pyridin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0513] To a suspension of sodium hydride (9 mg, 0.225 mmol) in tetrahydrofuran (5 mL) was added pyridin-3-ylmethanol (20 mg, 0.183 mmol) at room temperature and stirred for 10 minutes. Then to the mixture was added a solution of 4-(4-chloro-7-(1-methylpiperidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (30 mg, 0.089 mmol) in THF and the resulting mixture was refluxed for 48 hours. It was cooled, diluted with ethyl acetate (80 mL), washed with water (30 mL) and brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude product was purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(7-(1-methylpiperidin-4-yl)-4-(pyridin-3-ylmethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (14.5mg, 40%) as a white solid. 1H NMR(400MHz,DMSO-d6)δ8.61(d,J=1.6Hz,1H),8.50(dd,J=4.8,1.2Hz,1H),7 .80(d,J=8.0Hz,1H),7.39(dd,J=7.6,4.8Hz,1H),5.35(s,2H),3.74-3.70(m ,1H),3.59(s,8H),3.48(t,J=8.4Hz,2H),2.82-2.79(m,2H),2.71(t,J=8.4H z,2H),2.15(s,3H),1.94-1.89(m,2H),1.74-1.68(m,2H),1.56-1.53(m,2H). LCMS (ESI) m / z: 411.3 [M+H] + .

[0514] Synthesis of 3-((2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)propane-1,2-diol (Compound 43):

[0515]

[0516] Step 1: Synthesis of 4-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0517] To a suspension of sodium hydride (27 mg, 0.68 mmol) in THF (5 mL) at 0°C was added a solution of (2,2-dimethyl-1,3-dioxolan-4-yl)methanol (90 mg, 0.68 mmol) in THF (5 mL). The reaction mixture was refluxed for 2 hours and cooled. A solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 0.34 mmol) in 3 mL of THF was then added and the resulting mixture was stirred at reflux for 16 hours. The reaction mixture was then diluted with ethyl acetate (30 mL) and the resulting organic medium was washed with brine (10 mL), dried over sodium sulfate and concentrated to give 100 mg of the target compound. It was used in the next step without further purification.

[0518] Step 2: Synthesis of 3-((2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)propane-1,2-diol.

[0519] A solution of 4-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 0.24 mmol) in water (1 mL) and acetic acid (5 mL) was stirred overnight at 80° C. The resulting mixture was concentrated and the crude product was purified by preparative HPLC to give the title compound as a white solid, 5.2 mg. 1 H NMR (400MHz, DMSO-d6) δ7.76(d,J=8.0Hz,2H),7.34(t,J=7.6Hz,2H),6.97(t,J=7.6Hz,1H),4.87(d,J=5.2Hz 1H),4.64(t,J=8.8Hz,1H),4.25~4.30(m,1H),4.00~4.15(m,1H),4.02(t,J=8.4Hz,2H),3.75~3.8 0(m,1H),3.67(s,8H),3.40(t,J=5.6Hz,2H),2.88(t,J=9.2Hz,2H); LCMS(ESI)m / z:373.0[M+H]+.

[0520] Synthesis of 4-(7-phenyl-4-(2-(pyridin-2-yl)ethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 44):

[0521]

[0522] Step 1: Synthesis of 4-(4-chloro-5-(2-chloroethyl)-6-(2-(pyridin-2-yl)ethoxy)pyrimidin-2-yl)morpholine.

[0523] To a solution of sodium hydride (270 mg, 6.74 mmol) in DMF (60 mL) was added a solution of 2-(pyridin-2-yl)ethanol (830 mg, 6.74 mmol) in DMF at 0°C. The resulting mixture was warmed and stirred at room temperature for 10 minutes, then 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (2 g, 6.74 mmol) was added. The reaction mixture was stirred at room temperature for another 48 hours. It was quenched with water (200 mL) and extracted with ethyl acetate (300 mL x 2). The organic layers were combined, washed with water (200 mL x 2), brine (200 mL), dried over sodium sulfate, filtered and concentrated. The obtained crude product was purified by silica gel column chromatography, eluting with petroleum ether / ethyl acetate = 3 / 1 to obtain 4-(4-chloro-5-(2-chloroethyl)-6-(2-(pyridin-2-yl)ethoxy)pyrimidin-2-yl)morpholine (1.9 g, 74%) as an off-white solid. LCMS (ESI) m / z: 398.1 [M+16] + .

[0524] Step 2: Synthesis of 4-(7-phenyl-4-(2-(pyridin-2-yl)ethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0525] A mixture of 4-(4-chloro-5-(2-chloroethyl)-6-(2-(pyridin-2-yl)ethoxy)pyrimidin-2-yl)morpholine (100 mg, 0.261 mmol), aniline (49 mg, 0.526 mmol), tris(dibenzylideneacetone)dipalladium (24 mg, 0.026 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (30 mg, 0.052 mmol) and cesium carbonate (170 mg, 0.522 mmol) in dioxane (5 mL) was stirred at 100° C. for 16 hours under nitrogen atmosphere. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (100 mL), washed with water (30 mL×2), brine (30 mL), dried over sodium sulfate, filtered and concentrated. The resulting residue was subjected to silica gel column chromatography (eluted with petroleum ether / ethyl acetate = 2 / 1) and then to preparative HPLC (SunFire C18, 4.6*50 mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2 ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(7-phenyl-4-(2-(pyridin-2-yl)ethoxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (53.8 mg, 51%) as a white solid. 1H NMR(400MHz, DMSO-d6)δ8.50(dd,J=4.8,0.8Hz,1H),7.75-7.70(m,2H),7.35-7.31(m,3H),7.25-7.22(m,1H),6.96(t, J=7.2Hz,1H),4.63(t,J=6.8Hz,2H),3.99(t,J=8.6Hz,2H),3.66(s,8H),3.16(t,J=6.8Hz,2H),2.79(t,J=8.6Hz,2H). LCMS(ESI)m / z:404.2[M+H] + .

[0526] Synthesis of 4-(4-methyl-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 45) and 2-methyl-1-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)propan-2-ol (Compound 46):

[0527]

[0528] Step 1: Synthesis of 4-(4-methyl-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0529] A mixture of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.158 mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborane (40 mg, 0.316 mmol), tris(dibenzylideneacetone)dipalladium (15 mg, 0.016 mmol), tris(dibenzylideneacetone)dipalladium (9 mg, 0.032 mmol) and cesium carbonate (103 mg, 0.316 mmol) in dimethyl sulfoxide (2 mL) and water (0.5 mL) was stirred at 140° C. for 16 hours under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (80 mL), washed with water (40 mL×3), brine (30 mL), dried over sodium sulfate, filtered and concentrated. The obtained crude product was purified by silica gel column chromatography eluting with petroleum ether / ethyl acetate = 6 / 1 to give 4-(4-methyl-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (31.6 mg, 68%). 1HNMR(500MHz,DMSO-d6)δ7.80(d,J=7.5Hz,2H),7.36(dd,J=8.5,7.5Hz,2H),7.00(t, J=7.5Hz,1H),4.03(t,J=8.5Hz,2H),3.64(s,8H),2.95(t,J=8.5Hz,2H),2.13(s,3H). LCMS(ESI)m / z:297.2[M+H] + .

[0530] Step 2: Synthesis of 2-methyl-1-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)propan-2-ol.

[0531] To a stirred solution of 4-(4-methyl-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 0.338 mmol) in tetrahydrofuran (5 mL) at 0°C was added n-butyllithium (0.25 mL, 0.506 mmol) and the resulting mixture was stirred at 0°C for 0.5 hours. Propan-2-one (29 mg, 0.101 mmol) was then added and the mixture was stirred at room temperature for another 2 hours. Water (20 mL) was then added and the mixture was extracted with ethyl acetate (30 mL×3). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude product was purified by preparative HPLC (column Xbridge 21.2*250 mmC18, 10 um, mobile phase A: water (10 mmol / L ammonium bicarbonate) B: acetonitrile) to give 2-methyl-1-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)propan-2-ol (35.7 mg, 30%). 1 H NMR (400MHz, DMSO-d6) δ7.81(d,J=8.4Hz,2H),7.37(t,J=7.6Hz,2H),7.01(t,J=6.4Hz,1H),5.01(s,1H),4.0 3(t,J=8Hz,2H),3.66-3.60(m,8H),3.00(t,J-8.4Hz,2H),2.53(s,2H),1.17(s,6H); LC-MS: m / z=355.2(M+H) + .

[0532] Synthesis of 2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile (Compound 47):

[0533]

[0534] A mixture of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 0.316 mmol), zinc cyanide (74 mg, 0.631 mmol) and bis(tri-tert-butylphosphine)palladium(0) (32 mg, 0.063 mmol) in N,N-dimethylacetamide (4 mL) in a sealed vial was heated at 150 ° C for 0.5 hours under a nitrogen atmosphere with microwave irradiation. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (80 mL), washed with water (40 mL x 3) and brine (30 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The obtained crude product was purified by silica gel column chromatography eluting with petroleum ether / ethyl acetate=6 / 1 to give 2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile (33.0 mg, 34%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ7.81 (d, J = 8.0Hz, 2H), 7.42 (t, J = 8Hz, 2H), 7.12 (s, 1H), 4.16 (t, J = 8.0Hz, 2H), 3.65 (s, 8H), 3.16 (t, J = 8.0Hz, 2H). LCMS(ESI)m / z:308.1[M+H] + .

[0535] Synthesis of 4-(4-methoxy-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 48):

[0536]

[0537] To a solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 0.34 mmol) in methanol (80 mL) was added sodium methoxide (8 mL). The mixture was refluxed overnight and concentrated. The resulting crude product was purified by preparative HPLC to give 4-(4-methoxy-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (18.3) mg as a white solid. 1 H NMR (400MHz, DMSO-d6) δ7.75(d,J=6.8Hz,2H),7.34(t,J=6.0Hz,2H),6.97(t,J=5.6Hz,1H),4.0 1(t,J=6.8Hz,2H),3.85(s,3H),3.67(s,8H),2.86(t,J=6.8Hz,2H); LCMS(ESI)m / z:313[M+H]+.

[0538] Synthesis of 4-(7-phenyl-4-(pyridin-2-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 49) and 1-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyridin-2(1H)-one (Compound 50)

[0539]

[0540] To a solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 0.32 mmol) in DMF (10 mL) was added pyridine-2-ol (33 mg, 0.35 mmol) and K2CO3 (88 mg, 0.64 mmol) and the resulting mixture was stirred at 140 °C for 16 hours. The reaction was then quenched with water (5 mL) and extracted with EtOAc (20*3 mL). The organic layers were combined, washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5%~95%) to give 4-(7-phenyl-4-(pyridin-2-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (9.3 mg, 8%) and 1-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyridin-2(1H)-one (9.0 mg, 8%) as yellow solids.

[0541] Compound 49: 1 H NMR (400MHz, CDCl3) δ8.31 (dd, J=4.8, 1.2Hz, 1H), 7.79-7.75 (m, 3H), 7.41-7.36 (m, 2H), 7.15-7.04 ( m, 3H), 4.07 (t, J = 8.4Hz, 2H), 3.74-3.69 (m, 8H), 2.92 (t, J = 8.4Hz, 2H); LCMS (ESI) m / z: 376.1 [M+H]+.

[0542] Compound 50: 1H NMR (400MHz, CDCl3) δ7.77(d,J=7.6Hz,2H),7.67(dd,J=1.6,6.4Hz,1H),7.43-7.39(m,3H),7.10(t,J=7.6Hz,1H),7.63(d,J=9 .2Hz, 1H), 6.28 (t, J = 6.4Hz, 1H), 4.11 (t, J = 8.4Hz, 2H), 3.81-3.77 (m, 8H), 3.05 (t, J = 8.4Hz, 2H); LCMS (ESI) m / z: 376.1[M+H]+.

[0543] The following compounds were synthesized according to the scheme described above:

[0544]

[0545]

[0546]

[0547] Synthesis of 4-(7-phenyl-4-(pyridin-2-ylmethyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 57):

[0548]

[0549] To n-BuLi (1 mL, 2.5 mmol, 2.5 M hexane solution) was added a solution of 2-methylpyridine (64 mg, 0.7 mmol) in tetrahydrofuran (15 mL) at 0 ° C and stirred for 1 hour. Then a solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (200 mg, 0.64 mmol) in THF was added and the resulting mixture was warmed to room temperature and stirred for 16 hours. The reaction was then quenched with saturated NH4Cl aqueous solution (10 mL) and extracted with EtOAc (15*3 mL). The organic layers were combined, washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative HPLC (0.05% FA / H2O:CH3CN=5%~95%) to give 4-(7-phenyl-4-(pyridin-2-ylmethyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (39.3 mg, 17%) as a white solid.

[0550] 1H NMR (400MHz, DMSO-d6) δ8.47(d,J=4.0Hz,1H),7.80(d,J=8.0Hz,2H),7.74-7.00(m,1H),7.39–7.33(m,3H),7.25-7.22(m,1H) ,7.01(t,J=7.2Hz,1H),4.02(t,J=8.4Hz,2H),3.95(s,2H),3.63(s,8H),2.92(t,J=8.4Hz,2H); LCMS(ESI)m / z:374.3[M+H]+.

[0551] The following compounds were synthesized according to the scheme described above:

[0552]

[0553] Synthesis of 4-(7-phenyl-4-((pyridin-3-yloxy)methyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 59) and 5-hydroxy-1-((2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methyl)pyridin-1-ium-3-ylium (Compound 60):

[0554]

[0555] Step 1: Synthesis of methyl 2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-4-carboxylate.

[0556] A solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (500 mg, 1.578 mmol), triethylamine (479 mg, 4.734 mmol), palladium(II) acetate (36 mg, 0.160 mmol) and 1,1'-bis(diphenylphosphino)ferrocene (131 mg, 0.236 mmol) in methanol (12 mL) and dimethyl sulfoxide (15 mL) was stirred at 80°C for 16 hours under a carbon monoxide atmosphere. After cooling to room temperature, the reaction mixture was filtered through celite, the filtrate was diluted with ethyl acetate (150 mL), and washed with water (40 mL x 3) and brine (30 mL). The organics were dried over sodium sulfate, filtered, concentrated and the resulting crude product was purified by silica gel column chromatography, eluting with PE / EA=3 / 1 to give methyl 2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-4-carboxylate (400 mg, 74%) as a yellow solid. LCMS (ESI) m / z: 341.1 [M+H] + .

[0557] Step 2: Synthesis of (2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methanol.

[0558] To a solution of methyl 2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-4-carboxylate (400 mg, 1.175 mmol) in tetrahydrofuran (20 mL) was added lithium aluminum hydride (1.76 mL, 1.76 mmol) in portions at 0°C. The solution was stirred at 0°C for 1 hour, then quenched with sodium sulfate decahydrate (2 g), filtered through celite and washed with dichloromethane. The filtrate was concentrated to give (2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methanol (170 mg, 46%) as a white solid. LCMS (ESI) m / z: 313.1 [M+H] + The crude product was used in the next step without further purification.

[0559] Step 3: Synthesis of Compound 59 and Compound 60:

[0560] To a solution of triphenylphosphine (118 mg, 0.450 mmol), pyridin-3-ol (43 mg, 0.452 mmol) and (2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methanol (70 mg, 0.224 mmol) in tetrahydrofuran (15 mL) was added DIAD (91 mg, 0.450 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 hour and concentrated. The residue was subjected to preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2 ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give compound 59 (17.7 mg, 20%) and compound 60 (12 mg, 14%) as white solids.

[0561] Compound 59: 1 H NMR(400MHz, DMSO-d6)δ8.36(d,J=2.8Hz,1H),8.20-8.18(m,1H),7.81(d,J=8Hz,2H),7.45-7.32(m ,4H),7.03(t,J=7.6Hz,1H),5.03(s,2H),4.05(t,J=8.4Hz,2H),3.65(s,8H),3.05(t,J=8.4Hz,2H). LCMS(ESI)m / z:390.1[M+H]+ .

[0562] Compound 60: 1 H NMR (400MHz, DMSO-d6) δ7.79(d,J=6.0Hz,2H),7.46-7.43(m,2H),7.38(t,J=6.0Hz,2H),7.29(dd,J=7.2,4.4Hz,1H),7.05( t,J=6.0Hz,1H),6.97-6.94(m,1H),5.23(s,2H),4.09(t,J=6.6Hz,2H),3.59(dd,J=12.0,3.6Hz,8H),3.00(t,J=6.6Hz,2H). LCMS(ESI)m / z:390.1[M].

[0563] Synthesis of 4-(7-phenyl-4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 61):

[0564]

[0565] Step 1: Synthesis of (2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methyl methanesulfonate.

[0566] Methanesulfonyl chloride (37 mg, 0.33 mmol) was added to a solution of (2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methanol (70 mg, 0.22 mmol) and triethylamine (44 mg, 0.44 mmol) in dichloromethane (8 mL) at 0°C. The reaction mixture was stirred at 0°C for 1 hour under a nitrogen atmosphere, then quenched with saturated aqueous sodium bicarbonate solution (10 mL) and extracted with dichloromethane (20 mL*3). The organic layer was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated to give (2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methyl methanesulfonate (70 mg, 72%) as a brown solid. The crude product was used in the next step without further purification. LCMS (ESI) m / z: 391.0 [M+H] + .

[0567] Step 2: Synthesis of 4-(7-phenyl-4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0568] A suspension of tetrahydro-2H-pyran-4-ol (27 mg, 0.27 mmol) and sodium hydride (11 mg, 0.27 mmol) in tetrahydrofuran (10 mL) was stirred at room temperature for 30 minutes, and then (2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methyl methanesulfonate (70 mg, 0.18 mmol) was added to the mixture. The resulting mixture was then stirred at 80 ° C for 16 hours, then quenched with water (10 mL) and extracted with dichloromethane (20*3 mL). The organic layer was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5%~95%) to give 4-(7-phenyl-4-(((tetrahydro-2H-pyran-4-yl)oxy)methyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (4.3 mg, 6%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ7.79(d,J=7.6Hz,2H),7.41-7.37(m,2H),7.07(t,J=7.6Hz,1H),4.46(s,2H),4.06(t,J=8.4Hz,2H),4.01-3.96(m,2H) ,3.78(s,8H),3.69–3.62(m,1H),3.53-3.47(m,2H),3.17(t,J=8.4hz,2 H),2.01-1.97(m,2H),1.71-1.67(m,2H); LCMS(ESI)m / z:397.2[M+H]+.

[0569] Synthesis of 4-(7-phenyl-4-((pyridin-2-ylmethoxy)methyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 62):

[0570]

[0571] To a solution of pyridin-2-ylmethanol (29 mg, 0.27 mmol) in THF (8 mL) was added sodium hydride (11 mg, 0.27 mmol) portionwise at 0°C. The mixture was stirred at 0°C for 30 minutes, followed by the addition of (2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methyl methanesulfonate (70 mg, 0.18 mmol). The resulting mixture was stirred at 80°C for 16 hours, then quenched with water (10 mL) and extracted with dichloromethane (20 mL*3). The organic layer was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5%~95%) to give 4-(7-phenyl-4-((pyridin-2-ylmethoxy)methyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (10.8 mg, 15%) as a white solid. 1 H NMR (400MHz, CDCl3) δ8.59(d,J=4.4Hz,1H),7.79(d,J=8.0Hz,2H),7.74(dt,J=8.0,2.0Hz,1H),7.53(d,J=8.0Hz,1H),7.40(t,J=7.6Hz,2H),7.25-7 .22(m,1H),7.06(t,J=7.6Hz,1H),4.77(s,2H),4.56(s,2H),4.06(t,J=8. 4Hz, 2H), 3.79 (s, 8H), 3.16 (t, J = 8.4Hz, 2H); LCMS (ESI) m / z: 404.1[M+H]+.

[0572] The following compounds were synthesized according to the scheme described above:

[0573]

[0574]

[0575] Synthesis of 4-(7-(5-phenylpyridin-3-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 67):

[0576]

[0577] Step 1: Synthesis of 4-(4-chloro-5-(2-chloroethyl)-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine.

[0578] Sodium hydride (100 mg, 2.5 mmol) was added portionwise to a solution of pyridine-3-ol (122 mg, 1.29 mmol) in dry N,N-dimethylacetamide (8 mL) at 0 ° C. The mixture was stirred at room temperature for 10 minutes, followed by the addition of 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (380 mg, 1.29 mmol) and the mixture was stirred at room temperature for another 2 hours. The reaction was quenched by the addition of water and extracted with ethyl acetate (20 mL * 3), then washed with water (20 mL). The organic layer was dried and concentrated. The residue was subjected to flash chromatography, eluted with 0-50% ethyl acetate / petroleum ether to give 4-(4-chloro-5-(2-chloroethyl)-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine (30 mg, 66%) as a yellow solid. LCMS (ESI) m / z: 354.9 [M+H] + .

[0579] Step 2: Synthesis of 4-(7-(5-phenylpyridin-3-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0580] To a mixture of 5-phenylpyridin-3-amine (34 mg, 0.2 mmol), 4-(4-chloro-5-(2-chloroethyl)-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine (35 mg, 0.1 mmol) in dioxane (10 mL) was added cesium carbonate (98 mg, 0.3 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.01 mol, 9 mg) and xantphos (12 mg, 0.02 mmol). The resulting mixture was stirred at 100° C. for 16 hours under an argon atmosphere. Ethyl acetate (40 mL) was added to the mixture and washed with water (10 mL*2). The organic layer was dried and concentrated and the residue was subjected to preparative HPLC (BOSTON pHlex ODS 10um 21.2×250mm 120A. Mobile phase was acetonitrile / 0.1% formic acid) to give 4-(7-(5-phenylpyridin-3-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (25 mg, 55%) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ8.98(d,J=2.0Hz,1H),8.59-8.55(m,2H),8.49(d,J=2.4Hz,1H),8.43(dd,J=4.8Hz,1H),7.75 -7.67(m,3H),7.55-7.44(m,4H),4.24(t,J=8.8Hz,2H),3.58-3.60(m,4H),3.51-3.61(m,4H),3.06(t,J=8.4Hz,2H). LCMS(ESI)m / z:453.0[M+H] + .

[0581] Synthesis of 4-(7-(2-phenyl-2H-1,2,3-triazol-4-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 68):

[0582]

[0583] Step 1: Synthesis of 4-nitro-2-phenyl-2H-1,2,3-triazole.

[0584] To a solution of 4-nitro-2H-1,2,3-triazole (228 mg, 2 mmol) and phenylboronic acid (488 mg, 4 mmol) in dichloromethane (10 mL) was added cupric acetate (543 mg, 3 mmol) and pyridine (632 mg, 8 mmol). The reaction mixture was stirred at room temperature for 3 hours under an oxygen atmosphere. The mixture was concentrated and the crude product was purified by column chromatography, eluted with 15% acetate / petroleum ether to give 4-nitro-2-phenyl-2H-1,2,3-triazole (isomer A) (230 mg, 60%) as a yellow solid. 1 H NMR(400MHz, CDCl3)δ8.37(s,1H),8.19-8.08(m,2H),7.61-7.46(m,3H); LCMS(ESI)m / z:191.0[M+H] + Note: Positional isomer B was used to synthesize compound 69.

[0585] Step 2: Synthesis of 2-phenyl-2H-1,2,3-triazol-4-amine.

[0586] Palladium (10% palladium / carbon, 30 mg) was added to a solution of 4-nitro-2-phenyl-2H-1,2,3-triazole (230 mg, 1.2 mmol) in methanol (6 mL). The mixture was stirred at room temperature for 3 hours under a hydrogen atmosphere. It was filtered and the filtrate was concentrated to give 2-phenyl-2H-1,2,3-triazole-4-amine (180 mg, 94%) as a white solid. LCMS (ESI) m / z: 161.1 [M+H] + .

[0587] Step 3: Synthesis of 4-(7-(2-phenyl-2H-1,2,3-triazol-4-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0588] To a mixture of 2-phenyl-2H-1,2,3-triazole-4-amine (32 mg, 0.2 mmol) and 4-(4-chloro-5-(2-chloroethyl)-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine (35 mg, 0.1 mmol) in dioxane (10 mL) was added cesium carbonate (100 mg, 0.3 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.01 mol, 9 mg) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (12 mg, 0.02 mmol). The resulting mixture was stirred at 100 ° C for 16 hours under an argon atmosphere. The reaction mixture was then diluted with water (30 mL) and extracted with ethyl acetate (20 mL*3). The organic phases were combined, dried and concentrated. The resulting crude product was purified by preparative HPLC (BOSTON pHlex ODS10um Mobile phase: acetonitrile / 0.1% formic acid) to give 4-(7-(2-phenyl-2H-1,2,3-triazol-4-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (18 mg, 20.4%) as a white solid. 1 H NMR (400MHz, DMSO) δ8.49(d,J=2.7Hz,1H),8.45(s,1H),8.44(d,J=4.7Hz,1H),7.96(d,J=7.6Hz,2H),7.70-7.67(m,1H),7.56(t,J=8.0Hz,2H),7 .47(d,J=8.3Hz,1H),7.38(t,J=7.4Hz,1H),4.21(t,J=8.5Hz,2H),3.60(bs,4H),3.53(bs,4H),3.08(t,J=8.0Hz,2H); LCMS(ESI)m / z:443.0[M+H] + .

[0589] The following compounds were similarly synthesized using the protocol described above.

[0590]

[0591] Synthesis of 4-(7-(1-phenyl-1H-pyrazol-4-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 71):

[0592]

[0593] To a mixture of 1-phenyl-1H-pyrazol-4-amine (34 mg, 0.2 mmol) and 4-(4-chloro-5-(2-chloroethyl)-6-(pyridin-3-yloxy)pyrimidin-2-yl)morpholine (35 mg, 0.1 mmol) in dioxane (10 mL) was added cesium carbonate (98 mg, 0.3 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.01 mol, 9 mg) and xantphos (12 mg, 0.02 mmol). The resulting mixture was stirred at 100 ° C. for 16 hours under an argon atmosphere. The mixture was then extracted with ethyl acetate (20 mL*2) and washed with water (10 mL*2). The organic layer was dried and concentrated and the resulting residue was subjected to preparative HPLC (BOSTON pHlexODS10um 21.2×250mm120A. The mobile phase was acetonitrile / 0.1% formic acid) to give 4-(7-(1-phenyl-1H-pyrazol-4-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (20 mg, 45%). 1 HNMR(400MHz, DMSO-d6)δ8.48(s,1H),8.47(d,J=2.8Hz,1H),8.41(dd,J=4.8,1.2Hz,1H),8.26(s,1H),7.82(d,J=8.4Hz,2H),7.67-7.64(m,1H),7 .50(t,J=8.4Hz,2H),7.47-7.44(m,1H),7.30(t,J=7.6Hz,1H),4.01(t,J =8.4Hz,2H),3.61-3.59(m,4H),3.52-3.48(m,4H),3.05(t,J=8.4Hz,2H). LCMS(ESI)m / z:442.2[M+H] + .

[0594] Synthesis of (2-morpholino-4-(pyridin-3-yloxy)-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)(phenyl)methanone (Compound 72):

[0595]

[0596] Step 1: Synthesis of (4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)(phenyl)methanone.

[0597] A mixture of 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (600 mg, 2.0 mmol), benzamide (242 mg, 2.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (92 mg, 0.1 mmol), Xantphos (116 mg, 0.2 mmol) and cesium carbonate (1.3 g, 4.0 mmol) in dioxane (20 mL) was stirred at 100 ° C for 4 hours under a nitrogen atmosphere. The mixture was poured into water and extracted with ethyl acetate (150 mL*2). The organic phases were combined, concentrated, and the resulting residue was subjected to silica gel column chromatography (50% ethyl acetate / petroleum ether) to give (4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)(phenyl)methanone (320 mg, 82%) as a white solid. LCMS (ESI) m / z: 345.1 / 347.1 [M+H] + .

[0598] Step 2: Synthesis of (2-morpholino-4-(pyridin-3-yloxy)-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)(phenyl)methanone.

[0599] A mixture of (4-chloro-2-morpholino-5H-pyrrolo[2,3-d]pyrimidin-7(6H)-yl)(phenyl)methanone (280 mg, 0.81 mmol), pyridin-3-ol (77 mg, 0.81 mmol) and cesium carbonate (527 mg, 1.62 mmol) in N,N-dimethylacetamide (10 mL) was stirred at 120 °C for 16 hours. The resulting precipitate was filtered off and the filtrate was purified by preparative HPLC (column Xbridge 21.2*250mm C18, 10um, mobile phase A: water (10mmol / L ammonium bicarbonate) B: acetonitrile) to give (2-morpholino-4-(pyridin-3-yloxy)-5H-pyrrolidin[2,3-d]pyrimidin-7(6H)-yl)(phenyl)methanone (10 mg) and 4-(4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (80 mg, hydrolyzed byproduct - which was later converted into the desired product by amidation reaction using benzoyl chloride) as a white solid. 1 H NMR(400MHz, CDCl3)δ8.49(d,J=2.5Hz,1H),8.44(dd,J=4.7,1.2Hz,1H),7.55–7.50(m,2H),7.48(ddd,J=8.3,2.7, 1.4Hz,1H),7.43–7.29(m,4H),4.26(t,J=4.0Hz,2H),3.39(bs,4H),3.24–2.76(m,6H); LCMS(ESI)m / z:404.1[M+H] + .

[0600] Synthesis of 1-(2-morpholino-4-(pyridin-4-yl)-5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-phenylethane-1-one (Compound 73):

[0601]

[0602] Step 1: Synthesis of 4-(7-(4-methoxybenzyl)-4-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0603] To a solution of 4-(4-chloro-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (300 mg, 0.833 mmol) in DMSO (10 mL) was added pyridin-4-ylboronic acid (123 mg, 1.0 mmol), tris(dibenzylideneacetone)dipalladium (60 mg, 0.631 mmol), tricyclohexylphosphane (60 mg, 0.631 mmol) and cesium carbonate (541 mg, 1.66 mmol). The resulting mixture was stirred at 130 ° C for 8 hours and water (5 mL) was added. The mixture was extracted with ethyl acetate (20*3 mL), the organic layers were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was flash chromatographed on silica gel (petroleum ether:ethyl acetate=65:35) to give the target product (330 mg, 98.0%) as a yellow solid.

[0604] Step 2: Synthesis of 4-(4-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0605] To a solution of 4-(7-(4-methoxybenzyl)-4-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (330 mg, 0.819 mmol) in TFA (10 mL) was added concentrated sulfuric acid (5 mL). The mixture was stirred at 90 ° C for 2 hours and then diluted with water (20 mL). The mixture was extracted with ethyl acetate (20 mL*3), the organic layers were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was flash chromatographed on silica gel (petroleum ether: ethyl acetate = 45:55) to give the target product (220 mg, 94.56%) as a yellow solid.

[0606] Step 3: Synthesis of 1-(2-morpholino-4-(pyridin-4-yl)-5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-phenylethan-1-one.

[0607] 2-phenylacetyl chloride (520 mg, 3.39 mmol), pyridine (44 mg, 0.566 mmol) and N,N-dimethylpyridin-4-amine (69 mg, 0.566 mmol) were added to a solution of 4-(4-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (80 mg, 0.283 mmol) in acetonitrile (10 mL). The mixture was stirred at 30 ° C for 8 hours, then quenched with water (5 mL) and extracted with ethyl acetate (20 mL * 3). The organic layers were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5%~95%) to give 1-(2-morpholino-4-(pyridin-4-yl)-5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-phenylethan-1-one (65.4 mg, 57.6%) as a white solid. 1 H NMR(400MHz,DMSO-d6)δ8.74(d,J=6.0Hz,2H),7.87(dd,J=4.6,1.5Hz,2H),7.33–7.23(m,5H),4. 49(s,2H),4.08–3.95(m,2H),3.81–3.58(m,8H),3.27–3.18(m,2H); LCMS(ESI)m / z:402.1[M+H]+.

[0608] Synthesis of 4-(7-(2-phenylpyrimidin-4-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 74):

[0609]

[0610] Step 1: Synthesis of 2-phenylpyrimidin-4-amine.

[0611] A mixture of 2-chloropyrimidin-4-amine (1.17 g, 10 mmol), phenylboronic acid (1.83 g, 15 mmol), bis(triphenylphosphino)dichloropalladium(II) (700 mg, 1 mmol) and sodium carbonate (3.18 g, 30 mmol) in dioxane (50 mL) and water (5 mL) was stirred at 90 ° C under nitrogen for 16 hours. The mixture was concentrated and purified by flash chromatography using 0-50% ethyl acetate (ethyl) / petroleum ether to give 2-phenylpyrimidin-4-amine (1.5 g, 88%) as a yellow solid. LCMS (ESI) m / z: 172.2 [M+H] + .

[0612] Step 2: Synthesis of 4-(4-chloro-7-(2-phenylpyrimidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0613] Sodium hydride (80 mg, 2 mmol) was slowly added to a solution of 2-phenylpyrimidin-4-amine (188 mg, 1.1 mmol) in tetrahydrofuran (10 mL) at 0°C. The mixture was stirred at room temperature for 5 minutes and at 80°C for 2 hours, followed by the addition of 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (295 mg, 1 mmol). The resulting mixture was stirred at 80°C for another 16 hours. The reaction was quenched by the addition of water (10 mL) and ethyl acetate (20 mL). The precipitate formed was collected by filtration and dried to give 4-(4-chloro-7-(2-phenylpyrimidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 25%) as a white solid. LCMS (ESI) m / z: 395.0 [M+H] + .

[0614] Step 3: Synthesis of 4-(7-(2-phenylpyrimidin-4-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0615] A mixture of 4-(4-chloro-7-(2-phenylpyrimidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (40 mg, 0.11 mmol), pyridin-3-ol (19 mg, 0.2 mmol) and cesium carbonate (98 mmol, 0.3 mg) in N,N-dimethylacetamide (2 mL) was stirred at 150 °C under microwave irradiation for 1 hour. The resulting mixture was filtered and the filtrate was purified by preparative HPLC (BOSTON pHlex ODS 10um 21.2×250mm120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 4-(7-(2-phenylpyrimidin-4-yl)-4-(pyridin-3-yloxy)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (30 mg, 66%) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ8.67(d,J=6.0Hz,1H),8.51(d,J=2.8Hz,1H),8.46-8.39(m,4H),7.73-7 .69(m,1H),7.54-7.47(m,4H),4.45(t,J=8.0Hz,2H),3.62-3.51(m,8H),3.07(t,J=8.0Hz,2H). LCMS(ESI)m / z:454.2[M+H] + .

[0616] Synthesis of 4-(4-((5-phenylpyridin-3-yl)oxy)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 75):

[0617]

[0618] Step 1: Synthesis of 4-(4-((5-bromopyridin-3-yl)oxy)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0619] To a solution of 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 0.315 mmol) in dimethyl sulfoxide (10 mL) was added 5-bromopyridin-3-ol (71 mg, 0.410 mmol) and potassium carbonate (130 mg, 0.945 mmol). The reaction mixture was stirred at 100 °C for 48 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (50 mL). The organics were washed with water (20 mL) and brine (20 mL), dried over sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography eluting with dichloromethane / methanol=15 / 1 to give 4-(4-((5-bromopyridin-3-yl)oxy)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (35 mg, 24%) as a white solid. LCMS (ESI) m / z: 455.0 [M+H] + .

[0620] Step 2: Synthesis of 4-(4-((5-phenylpyridin-3-yl)oxy)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine Morpholine.

[0621] To a solution of 4-(4-((5-bromopyridin-3-yl)oxy)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (35 mg, 0.077 mmol), phenylboronic acid (19 mg, 0.154 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (5.8 mg, 0.008 mmol) in dioxane (2 mL) and water (0.5 mL) was added potassium carbonate (170 mg, 0.522 mmol) at room temperature. The resulting mixture was stirred at 100°C for 3 hours under nitrogen atmosphere and cooled. It was then diluted with ethyl acetate (50 mL), the organic phase was washed with water (20 mL x 2) and brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(4-((5-phenylpyridin-3-yl)oxy)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (15.6mg, 44%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.04(s,1H),8.77(d,J=2.0Hz,1H),8.50(d,J=2.5Hz,1H),8.24-8.20(m,2H),7.99-7.97(m,1H),7.7 7(d,J=7.3Hz,2H),7.52(t,J=7.4Hz,2H),7.44-7.40(m,2H),4.16(t,J=8.5Hz,2H),3.58-3.50(m,8H),3.06(t,J=8.3Hz,2H). LCMS(ESI)m / z:453.1[M+H] + .

[0622] Synthesis of 2-morpholino-N-(oxetane-3-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine (Compound 76):

[0623]

[0624] To a solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (120 mg, 0.38 mmol) in dioxane (10 mL) was added oxetane-3-amine (55 mg, 0.76 mmol), Pd2(dba)3 (52 mg, 0.057 mmol), Xantphos (66 mg, 0.11 mmol) and Cs2CO3 (371 mg, 1.14 mmol). The resulting mixture was stirred at 110°C for 16 hours and concentrated. The obtained crude product was purified by preparative HPLC (0.05% FA / H2O:CH3CN=5%~95%) to give 2-morpholino-N-(oxetan-3-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine (14.3 mg, 11%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ8.47(s,1H),7.67(d,J=8.0Hz,2H),7.40(t,J=7.6Hz,2H),7.11(t,J=7.6Hz,1H),4.44(t,J=9.6Hz,1H),4.21(t ,J=8.4Hz,3H),4.08(dd,J=10.4,5.6Hz,1H),3.73(t,J=4.4Hz,4H),3.57-3.45(m,6H),2.95-2.91(m,2H); LCMS(ESI)m / z:354.1[M+H]+.

[0625] The following compounds were synthesized according to the scheme described above:

[0626]

[0627] Synthesis of 4,4'-(7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)dimorpholine (Compound 78):

[0628]

[0629] To a solution of morpholine (45 mg, 0.52 mmol) in THF (10 mL) was added NaH (38 mg, 0.95 mmol) at 0°C. The suspension was stirred at room temperature for 15 minutes, then 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (150 mg, 0.47 mmol) was added to the mixture. The mixture was then stirred at 80°C for 16 hours and quenched with water (10 mL), extracted with ethyl acetate (30*3 mL), washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude product was purified by preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5%-95%) to give 4,4'-(7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)dimorpholine (18.6 mg, 11%) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ7.72(d,J=8.0Hz,2H),7.36(t,J=8.0Hz,2H),7.01(t,J=7.6Hz,1H),3.98(t,J=8 .4Hz, 1H), 3.87-3.74 (m, 12H), 3.64-3.62 (m, 4H), 3.16 (t, J = 8.4Hz, 2H); LCMS (ESI) m / z: 368.1[M+H]+.

[0630] Synthesis of 8-(2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)octahydropyrazino[2,1-c][1,4]oxazine (Compound 79):

[0631]

[0632] A mixture of octahydropyrazino[2,1-c][1,4]oxazine hydrochloride (60 mg, 0.337 mmol), 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (107 mg, 0.337 mmol) and cesium carbonate (328 mg, 1.011 mmol) in N,N-dimethylformamide (5 mL) was stirred at 85° C. for 4 hours. Water (10 mL) was then added and the mixture was extracted with ethyl acetate (20 mL×3). The organic layer was dried and concentrated. The resulting crude product was purified by SGC (50:1 to 10:1 dichloromethane:methanol) to afford 8-(2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)octahydropyrazino[2,1-c][1,4]oxazine (23.2 mg, 16%) as a yellow solid. 1H NMR(400MHz, DMSO-d6)δ8.97(d,J=2.8Hz,1H),8.15-8.10(m,2H),7.34(dd,J=7.6, 4.4Hz,1H),4.26(d,J=14Hz,1H),4.09(d,J=12.4Hz,1H),3.94(t,J=8.4Hz,2H),3. 75-3.71(m,2H),3.64-3.52(m,9H),3.31(s,1H),3.17-3.13(m,3H),2.98-2.97(m, 1H),2.76-2.73(m,1H),2.65-2.62(m,1H),2.20-2.11(m,3H); LC-MS: m / z=424(M+H) + .

[0633] The following compounds were synthesized according to the scheme described above:

[0634]

[0635]

[0636] Synthesis of (E)-4-(4-(2-(3-methylbenzylidene)hydrazino)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 82):

[0637]

[0638] Step 1: Synthesis of 4-(4-hydrazino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0639] To a suspension of 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.157 mmol) in 1,4-dioxane (1.5 mL) was added hydrazine monohydrate (98.5 mg, 1.57 mmol), and the suspension was stirred at reflux for 5 hours. After cooling to room temperature, the reaction mixture was treated with water (40 mL) and extracted with ethyl acetate (5 mL x 3). The organic layers were combined and concentrated to give 4-(4-hydrazine-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (70 mg, 99%). LCMS (ESI) m / z: 314.3 [M+H] + .

[0640] Step 2: Synthesis of (E)-4-(4-(2-(3-methylbenzylidene)hydrazino)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0641] To a solution of 4-(4-hydrazino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.16 mmol) and 3-methylbenzaldehyde (38 mg, 0.32 mmol) in ethanol (10 mL) was added acetic acid (0.05 mL). The mixture was refluxed at 80 ° C for 16 hours, then diluted with water (80 mL) and extracted with ethyl acetate (100 mL * 3). The organic layers were combined, washed with brine (150 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC to give (E)-4-(4-(2-(3-methylbenzylidene)hydrazino)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (12.5 mg, 2-step yield 19%) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ10.77(s,1H),9.04(d,J=2.5Hz,1H),8.18(t,J=6.8Hz,2H),7.99(s,1H),7.58–7.28(m,4H ),7.16(d,J=7.1Hz,1H),4.05(t,J=8.6Hz,2H),3.66(s,8H),3.34(m,2H),2.34(s,3H); LCMS(ESI)m / z:416.2[M+H] + .

[0642] Synthesis of 4-(7-(pyridin-3-yl)-4-(3-(m-tolyl)-1H-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 83):

[0643]

[0644] Step 1: Synthesis of (E)-3-(dimethylamino)-1-(m-tolyl)prop-2-en-1-one.

[0645] A solution of 1-(m-tolyl)ethane-1-one (500 mg, 3.72 mmol) in N,N-dimethylformamide dimethyl acetal (5 mL) was stirred at 110° C. for 17 hours. The mixture was concentrated to give (E)-3-(dimethylamino)-1-(m-tolyl)prop-2-en-1-one as a yellow oil. LCMS (ESI) m / z: 190.2 [M+H] +The product was used in the next step without further purification.

[0646] Step 2: Synthesis of 3-(m-tolyl)-1H-pyrazole.

[0647] A mixture of (E)-3-(dimethylamino)-1-(m-tolyl)prop-2-en-1-one (567.78 mg, 3 mmol) and hydrazine hydrate (563.18 mg, 9 mmol) in ethanol (6 mL) was stirred under reflux for 2 hours. The reaction mixture was concentrated to give 3-(m-tolyl)-1H-pyrazole (450 mg, two-step yield 94%) as a yellow oil. LCMS (ESI) m / z: 159.1 [M+H] + .

[0648] Step 3: Synthesis of 4-(7-(pyridin-3-yl)-4-(3-(m-tolyl)-1H-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0649] A mixture of 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.16 mmol), 3-(m-tolyl)-1H-pyrazole (38 mg, 0.32 mmol) and cesium carbonate (156 mmol, 0.48 mg) in N,N-dimethylacetamide (4 mL) was stirred at 120° C. for 16 hours. The mixture was filtered and the filtrate was purified by preparative HPLC to give 4-(7-(pyridin-3-yl)-4-(3-(m-tolyl)-1H-pyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (12.4 mg, 18%) as a white solid. 1H NMR(400MHz,DMSO-d6)δ9.10(d,J=2.3Hz,1H),8.73(d,J=2.7Hz,1H),8.47–8.0 4(m,2H),7.77(d,J=9.5Hz,2H),7.44(dd,J=8.4,4.6Hz,1H),7.36(t,J=7.6Hz, 1H),7.21(d,J=8.2Hz,1H),7.06(d,J=2.7Hz,1H),4.19(t,J=8.3Hz,2H),3.78- 3.70(m,8H),3.57(t,J=8.5Hz,2H),2.39(s,J=1H); LCMS(ESI)m / z:440.1[M+H] + .

[0650] Synthesis of 4-(4-(3-phenyl-1H-pyrazol-1-yl)-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 84):

[0651]

[0652] Step 1: Synthesis of 4-(4-chloro-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0653] To a solution of pyridin-4-amine (517 mg, 5.5 mmol) in tetrahydrofuran (50 mL) was slowly added sodium hydride (400 mg, 10.0 mmol) at 0°C. The mixture was stirred at 80°C for 2 hours and a solution of 4-(4,6-dichloro-5-(2-chloroethyl)pyrimidin-2-yl)morpholine (1.5 g, 5.0 mmol) in THF (3 mL) was added. The resulting mixture was stirred at 80°C for another 16 hours. It was poured onto crushed ice and extracted with ethyl acetate (150*2 mL). The organic layers were combined, concentrated, and the resulting crude product was purified by silica gel column chromatography [(20% dichloromethane / methanol) and then washed with methanol (10 mL)] to give 4-(4-chloro-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (280 mg, 18%) as a gray solid. LCMS (ESI) m / z: 318.1 / 320.1 [M+H] + .

[0654] Step 2: Synthesis of 4-(4-(3-phenyl-1H-pyrazol-1-yl)-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0655] A mixture of 4-(4-chloro-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (63 mg, 0.2 mmol), 3-phenyl-1H-pyrazole (43 mg, 0.3 mmol) and cesium carbonate (130 mg, 0.4 mmol) in N,N-dimethylformamide (5 mL) was stirred at 110° C. for 4 hours. It was then poured into water and the formed precipitate was collected by filtration, washed with methanol (10 mL) and dried in vacuo to give 4-(4-(3-phenyl-1H-pyrazol-1-yl)-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (40 mg, 47%) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ8.75(d,J=2.7Hz,1H),8.47(d,J=5.4Hz,2H),7.97(d,J=7.3Hz,2H),7.83(d,J=6.1Hz,2H),7.48(t,J=7.5Hz,2H),7.39(s ,1H),7.09(d,J=2.7Hz,1H),4.13(t,J=8.3Hz,2H),3.78(d,J=4.8Hz,4H),3.73(d,J=4.8Hz,4H),3.55(t,J=8.2Hz,2H); LCMS(ESI)m / z:425.9[M] + .

[0656] Synthesis of 4-(4-((3-methoxyphenyl)ethynyl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 85):

[0657]

[0658] To a suspension of 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.157 mmol), bis(triphenylphosphine)palladium(II) chloride (11 mg, 0.0157 mmol) and cuprous iodide (6 mg, 0.0315 mmol) in triethylamine (0.5 mL) under argon atmosphere was added 1-ethynyl-3-methoxybenzene (51 mg, 0.393 mmol) using a syringe and the resulting mixture was heated at 70° C. for 16 hours. The mixture was filtered and the filtrate was washed with saturated ammonium chloride solution (25 mL×2) and water (25 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC to give 4-(4-((3-methoxyphenyl)ethynyl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (11.1 mg, 17%) as a yellow solid. 1H NMR (400MHz, CD3OD) δ9.22(s,1H),8.26(d,J=8.9Hz,2H),7.50-7.48(m,1H),7.35(t,J=8.0Hz,1H),7.19–7.14(m,2H),7.05 -7.02(m,J=8.0Hz,1H),4.19(t,J=8.0Hz,2H),3.87(s,3H),3.78(s,8H),3.25(t,J=8.0Hz,2H); LCMS(ESI)m / z:414.0[M+H] + .

[0659] Synthesis of 4-(7-phenyl-4-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 86):

[0660]

[0661] Step 1: Synthesis of 4-(4-(3,6-dihydro-2H-pyran-4-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0662] A mixture of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (100 mg, 0.32 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (199 mg, 0.95 mmol), Cs2CO3 (309 mg, 0.95 mmol), Pd2(dba)3 (29 mg, 0.03 mmol) and P(Cy)3 (17 mg, 0.06 mmol) in DMSO (10 mL) / H2O (2 mL) was stirred at 140 °C for 16 hours under nitrogen atmosphere. The reaction was then quenched with water (10 mL) and the mixture was extracted with EtOAc (20*3 mL). The organic layers were combined, washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. The residue was subjected to preparative HPLC (PE / EA=4:1) to give 4-(4-(3,6-dihydro-2H-pyran-4-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (70 mg, 60%) as a yellow solid. LCMS (ESI) m / z: 365.2 [M+H]+.

[0663] Step 2: Synthesis of 4-(7-phenyl-4-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0664] A suspension of 4-(4-(3,6-dihydro-2H-pyran-4-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.14 mmol) and 10% Pd / C (5 mg) in MeOH (10 mL) was stirred at room temperature for 1 hour under a hydrogen atmosphere. The mixture was then filtered, concentrated and subjected to preparative HPLC (0.05% FA / H2O:CH3CN=5% to 95%) to give 4-(7-phenyl-4-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (26.6 mg, 52%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ7.80(d,J=8.0Hz,2H),7.37(t,J=8Hz,2H),7.01(t,J=7.2Hz,1H),4.04(t,J=8.4Hz,2H),3.93(dd,J=11.6,3.2Hz,2H),3.66(s ,8H),3.43(t,J=10.8Hz,2H),3.02(t,J=8.4Hz,2H),2.75(t,J=11.6Hz,1H ), 1.87-1.83 (m, 2H), 1.57 (d, J = 11.2Hz, 2H); LCMS (ESI) m / z: 367.2[M+H]+.

[0665] Synthesis of 4-(7-phenyl-4-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 87):

[0666]

[0667] Step 1: Synthesis of 4-(4-(furan-3-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0668] A mixture of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (85 mg, 0.27 mmol), furan-3-ylboronic acid (90 mg, 0.81 mmol), Cs2CO3 (263 mg, 0.81 mmol) and Pd(dppf)Cl2 (19 mg, 0.027 mmol) in DMSO (8 mL) / H2O (2 mL) was stirred at 130°C for 16 hours under nitrogen atmosphere. The mixture was then diluted with EtOAc (45 mL), washed with water (15 mL), brine (30 mL), dried over Na2SO4, filtered and concentrated. The residue was subjected to SGC (PE / EA=4:1) to give 4-(4-(furan-3-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 54%) as a yellow solid; LCMS (ESI) m / z: 349.1 [M+H]+.

[0669] Step 2: Synthesis of 4-(7-phenyl-4-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0670] A suspension of 4-(4-(furan-3-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.14 mmol) and 10% Pd / C (5 mg) in MeOH (15 mL) was stirred at room temperature for 2 hours under a hydrogen atmosphere. The mixture was then filtered and the filtrate was concentrated. The residue was subjected to preparative HPLC (0.05% FA / H2O:CH3CN=5% to 95%) to give 4-(7-phenyl-4-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (13.3 mg, 26%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ7.80(d,J=7.6Hz,2H),7.37(t,J=8.0Hz,2H),7.02(t,J=7.4Hz,1H),4.07-3.99(m,3H),3.92-3.86(m,1H),3.8 3-3.79(m,1H),3.77-3.71(m,1H),3.65(s,8H),3.40-3.35(m,1H),3.05-3.00(m,2H),2.16-2.11(m,2H); LCMS(ESI)m / z:353.1[M+H]+.

[0671] Synthesis of 4-(4-(furan-3-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 88) and 4-(7-(pyridin-3-yl)-4-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 89):

[0672]

[0673] Step 1: Synthesis of 4-(4-(furan-3-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0674] To a stirred mixture of 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (200 mg, 0.62 mmol), furan-3-ylboronic acid (211 mg, 1.88 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (69 mg, 0.094 mmol) in acetonitrile (6 mL) and water (1.5 mL) at 20 °C was added cesium carbonate (615 mg, 1.88 mmol). The resulting mixture was stirred at 80 °C under nitrogen for 18 hours and cooled. The reaction mixture was then quenched with water (50 mL) and extracted with dichloromethane (50 mL x 2). The organic fractions were combined, washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparative HPLC to give the title compound (28.1 mg, 13%) as a white solid. 1H NMR (400 MHz, CDCl3) δ9.13 (s, 1H), 8.29 (d, J = 3.5 Hz, 1H), 8.21 (d, J = 8.7 Hz, 1H), 7.95 (s, 1H), 7.51 (t, J = 1.7 Hz, 1H), 7.34 (dd, J = 8.5, 4.7 Hz, 1H), 6.95 (s, 1H), 4.14 (t, J = 8 Hz, 2H), 3.84-3.80 (m, 98), 3.24 (t, J = 8 Hz, 2H); LCMS (ESI) m / z: 350.1 [M+H] +

[0675] Step 2: Preparation of 4-(7-(pyridin-3-yl)-4-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0676] To a solution of 4-(4-(furan-3-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (74 mg, 0.21 mmol) in methanol (25 mL) and acetate (25 mL) was added 10% Pd in ​​palladium / activated carbon (74 mg). The resulting suspension was stirred at 50° C. under a hydrogen atmosphere for 5 hours. The reaction mixture was filtered and the filtrate was concentrated. The residue was subjected to preparative HPLC (BOSTON pHlex ODS 10um 21.2×250mm 120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 4-(7-(pyridin-3-yl)-4-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (16.1 mg, 21%) as a white solid. 1 H NMR (500MHz, chloroform-d) δ9.08(d,J=2.8Hz,1H),8.29(dd,J=4.0,0.4Hz,1H),8.15(dt,J=9.2,0.8Hz,1H),7.30(dd,J=8.5,4.7Hz,1H),4.11(t,J=8.0Hz ,1H),4.08–4.00(m,3H),3.96–3.88(m,2H),3.80–3.75(m,8H),3.36(pen t,J=6.4Hz,1H),3.14–3.02(m,2H),2.34–2.26(m,1H),2.22–2.14(m,1H). LCMS(ESI)m / z:354.2[M+H] + .

[0677] Synthesis of 4-(7-phenyl-4-(pyridin-2-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 90):

[0678]

[0679] A solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (250 mg, 0.79 mmol), pyridin-2-ylboronic acid (486 mg, 3.95 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (131 mg, 0.16 mmol) and cesium carbonate (772 mg, 2.37 mmol) in water (5.0 mL) and DMSO (20 mL) was stirred at 130° C. for 8 hours under an argon atmosphere. The mixture was diluted with ethyl acetate (150 mL), washed with water (150 mL), and the organic layer was concentrated. The obtained crude product was purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5umcolumn Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(7-phenyl-4-(pyridin-2-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (44.3mg, 15%) as a yellow solid. 1 H NMR (400MHz, chloroform-d) δ8.67(d,J=4.9,1.7Hz,1H),8.37(d,J=8.0Hz,1H),7.90–7.72(m,3H),7.42(t,J=8.0Hz,2 H),7.30–7.27(m,1H),7.06(t,J=7.4Hz,1H),4.12(t,J=8.3Hz,2H),3.94–3.75(m,8H),3.60(t,J=8.3Hz,2H). LCMS(ESI)m / z:360.2[M+H] + .

[0680] The following compounds were synthesized according to the above scheme.

[0681]

[0682]

[0683]

[0684] Synthesis of 4-(6-methyl-7-(pyridin-4-yl)-4-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 98):

[0685]

[0686] Step 1: Synthesis of methyl 5-methyl-2-oxotetrahydrofuran-3-carboxylate.

[0687] To lithium bis(trimethylsilyl)amide (1.6M in tetrahydrofuran, 330mL, 528mmol) was added dropwise a solution of methyldihydrofuran-2(3H)-one (25g, 250mmol) in tetrahydrofuran (100mL) at -78°C. After stirring at -78°C for 10 minutes, dimethyl carbonate (23.6g, 263mmol) was added to the mixture at -78°C, and the reaction mixture was warmed and stirred at room temperature for 16 hours. It was then poured into a mixture of concentrated hydrochloric acid (80mL) and ice (800mL), followed by extraction with ethyl acetate (800mL x 2). The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to give the title compound (40g). The product was used in the next step without further purification. LCMS (ESI) m / z: 159.1 [M+H] + .

[0688] Step 2: Synthesis of 5-(2-hydroxypropyl)-2-morpholinopyrimidine-4,6-diol.

[0689] To a solution of morpholine-4-carboximidamide hydrochloride (31 g, 192 mmol) and sodium methoxide (104 g, 576 mmol) in methanol (150 mL) was added 5-methyl-2-oxotetrahydrofuran-3-carboxylic acid methyl ester (40 g, 250 mmol) at room temperature. The reaction mixture was then refluxed for 16 hours and cooled. Water (200 mL) was added to the mixture and stirred for 0.5 hours, followed by the addition of acetic acid (30 mL) and the mixture was stirred at room temperature for another 2 hours. The precipitated solid was filtered and dried to give the title compound (41 g, 83%) as a white solid. LCMS (ESI) m / z: 256.2 [M+H] + .

[0690] Step 3: Synthesis of 4-(4,6-dichloro-5-(2-chloropropyl)pyrimidin-2-yl)morpholine.

[0691] Phosphorus oxychloride (64 mL) was added to a solution of 5-(2-hydroxypropyl)-2-morpholinopyrimidine-4,6-diol (41 g, 81 mmol) and N-ethyl-N-isopropylpropane-2-amine (44 mL) in toluene (400 mL) at room temperature. The resulting mixture was stirred at 110 ° C for 16 hours and concentrated. The residue was then dissolved in ethyl acetate (1600 mL), washed with water (300 mL x 2), brine (300 mL), and dried over sodium sulfate. Concentrate and purify the resulting residue by silica gel column chromatography (petroleum ether / ethyl acetate=10 / 1) to give the title compound (38 g, 76%) as an off-white solid. LCMS (ESI) m / z: 312.0 [M+H] + .

[0692] Step 4: Synthesis of 4-(4-chloro-6-methyl-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0693] A mixture of pyridine-4-amine (151 mg, 1.60 mmol) and sodium hydride (161 mg, 4.025 mmol) in tetrahydrofuran (40 mL) was refluxed for 1 hour. After cooling to room temperature, 4-(4,6-dichloro-5-(2-chloropropyl)pyrimidin-2-yl)morpholine (500 mg, 1.61 mmol) was added. The resulting mixture was refluxed for 16 hours, then poured into ice water (80 mL) and extracted with ethyl acetate (120 mL x 2). The organic layer was washed with brine (50 mL) and dried over sodium sulfate. It was filtered and concentrated, and the residue was subjected to silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1 to 0 / 100) to obtain 4-(4-chloro-6-methyl-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (200 mg, 37%) as a brown solid. LCMS (ESI) m / z: 332.2 [M+H] + .

[0694] Step 5: Synthesis of 4-(4-(furan-3-yl)-6-methyl-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0695] To a stirred mixture of 4-(4-chloro-6-methyl-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (200 mg, 0.603 mmol), furan-3-ylboronic acid (135 mg, 1.207 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II):CH2Cl2 (49 mg, 0.06 mmol) in acetonitrile (8 mL) and water (2 mL) was added cesium carbonate (393 mg, 1.206 mmol) at room temperature. The resulting reaction mixture was stirred at 80°C under nitrogen for 4 hours and cooled. The reaction was quenched with water (50 mL) and extracted with dichloromethane (100 mL x 2). The extracts were combined, washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The obtained residue was subjected to silica gel column chromatography and eluted with petroleum ether / ethyl acetate = 1 / 1 to obtain 4-(4-(furan-3-yl)-6-methyl-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (200 mg, 91%) as a yellow solid. LCMS (ESI) m / z: 364.0 [M+H] + .

[0696] Step 6: Synthesis of 4-(6-methyl-7-(pyridin-4-yl)-4-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0697] A suspension of 4-(4-(furan-3-yl)-6-methyl-7-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (200 mg, 0.55 mmol) and palladium / activated carbon (10%, 100 mg) in methanol (20 mL) and ethyl acetate (10 mL) was stirred under a hydrogen atmosphere at 30° C. for 16 hours. The mixture was filtered through celite and concentrated. The obtained residue was purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, the flow rate was 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(6-methyl-7-(pyridin-4-yl)-4-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (17.1mg, 8%) as a white solid. 1H NMR(500MHz,MeOD)δ8.42(d,J=6.0Hz,2H),7.83(d,J=6.0Hz,2H),4.80(bs,1H),4.01-3.97(m,1H),3.89-3.87(m,1H) ,3.82-3.62(m,10H),3.32-3.30(m,1H),3.27-3.22(m,1H),2.69-2.63(m,1H),2.19-2.10(m,2H),1.25-1.22(m,3H). LCMS(ESI)m / z:368.1[M+H] + .

[0698] Synthesis of 4-(7-phenyl-4-(pyridazin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 99):

[0699]

[0700] A solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (60 mg, 0.19 mmol), 4-(tributylstannyl)pyridazine (70 mg, 0.19 mmol), LiCl (8 mg, 0.19 mmol) and Pd(PPh3)4 (22 mg, 0.019 mmol) in dioxane (5 mL) was stirred at 100° C. for 16 hours under a nitrogen atmosphere. It was concentrated and the residue was subjected to preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5% to 95%) to give 4-(7-phenyl-4-(pyridazin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (1.8 mg, 3%) as a yellow solid. 1 HNMR (400MHz, CDCl3) δ9.74(d,J=0.8Hz,1H),9.33(dd,J=5.2,1.2Hz,1H),8.00(dd,J=5.2,2.4Hz,1H),7.81(d,J=8.0Hz,2H),7.44(t ,J=8.0Hz,2H),7.14(t,J=7.6Hz,1H),4.20(t,J=8.0Hz,2H),3.90-3.82(m,8H),3.42(t,J=8.0Hz,2H); LCMS(ESI)m / z:361.2[M+H]+.

[0701]

[0702]

[0703]

[0704] Synthesis of tert-butyl 4-(2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-1-carboxylate (Compound 107), 4-(4-(piperidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 108), and 4-(4-(1-methylpiperidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 109):

[0705]

[0706] Step 1: Synthesis of tert-butyl 4-(2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate.

[0707] A mixture of 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.157 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (97 mg, 0.314 mmol), tris(dibenzylideneacetone)dipalladium (15 mg, 0.016 mmol), tricyclohexylphosphine (9 mg, 0.032 mmol) and cesium carbonate (103 mg, 0.316 mmol) in acetonitrile (8 mL) and water (2 mL) was refluxed under nitrogen atmosphere for 16 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (80 mL), washed with water (30 mL) and brine (20 mL), dried over sodium sulfate, filtered and concentrated. The obtained crude product was purified by silica gel column chromatography, eluting with petroleum ether / ethyl acetate = 1 / 1 then 0 / 100 to give tert-butyl 4-(2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate (50 mg, 68%) as a brown solid. LCMS (ESI) m / z: 465.3 [M+H] + .

[0708] Step 2: Synthesis of tert-butyl 4-(2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-1-carboxylate.

[0709] A suspension of tert-butyl 4-(2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-5,6-dihydropyridine-1(2H)-carboxylate (50 mg, 0.108 mmol) and palladium / activated carbon (10%, 30 mg) in methanol (5 mL) and ethyl acetate (5 mL) was stirred at room temperature for 5 hours under a hydrogen atmosphere. The resulting mixture was filtered through celite and concentrated. The obtained crude product was purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C183.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, the flow rate was 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give tert-butyl 4-(2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-1-carboxylate (4.9mg, 10%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.03 (d, J = 2.4Hz, 1H), 8.22-8.19 (m, 2H), 7.40-7.37 (m, 1H), 4.09-4.03 (m,4H),3.65(s,8H),3.05(t,J=8.4Hz,2H),2.89-2.67(m,3H),1.67-1.61(m,4H),1.41(s,9H). LCMS(ESI)m / z:467.2[M+H] + .

[0710] Step 3: Synthesis of 4-(4-(piperidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0711] To a solution of tert-butyl 4-(2-morpholino-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-1-carboxylate (50 mg, 0.107 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) at room temperature. After the mixture was stirred at room temperature for 2 hours, it was concentrated and the residue was subjected to preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, the flow rate was 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(4-(piperidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (12.3mg, 31%) as a white solid. 1 H NMR(400MHz, DMSO-d6)δ9.04(d,J=2.4Hz,1H),8.22-8.19(m,2H),7.40-7.37(m,1H),4.01(t,J=8.4H z, 2H), 3.67 (s, 8H), 3.14-3.11 (m, 2H), 3.04 (t, J = 8.4Hz, 2H), 2.74-2.66 (m, 3H), 1.83-1.64 (m, 4H). LCMS(ESI)m / z:367.3[M+H] + .

[0712] Step 4: Synthesis of 4-(4-(1-methylpiperidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0713] To a mixture of 4-(4-(piperidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.136 mmol) and formaldehyde solution (37 wt% in water) (1 mL) in methanol (10 mL) was added acetic acid (16 mg, 0.266 mmol) at room temperature. After stirring at room temperature for 2 hours, sodium cyanoborohydride (17 mg, 0.271 mmol) was added to the mixture and stirred for another 2 hours. It was then concentrated and the residue was subjected to preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C18 3.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give 4-(4-(1-methylpiperidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (34.7mg, 67%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.04 (s, 1H), 8.21-8.20 (m, 2H), 7.40-7.37 (m, 1H), 4.06 (t, J = 8.2Hz, 2H), 3.66 (s, 9H), 3.03(t,J=8.2Hz,2H),2.85-2.82(m,2H),2.45-2.41(m,1H),2.17(s,3H),1.94-1.84(m,4H),1.63-1.60(m,2H). LCMS(ESI)m / z:381.3[M+H] + .

[0714] Synthesis of tert-butyl 4-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-1-carboxylate (Compound 110), 4-(7-phenyl-4-(piperidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 111), and 4-(4-(1-methylpiperidin-4-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 112):

[0715]

[0716] Step 1: Synthesis of tert-butyl 4-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate.

[0717] A mixture of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (200 mg, 0.63 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (391 mg, 1.26 mmol), Cs2CO3 (619 mg, 1.90 mmol), Pd2(dba)3 (58 mg, 0.063 mmol) and P(Cy)3 (35 mg, 0.126 mmol) in CH3CN (20 mL) / H2O (5 mL) was stirred at 100°C for 4 hours under nitrogen atmosphere. The mixture was concentrated and the residue was extracted with EtOAc (20*3 mL) / H2O (10 mL). The organic layer was washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by SGC (PE / EA=4:1) to give tert-butyl 4-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate (160 mg, 55%) as a yellow solid. LCMS (ESI) m / z: 464.3 [M+H]+.

[0718] Step 2: Synthesis of tert-butyl 4-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-1-carboxylate.

[0719] To a solution of tert-butyl 4-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1(2H)-carboxylate (160 mg, 0.35 mmol) in MeOH (20 mL) was added 10% Pd / C (16 mg) and the resulting mixture was stirred at room temperature under a hydrogen atmosphere for 1 hour. The mixture was filtered and concentrated, and the resulting crude product was purified by preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5% to 95%) to give tert-butyl 4-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-1-carboxylate (130 mg, 81%) as a yellow solid. 1H NMR (400MHz, CDCl3) δ7.78(d,J=8.0Hz,2H),7.39(t,J=8.0Hz,2H),7.05(t,J=7.2Hz,1H),4.22(bs,2H),4.06(t,J=8.4Hz,2H),3.79(s,8H) ,3.06-3.02(m,2H),2.86-2.79(m,2H),2.61-2.60(m,1H),1.89-1.82(m,2H),1.73-1.69(m,2H),1.51(s,9H); LCMS(ESI)m / z:466.2[M+H]+.

[0720] Step 3: Synthesis of 4-(7-phenyl-4-(piperidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0721] To a solution of tert-butyl 4-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-1-carboxylate (100 mg, 0.2 mmol) in dichloromethane (2 mL) was added TFA (0.5 mL) at 0°C. The mixture was then stirred at room temperature for 2 hours and concentrated. The residue was purified by preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5% to 95%) to give 4-(7-phenyl-4-(piperidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (55 mg, 70%) as a white solid. 1 H NMR (400MHz, CDCl3) δ7.79(d,J=8.0Hz,2H),7.38(t,J=8.0Hz,2H),7.05(t,J=7.2Hz,1H),4.06(t,J=8.0Hz,2H),3.80(s,8H),3.27(d,J=12 .0Hz,2H),3.04(t,J=8.4Hz,2H),2.82-2.76(m,2H),2.64-2.60(m,1H),1.97-1.89(m,2H),1.69-1.66(m,2H); LCMS(ESI)m / z:366.1[M+H]+.

[0722] Step 4: Synthesis of 4-(4-(1-methylpiperidin-4-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0723] To a solution of 4-(7-phenyl-4-(piperidin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (40 mg, 0.11 mmol) in methanol (5 mL) was added formaldehyde (4 mg, 0.12 mmol). The mixture was stirred at room temperature for 2 hours, and then sodium cyanoborohydride (35 mg, 0.55 mmol) was added to the mixture. The mixture was stirred at room temperature for another 12 hours and concentrated. The resulting crude product was purified by preparative HPLC (0.05% NH4HCO3 / H2O:CH3CN=5% to 95%) to give 4-(4-(1-methylpiperidin-4-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (35.9 mg, 85%) as a white solid. 1 H NMR (400MHz, CDCl3) δ7.78(d,J=8.0Hz,2H),7.38(t,J=8.0Hz,2H),7.04(t,J=7.2Hz,1H),4.05(t,J=8.4Hz,2H),3.79(s ,8H),3.06-2.99(m,4H),2.43(bs,1H),2.34(s,3H),2.09-2.00(m,4H),1.74-1.63(m,2H); LCMS(ESI)m / z:380.3[M+H]+.

[0724] Synthesis of tert-butyl 3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)azetidine-1-carboxylate (Compound 113):

[0725]

[0726] To a solution of 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (50 mg, 0.158 mmol) and bis(tri-tert-butylphosphine)palladium(0) (16 mg, 0.031 mmol) in N,N-dimethylacetamide (2 mL) was added a solution of (1-(tert-butoxycarbonyl)azetidin-3-yl)zinc(II) iodide (0.5 M in N,N-dimethylacetamide) (1.264 mL, 0.632 mmol) at room temperature. The resulting mixture was stirred at 80° C. for 16 hours and then quenched with saturated ammonium chloride solution (10 mL). The mixture was then extracted with ethyl acetate (20 mL×3), and the organic layers were combined, washed with water (20 mL×2), brine (20 mL), dried over sodium sulfate, filtered and concentrated. The obtained crude product was purified by preparative HPLC (SunFire C18, 4.6*50mm, 3.5um column Xbridge C183.5μm 4.6×50mm column. The elution system used was a gradient of 5%-95% within 1.5 minutes, a flow rate of 2ml / min, and the solvent was acetonitrile / 0.01% aqueous ammonium bicarbonate solution) to give tert-butyl 3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)azetidine-1-carboxylate (4.7mg, 7%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ7.82(d,J=8.0Hz,2H),7.36(t,J=7.6Hz,2H),7.03(t,J=7.2Hz,1H),4. 21-4.17(m,4H),4.08(t,J=8.4Hz,2H),3.80-3.73(m,9H),3.00(t,J=8.4Hz,2H),1.48(s,9H). LCMS(ESI)m / z:438.1[M+H] + .

[0727] The following compounds were synthesized according to the scheme described above:

[0728]

[0729]

[0730]

[0731] Synthesis of cyclopropyl(3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-1-yl)methanone (Compound 118):

[0732]

[0733] Step 1: Synthesis of tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-2,5-dihydro-1H-pyrrole-1-carboxylate.

[0734] A solution of tert-butyl 3-oxopyrrolidine-1-carboxylate (1400 mg, 7.567 mmol) and N,N-diisopropylethylamine (2928 mg, 22.701 mmol) in dichloromethane (50 mL) was cooled to -78 ° C and stirred for 10 minutes. Trifluoromethanesulfonic anhydride (2560 mg, 9.081 mmol) was then added, and the mixture was warmed and stirred at 25 ° C for 16 hours. The reaction was quenched with aqueous ammonium chloride and extracted with dichloromethane (50 mL×3). The organic layer was dried and concentrated to give tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-2,5-dihydro-1H-pyrrole-1-carboxylate (800 mg, 33%) as a yellow oil. LC-MS: m / z=262(M-56+H) + .

[0735] Step 2: Synthesis of tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate.

[0736] A solution of tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-2,5-dihydro-1H-pyrrole-1-carboxylate (2800 mg, 8.832 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (4487 mg, 17.665 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (325 mg, 0.441 mmol) and potassium acetate (2600 mg, 26.532 mmol) in dioxane (80 mL) was stirred at 75° C. for 4 hours. Water was then added and the resulting mixture was extracted with ethyl acetate (50 mL×3). The organic layer was dried and concentrated. The crude product was purified by silica gel column (petroleum ether:ethyl acetate 50:1 to 10:1) to give tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (2050 mg, 78%) as a yellow solid. LC-MS: m / z=240 (M-56+H) + .

[0737] Step 3: Synthesis of tert-butyl 3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate.

[0738] A solution of tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (280 mg, 0.95 mmol), 4-(4-chloro-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (200 mg, 0.63 mmol), bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg, 0.03 mmol) and potassium carbonate (260 mg, 1.89 mmol) in dioxane / water (30 mL) was stirred at 85° C. for 4 hours. Water was then added and the mixture was extracted with ethyl acetate (50 mL×3). The organic layer was dried and concentrated, and the resulting crude product was purified by silica gel column chromatography (petroleum ether:ethyl acetate, 50:1 to 10:1) to give tert-butyl 3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (200 mg, 71%) as a yellow solid. LC-MS: m / z=450 (M+H) + .

[0739] Step 4: Synthesis of tert-butyl 3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidine-1-carboxylate.

[0740] A suspension of tert-butyl 3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,5-dihydro-1H-pyrrole-1-carboxylate (200 mg, 0.445 mmol) and palladium / carbon (100 mg) in methanol (5 mL) was stirred at 25° C. for 16 hours. The mixture was filtered, and the filtrate was concentrated and dried to give tert-butyl 3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidine-1-carboxylate (180 mg, 90%) as a yellow solid. LC-MS: m / z=452 (M+H) + .

[0741] Step 5: Synthesis of 4-(7-phenyl-4-(pyrrolidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0742] A solution of tert-butyl 3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidine-1-carboxylate (420 mg, 0.931 mmol) and HCl / dioxane (4 mL) in dichloromethane (6 mL) was stirred at 25° C. for 2 hours. The mixture was concentrated to give 4-(7-phenyl-4-(pyrrolidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (280 mg, 85%) as a yellow solid. LC-MS: m / z=352 (M+H) + .

[0743] Step 6: Synthesis of cyclopropyl(3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-1-yl)methanone.

[0744] A solution of 4-(7-phenyl-4-(pyrrolidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (80 mg, 0.228 mmol) and triethylamine (69 mg, 0.684 mmol) in dichloromethane (5 mL) was stirred at 25° C. for 10 minutes. Cyclopropanecarbonyl chloride (28 mg, 0.274 mmol) was then added and the resulting mixture was stirred at room temperature for 2 hours. It was filtered and the filtrate was concentrated. The obtained crude product was purified by preparative HPLC (column Xbridge 21.2*250mm C18, 10um, mobile phase A: water (10mmol / L ammonium bicarbonate) B: acetonitrile) to give cyclopropyl(3-(2-morpholino-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-1-yl)methanone (43.1 mg, 45%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ7.80(d,J=8.0hz,2H),7.37(t,J=7.2Hz,2H),7.01(t,J=7.2Hz,1H),4.08 -4.05(m,2H),3.93-3.84(m,2H),3.76-3.64(m,9H),3.56-3.49(m,2H),3.07-3.00(m ,2H),2.22-2.04(m,2H),1.79-1.76(m,1H),0.75-0.73(m,4H); LC-MS: m / z=420(M+H) + .

[0745] The following compounds were synthesized according to the scheme described above:

[0746]

[0747]

[0748] Synthesis of 4-(4-(1-methylpyrrolidin-3-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 121):

[0749]

[0750] A mixture of 4-(7-phenyl-4-(pyrrolidin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (70 mg, 0.112 mmol), formaldehyde (13 mg, 0.398 mmol) and sodium cyanoborohydride (25 mg, 0.398 mmol) in methanol (4 mL) was stirred at 25 ° C for 2 hours. Water (10 mL) was then added and the mixture was extracted with ethyl acetate (30 mL×3). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column (50:1 to 10:1 dichloromethane:methanol) to give 4-(4-(1-methylpyrrolidin-3-yl)-7-phenyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (22.4 mg, 28%). 1 H NMR (400MHz, DMSO-d6) δ7.80(d,J=8.0Hz,2H),7.36(t,J=7.6Hz,2H),7.00(t,J=7.2Hz,1H),4.03(t,J=8.4Hz,2H),3.66(s,8H),3. 31-3.27(m,2H),3.01-2.92(m,3H),2.79-2.78(m,1H),2.48-2.44(m,1H),2.31(s,3H),2.09-2.04(m,2H); LC-MS: m / z=366.3(M+H) + .

[0751] Synthesis of 4-(4-(2-(3-methoxyphenyl)cyclopropyl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 122):

[0752]

[0753] Step 1: Synthesis of (E)-4-(4-(3-methoxyphenylvinyl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0754] A mixture of 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (317 mg, 1.0 mmol), 1-methoxy-3-vinylbenzene (134 mg, 1.0 mmol), palladium(II) acetate (23 mg, 0.1 mmol), tri(o-tolyl)phosphine (60 mg, 0.2 mmol) and triethylamine (202 mg, 2.0 mmol) in N,N-dimethylformamide (10 mL) was stirred at 120° C. for 16 hours under a nitrogen atmosphere. The mixture was poured into water and extracted with ethyl acetate (100 mL*2). The organic phases were combined and concentrated, and the residue was subjected to silica gel column chromatography to obtain (E)-4-(4-(3-methoxyphenylvinyl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (220 mg, 0.53 mmol) as a brown solid. LCMS (ESI) m / z: 416.1 [M+H] + .

[0755] Step 2: Synthesis of 4-(4-(2-(3-methoxyphenyl)cyclopropyl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0756] To a stirred suspension of nitrosomethylurea (4.0 g, 38.8 mmol) in diethyl ether (25 mL) was added aqueous potassium hydroxide solution (50%, 25 mL) at 0°C. The ether phase was separated and dried over potassium hydroxide. This resulting solution (25 mL) was added dropwise to a solution of (E)-4-(4-(3-methoxyphenylvinyl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (180 mg, 25.7 mmol) in tetrahydrofuran (50 mL), followed by the addition of palladium(II) acetate (38 mg, 0.17 mmol) and the mixture was stirred at 0°C for 30 minutes. The reaction was then quenched with 2 mL of acetic acid, followed by the addition of water (100 mL) and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (100 mL*2), and the organic layers were combined and concentrated. The residue was subjected to silica gel column chromatography to give 4-(4-(2-(3-methoxyphenyl)cyclopropyl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (70 mg) as an off-white solid. 1H NMR (400MHz, CDCl3) δ9.07 (d, J=2.6Hz, 1H), 8.25 (dd, J=4.7, 1.2Hz, 1H), 8.12 (ddd, J=8.5, 2. 7,1.4Hz,1H),7.30–7.27(m,1H),7.21(t,J=7.9Hz,1H),6.80–6.67(m,3H),4.03(dt,J=12.0, 4.0Hz,2H),3.81(s,3H),3.77(s,8H),3.11(dt,J=9.0,7.3Hz,2H),2.62–2.55(m,1H),2.04–1 .94(m,1H),1.86–1.79(m,1H),1.40(ddd,J=8.3,6.1,4.1Hz,1H); LCMS(ESI)m / z:430.2[M+H] + .

[0757] Synthesis of 4-(4-(2-(3-methoxyphenyl)pyrimidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (Compound 123):

[0758]

[0759] Step 1: Synthesis of 4-methoxy-2-(3-methoxyphenyl)pyrimidine.

[0760] A mixture of 2-chloro-4-methoxypyrimidine (2.88 g, 20.0 mmol), 3-methoxyphenylboronic acid (3.04 g, 20.0 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (816 mg, 1.0 mmol) and sodium carbonate (4.24 g, 40.0 mmol) in dioxane (100 mL) and water (4 mL) was stirred at 90 ° C for 4 hours under a nitrogen atmosphere. The mixture was then poured into water and extracted with ethyl acetate (200 mL*2). The organic phases were combined, concentrated, and the residue was subjected to silica gel column chromatography (10% ethyl acetate / petroleum ether) to give 4-methoxy-2-(3-methoxyphenyl)pyrimidine (3.8 g) as a white solid. LCMS (ESI) m / z: 217.2 [M+H] + .

[0761] Step 2: Synthesis of 2-(3-methoxyphenyl)pyrimidin-4-ol.

[0762] A mixture of 4-methoxy-2-(3-methoxyphenyl)pyrimidine (3.7 g, 17.1 mmol) and hydrochloric acid (6N, 15 mL) was stirred at 100 ° C for 2 hours. The mixture was poured into water and extracted with dichloromethane (200 mL*2). The organic phases were combined, dried and concentrated to give 2-(3-methoxyphenyl)pyrimidin-4-ol (2.2 g) as a white solid. LCMS (ESI) m / z: 203.1 [M+H] + .

[0763] Step 3: Synthesis of 4-chloro-2-(3-methoxyphenyl)pyrimidine.

[0764] A mixture of 2-(3-methoxyphenyl)pyrimidine-4-ol (2.0 g, 10.0 mmol) in phosphorus oxychloride (20 mL) was stirred at 120 ° C for 2 hours. The mixture was concentrated, the residue was dissolved in dichloromethane (200 mL) and poured onto crushed ice. The organic layer was separated, and the aqueous layer was extracted with dichloromethane (200 mL*3). The organic phases were combined, concentrated, and the residue was subjected to silica gel column chromatography (30% ethyl acetate / petroleum ether) to give 4-chloro-2-(3-methoxyphenyl)pyrimidine (1.8 g, 81%) as a gray solid. LCMS (ESI) m / z: 221.1 / 223.1 [M+H] + .

[0765] Step 4: Synthesis of 4-(4-(2-(3-methoxyphenyl)pyrimidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine.

[0766] A mixture of 4-chloro-2-(3-methoxyphenyl)pyrimidine (200 mg, 0.9 mmol), hexamethyldistanane (589 mg, 1.8 mmol) and bis(triphenylphosphine)palladium(II) chloride (64 mg, 0.09 mmol) in dioxane (15 mL) was stirred at 100° C. for 2 hours under a nitrogen atmosphere. The mixture was poured into dichloromethane (200 mL), and the organic phase was washed successively with saturated aqueous potassium fluoride solution (100 mL) and brine, and concentrated to give 2-(3-methoxyphenyl)-4-(trimethylstannyl)pyrimidine (340 mg) as a brown oil. The oil was mixed with 4-(4-chloro-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (200 mg, 0.63 mmol), tetrakis(triphenylphosphine)palladium (104 mg, 0.09 mmol) in dioxane (15 mL) and stirred for another 2 hours at 100° C. The mixture was concentrated, purified by silica gel column chromatography (25% methanol / dichloromethane) and washed with methanol (20 mL) to give 4-(4-(2-(3-methoxyphenyl)pyrimidin-4-yl)-7-(pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine (56.4 mg, 19%) as a yellow solid. 1 H NMR(400MHz, CDCl3)δ9.16(s,1H),8.89(d,J=5.1Hz,1H),8.32(d,J=3.7Hz,1H),8.17(t,J=6.3Hz,2H),8.10–8.02(m,2H), 7.42(t,J=7.9Hz,1H), 7.32(dd,J=8.4,4.7Hz,1H), 7.05(dd,J=8.1,2.3Hz,1H), 4.13(t,J=8.1Hz,2H), 3.93–3.76(m,13H). LCMS(ESI)m / z:468.1[M+H] + .

[0767] The following compounds were synthesized according to the scheme described above:

[0768]

[0769]

[0770] Synthesis of 4-(6-(1-methylpyrrolidin-3-yl)-9-phenyl-9H-purin-2-yl)morpholine (Compound 126):

[0771]

[0772] Step 1: Synthesis of 2,6-dichloro-9-phenyl-9H-purine.

[0773] To a solution of 2,6-dichloro-9H-purine (1.88 g, 10 mmol) and phenylboronic acid (1.83 g, 15 mmol) in dichloromethane (50 mL) was added copper acetate (900 mg, 5 mmol) and 1,10-phenanthroline (900 mg, 5 mmol) and the resulting mixture was stirred at room temperature under oxygen for 2 days. The mixture was filtered and the filtrate was concentrated. The residue was subjected to flash chromatography and eluted with 0-5% methanol / dichloromethane to give 2,6-dichloro-9-phenyl-9H-purine (1.1 g, 42%) as a white solid. 1H NMR (400MHz, CDCl3) δ8.40 (s, 1H), 7.60-7.60 (m, 2H), 7.56-7.46 (m, 2H), 7.48-7.44 (m, 1H); LCMS (ESI) m / z: 265.0 [M+H]+.

[0774] Step 2: Synthesis of tert-butyl 4-(2-chloro-9-phenyl-9H-purin-6-yl)-2,3-dihydro-1H-pyrrole-1-carboxylate.

[0775] To a solution of 2,6-dichloro-9-phenyl-9H-purine (132 mg, 0.5 mmol) in dioxane (5 mL) and water (1 mL) were added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-pyrrole-1-carboxylate (148 mg, 0.5 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (40 mg, 0.05 mmol) and sodium carbonate (159 mg, 1.5 mmol) at 25° C. and the resulting mixture was stirred at 80° C. for 6 hours under argon protection. It was cooled and the mixture was diluted with water (20 mL). The resulting precipitate was collected by filtration, washed with water (20 mL) and dried to give tert-butyl 4-(2-chloro-9-phenyl-9H-purin-6-yl)-2,3-dihydro-1H-pyrrole-1-carboxylate (180 mg, 90%) as a yellow solid. LCMS (ESI) m / z: 342.1 [M-56+H]+.

[0776] Step 3: Synthesis of tert-butyl 4-(2-morpholino-9-phenyl-9H-purin-6-yl)-2,3-dihydro-1H-pyrrole-1-carboxylate.

[0777] To a mixture of tert-butyl 4-(2-chloro-9-phenyl-9H-purine-6-yl)-2,3-dihydro-1H-pyrrole-1-carboxylate (40 mg, 0.1 mmol) in N,N-dimethylacetamide (2 mL) was added morpholine (44 mg, 0.5 mmol) and the mixture was stirred at 100 ° C for 16 hours. It was then extracted with ethyl acetate (10 mL * 3) and washed with water (10 mL * 3). The organic layers were combined, dried and concentrated. The residue was subjected to preparative TLC (UV254, silica, petroleum ether / ethyl acetate = 1 / 1) to give tert-butyl 4-(2-morpholino-9-phenyl-9H-purine-6-yl)-2,3-dihydro-1H-pyrrole-1-carboxylate (20 mg, 44%) as a yellow solid. LCMS (ESI) m / z: 449.1 [M + H] +.

[0778] Step 4: Synthesis of tert-butyl 3-(2-morpholino-9-phenyl-9H-purin-6-yl)pyrrolidine-1-carboxylate.

[0779] To a mixture of tert-butyl 4-(2-morpholino-9-phenyl-9H-purine-6-yl)-2,3-dihydro-1H-pyrrole-1-carboxylate (45 mg, 0.1 mmol) in methanol (5 mL) was added palladium / carbon (10%, 20 mg) and the suspension was stirred at room temperature under hydrogen for 2 hours. The mixture was filtered and the filtrate was concentrated to give tert-butyl 3-(2-morpholino-9-phenyl-9H-purine-6-yl)pyrrolidine-1-carboxylate (45 mg, 99%) as a yellow solid. LCMS (ESI) m / z: 451.2 [M+H] +.

[0780] Step 5: Synthesis of 4-(9-phenyl-6-(pyrrolidin-3-yl)-9H-purin-2-yl)morpholine.

[0781] A mixture of tert-butyl 3-(2-morpholino-9-phenyl-9H-purine-6-yl)pyrrolidine-1-carboxylate (45 mg, 0.1 mmol) and hydrochloric acid / dioxane (4M, 2 mL) in dichloromethane (5 mL) was stirred at room temperature for 2 hours. It was then diluted with 10 mL of dichloromethane and the mixture was washed with aqueous sodium bicarbonate solution (10 mL). The organic layer was concentrated to give 4-(9-phenyl-6-(pyrrolidin-3-yl)-9H-purine-2-yl)morpholine (35 mg, 99%) as a yellow solid. LCMS (ESI) m / z: 351.2 [M+H] +.

[0782] Step 6: Synthesis of 4-(6-(1-methylpyrrolidin-3-yl)-9-phenyl-9H-purin-2-yl)morpholine.

[0783] To a solution of 4-(9-phenyl-6-(pyrrolidin-3-yl)-9H-purin-2-yl)morpholine (35 mg, 0.1 mmol) and formaldehyde (35%, 5 drops) in methanol (1 mL) and dichloroethane (2 mL) was added a drop of acetic acid and the mixture was stirred for 1 hour. Sodium cyanoborohydride (31 mg, 0.5 mmol) was then added and the resulting mixture was stirred at room temperature for 16 hours. The reaction was quenched with water (10 mL) and the mixture was extracted with dichloromethane (10 mL*2). The organic phase was concentrated and the crude product was purified by preparative HPLC (BOSTON pHlex ODS10um 21.2×250mm120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 4-(6-(1-methylpyrrolidin-3-yl)-9-phenyl-9H-purin-2-yl)morpholine (6.5 mg, 18%) as a white solid. 1 HNMR (400MHz, CD3OD) δ8.40(s,1H),7.86(d,J=8.0Hz,2H),7.60(t,J=8.0Hz,2H),7.47(t,J=7.6Hz,1H),4.19(pent,J=8.4Hz, 1H), 3.88-3.77 (m, 8H), 3.26 (tJ=9.2Hz, 1H), 3.08-2.83 (m, 3H), 2.52 (s, 3H), 2.44-2.37 (m, 2H); LCMS (ESI) m / z: 365.3[M+H]+.

[0784] The following compounds were synthesized using a similar protocol to that described above:

[0785]

[0786] Synthesis of 4-(9-phenyl-6-(pyridin-4-yl)-9H-purin-2-yl)morpholine (Compound 128):

[0787]

[0788] Step 1: Synthesis of 2-chloro-9-phenyl-6-(pyridin-4-yl)-9H-purine.

[0789] Pyridin-4-ylboronic acid (123 mg, 1 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (81 mg, 0.1 mmol) and potassium carbonate (414 mg, 3 mmol) were added to a solution of 2,6-dichloro-9-phenyl-9H-purine (264 mg, 1 mmol) in dioxane (10 mL) and water (2 mL) at 25 ° C. The resulting mixture was stirred at 90 ° C. for 16 hours under argon protection. The mixture was extracted with ethyl acetate (20 mL*3) and washed with water (20 mL). The organic layer was concentrated and the crude product was purified by preparative TLC (silica, UV254, ethyl acetate / petroleum ether=3 / 1) to give 2-chloro-9-phenyl-6-(pyridin-4-yl)-9H-purine (50 mg, 16%) as a yellow solid. LCMS (ESI) m / z: 308.1 [M+H] +. (This step also produced 9-phenyl-2,6-di(pyridin-4-yl)-9H-purine (13 mg, 4%) as a by-product).

[0790] Step 2: Synthesis of 4-(9-phenyl-6-(pyridin-4-yl)-9H-purin-2-yl)morpholine.

[0791] To a mixture of 2-chloro-9-phenyl-6-(pyridin-4-yl)-9H-purine (31 mg, 0.1 mmol) in N,N-dimethylacetamide (2 mL) was added morpholine (44 mg, 0.5 mmol) and stirred at 100° C. for 16 hours. The mixture was purified by preparative HPLC (BOSTON pHlex ODS10um 21.2×250mm120A. The mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 4-(9-phenyl-6-(pyridin-4-yl)-9H-purin-2-yl)morpholine (26 mg, yield 72%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ8.83(d,J=6.0Hz,2H),8.79(s,1H),8.67(d,J=6.0Hz,2H),7.94(d,J=7.6Hz ,2H),7.63(t,J=8.0Hz,2H),7.49(t,J=7.6Hz,1H),3.83-3.72(m,8H); LCMS(ESI)m / z:359.2[M+H]+.

[0792] Synthesis of 2-morpholino-8-phenyl-4-(pyridin-3-ylmethoxy)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one (Compound 129):

[0793]

[0794] Step 1: Synthesis of methyl 2-(6-hydroxy-2-morpholino-4-oxo-1,4-dihydropyrimidin-5-yl)acetate.

[0795] To a solution of triethyl ethane-1,1,2-tricarboxylate (3 g, 12.18 mmol) and morpholine-4-carboximidamide hydrochloride (2 g, 12.18 mmol) in methanol (40 mL) was added sodium methoxide (30% solution in methanol, 6.7 mL, 34.35 mmol). After addition, the mixture was stirred at 80 ° C for 17 hours and concentrated. The crude product methyl 2-(6-hydroxy-2-morpholino-4-oxo-1,4-dihydropyrimidin-5-yl)acetate (3 g, 91.56%) obtained as a brown solid was used in the next step without further purification. LCMS (ESI) m / z: 270.0 [M+H] + .

[0796] Step 2: Synthesis of methyl 2-(4,6-dichloro-2-morpholinopyrimidin-5-yl)acetate.

[0797] A mixture of 2-(6-hydroxy-2-morpholino-4-oxo-1,4-dihydropyrimidin-5-yl)acetic acid methyl ester (3g, 11.15mmol) and phosphorus oxychloride (20mL) was stirred at 110 ° C for 16 hours and then concentrated. The residue was diluted with ethyl acetate / water (20mL / 20mL), the organic layer was separated, and the aqueous layer was extracted twice with ethyl acetate (20mL). The organic phase was combined, washed with brine (30mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by Combi-Flash (Biotage, 40g silica gel, eluted with 10% to 30% ethyl acetate / petroleum ether) to obtain 2-(4,6-dichloro-2-morpholinopyrimidin-5-yl)acetic acid methyl ester (1.3g, 38.2%) as a white solid. LCMS (ESI) m / z: 306.1 [M+H] + .

[0798] Step 3: Synthesis of methyl 2-(4-chloro-2-morpholino-6-(pyridin-3-ylmethoxy)pyrimidin-5-yl)acetate.

[0799] To a solution of pyridin-3-ylmethanol (0.18 g, 1.65 mmol) in tetrahydrofuran (10 mL) was added sodium hydride (100 mg, 2.5 mmol) in portions and the mixture was stirred at 20 ° C for 10 minutes. Then a solution of methyl 2-(4,6-dichloro-2-morpholinopyrimidin-5-yl)acetate (0.5 g, 1.64 mmol) in tetrahydrofuran (2 mL) was slowly added. After addition, the mixture was stirred at 20 ° C for 2 hours, then quenched with water (15 mL) and extracted with ethyl acetate (20 mL). The organic phase was dried over sodium sulfate, filtered and concentrated. The residue was purified by Combi-Flash (Biotage, 40 g silica gel, eluted with 30% to 40% ethyl acetate / petroleum ether) to give methyl 2-(4-chloro-2-morpholino-6-(pyridin-3-ylmethoxy)pyrimidin-5-yl)acetate (0.3 g, 48.4%) as a white solid. LCMS (ESI) m / z: 379.2 [M+H] + .

[0800] Step 4: Synthesis of 2-morpholino-4-(pyridin-3-ylmethoxy)-7-m-tolyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one.

[0801] A mixture of 2-(4-chloro-2-morpholino-6-(pyridin-3-ylmethoxy)pyrimidin-5-yl)acetic acid methyl ester (0.16 g, 0.42 mmol), tris(dibenzylideneacetone)dipalladium (39 mg, 0.042 mmol), 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (40 mg, 0.084 mmol) and cesium carbonate (0.34 g, 1.06 mmol) in toluene (15 mL) was stirred at 90 ° C for 3 hours under a nitrogen atmosphere. The reaction mixture was filtered and concentrated. The residue was purified by preparative HPLC to give 2-morpholino-4-(pyridin-3-ylmethoxy)-7-m-tolyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one (48 mg, 27.4%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ8.69(d,J=1.6Hz,1H),8.55(dd,J=4.8,1.2hz,1H),7.88(d,J=8Hz,1H),7.46-7. 34(m,2H),7.27-7.16(m,3H),5.49(s,2H),3.64-3.51(m,10H),2.35(s,3H); LCMS(ESI)m / z:417.9[M+H] + .

[0802] Synthesis of 2-morpholino-8-phenyl-4-(pyridin-3-ylmethoxy)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one (Compound 130):

[0803]

[0804] Step 1: Synthesis of dimethyl 2-(2-ethoxy-2-oxoethoxy)malonate.

[0805] A mixture of 1,3-dimethoxy-1,3-dioxopropane-2-diazonium salt (4g, 25mmol), ethyl 2-hydroxyacetate (1.2mL, 12.5mmol) and rhodium acetate (II) dimer (2g, 4.5mmol) in dichloromethane (40mL) was stirred at 25 ° C for 16 hours. The reaction mixture was diluted with dichloromethane (20mL) and filtered. The filtrate was concentrated and the residue was purified by flash chromatography (Biotage, 40g silica gel, eluted with 30% to 60% ethyl acetate / petroleum ether) to give dimethyl 2-(2-ethoxy-2-oxoethoxy)malonate (3.3g, 56%) as a colorless oil. LCMS (ESI) m / z: 235.1 [M+H] + .

[0806] Step 2: Synthesis of methyl 2-(6-hydroxy-2-morpholino-4-oxo-1,4-dihydropyrimidin-5-yloxy)acetate.

[0807] To a solution of dimethyl 2-(2-ethoxy-2-oxoethoxy)malonate (3 g, 12.82 mmol) and morpholine-4-carboximidamide hydrochloride (2.1 g, 12.82 mmol) in methanol (70 mL) was added sodium methoxide (30% solution in methanol, 7.5 mL, 38.46 mmol). After addition, the mixture was stirred at 80 °C for 17 hours and concentrated to give methyl 2-(6-hydroxy-2-morpholino-4-oxo-1,4-dihydropyrimidin-5-yloxy)acetate (2.1 g, 57.5%) as a brown solid, which was used directly in the next step without further purification. LCMS (ESI) m / z: 286.1 [M+H] + .

[0808] Step 3: Synthesis of methyl 2-(4,6-dichloro-2-morpholinopyrimidin-5-yloxy)acetate.

[0809] A mixture of 2-(6-hydroxy-2-morpholino-4-oxo-1,4-dihydropyrimidin-5-yloxy)acetic acid methyl ester (2g, 7mmol), N,N-dimethylaniline (0.85g, 7mmol) and phosphorus oxychloride (15mL) was stirred at 110 ° C for 16 hours. It was concentrated, the residue was diluted with ethyl acetate / water (20mL / 20mL), the organic layer was separated, and the aqueous phase was extracted twice with ethyl acetate (20mL). The organic phases were combined, washed with brine (30mL), dried over sodium sulfate, filtered and concentrated. The residue was subjected to flash chromatography (Biotage, 40g silica gel, eluted with 10% to 30% ethyl acetate / petroleum ether) to obtain 2-(4,6-dichloro-2-morpholinopyrimidin-5-yloxy)acetic acid methyl ester (0.85g, 37.8%) as a yellow solid. LCMS (ESI) m / z: 322.1 [M+H] + .

[0810] Step 4: Synthesis of 2-(4-chloro-2-morpholino-6-(pyridin-3-ylmethoxy)pyrimidin-5-yloxy)acetic acid.

[0811] To a solution of pyridin-3-ylmethanol (68 mg, 0.62 mmol) in tetrahydrofuran (10 mL) was added sodium hydride (38 mg, 0.93 mmol) in batches and the mixture was stirred at 20 ° C for 10 minutes. Then a solution of 2-(4,6-dichloro-2-morpholinopyrimidin-5-yloxy)acetic acid methyl ester (0.2 g, 0.62 mmol) in tetrahydrofuran (2 mL) was slowly added and the resulting mixture was stirred at 20 ° C for 2 hours. It was then quenched with water (15 mL) and extracted with ethyl acetate (20 mL). The aqueous phase was freeze-dried to give crude 2-(4-chloro-2-morpholino-6-(pyridin-3-ylmethoxy)pyrimidin-5-yloxy)acetic acid (0.2 g, 87%) as a white solid, which was used directly in the next step without further purification. LCMS (ESI) m / z: 381.1 [M+H] + .

[0812] Step 5: Synthesis of 2-(4-chloro-2-morpholino-6-(pyridin-3-ylmethoxy)pyrimidin-5-yloxy)-N-phenylacetamide.

[0813] To a solution of 2-(4-chloro-2-morpholino-6-(pyridin-3-ylmethoxy)pyrimidin-5-yloxy)acetic acid (0.18 g, 0.47 mmol) and aniline (66 mg, 0.71 mmol) in N,N-dimethylformamide (15 mL) was added 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.32 g, 0.85 mmol) in portions followed by N,N-diisopropylethylamine (0.18 g, 1.42 mmol). The resulting mixture was stirred at 20 °C for 2 hours and then diluted with ethyl acetate / water (30 mL, 1:1). The layers were separated and the aqueous phase was extracted twice with ethyl acetate (20 mL). The organic phases were combined, washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography (Biotage, 20 g silica gel, with 15% to 20% 7N ammonia in dichloromethane / methanol: dichloromethane = 1:10) to give 2-(4-chloro-2-morpholino-6-(pyridin-3-ylmethoxy)pyrimidin-5-yloxy)-N-phenylacetamide (0.11 g, 51%) as a yellow oil. LCMS (ESI) m / z: 456.1 [M+H] + .

[0814] Step 6: Synthesis of 2-morpholino-8-phenyl-4-(pyridin-3-ylmethoxy)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one.

[0815] A mixture of 2-(4-chloro-2-morpholino-6-(pyridin-3-ylmethoxy)pyrimidin-5-yloxy)-N-phenylacetamide (0.1 g, 0.22 mmol), tris(dibenzylideneacetone)dipalladium (20 mg, 0.022 mmol), 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (21 mg, 0.044 mmol) and cesium carbonate (0.18 g, 0.55 mmol) in toluene (10 mL) was stirred at 100° C. for 16 hours under a nitrogen atmosphere. It was filtered and concentrated, and the residue was subjected to preparative HPLC to give 2-morpholino-8-phenyl-4-(pyridin-3-ylmethoxy)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one (5 mg, 5.4%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ8.69(s,1H),8.56(d,J=4.8Hz,1H),7.89(d,J=8Hz,1H),7.52-7.38(m,4H),7.28(d ,J=7.2Hz,2H),5.46(s,2H),4.77(s,2H),3.54-3.57(m,4H),3.34-3.27(m,4H); LCMS(ESI)m / z:420.0[M+H] + .

[0816] Synthesis of 4-(1-phenyl-6-(pyridin-3-ylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine (Compound 131):

[0817]

[0818] Step 1: Synthesis of 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine.

[0819] To a stirred solution of 2,4,6-trichloropyrimidine-5-carbaldehyde (630 mg, 3 mmol) in ethanol (20 mL) was added phenylhydrazine (324 mg, 3 mmol) and triethylamine (910 mg, 9 mmol) dropwise in sequence at -78 ° C. The resulting mixture was stirred at -78 ° C for 0.5 hours and at 0 ° C for 2 hours. The mixture was then quenched with water (20 mL), and the resulting precipitate was collected by filtration and dried to give 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine (790 mg, 99%) as a white solid. LCMS (ESI) m / z: 265.0 [M+H] +.

[0820] Step 2: Synthesis of 4-(6-chloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine.

[0821] To a mixture of 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine (792 mg, 3 mmol) in dichloromethane (10 mL) was added morpholine (520 mg, 6 mmol) and DIPEA (774 mg, 6 mmol) at 0°C and the resulting mixture was stirred at room temperature for 16 hours. The mixture was concentrated and purified by column chromatography, eluting with 0-30% ethyl acetate / petroleum ether to give 4-(6-chloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine (800 mg, 85%) as a yellow solid. LCMS (ESI) m / z: 316.0 [M+H]+.

[0822] Step 3: Synthesis of 4-(1-phenyl-6-(pyridin-3-ylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine.

[0823] To a mixture of pyridin-3-ylmethanol (218 mg, 2 mmol) in tetrahydrofuran (10 mL) was added sodium hydride (120 mg, 3 mmol) followed by 4-(6-chloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine (315 mg, 1 mmol) at 0°C and the resulting mixture was stirred at room temperature for 16 hours. The reaction was quenched with water (10 mL) and the precipitate formed was collected by filtration and dried. The crude product thus obtained was purified by preparative HPLC (BOSTON pHlex ODS10um 21.2×250mm120A. Mobile phase was acetonitrile / 0.1% formic acid) to give 4-(1-phenyl-6-(pyridin-3-ylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine (75 mg, 19%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ8.70(d,J=1.6Hz,1H),8.54(dd,J=4.8,1.6Hz,1H),8.47(s,1H),8.11(dd,J=4.8,0.8Hz,2H),7.90-7.87(m, 1H),7.56-7.52(m,2H),7.43-7.32(m,2H),5.44(s,2H),3.92(t,J=4.8Hz,4H),3.75(t,J=4.8Hz,4H); LCMS(ESI)m / z:389.2[M+H]+.

[0824] Synthesis of 4-(1-phenyl-4-(pyridin-3-ylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)morpholine (Compound 132):

[0825]

[0826] Step 1: Synthesis of 6-chloro-1-phenyl-4-(pyridin-3-ylmethoxy)-1H-pyrazolo[3,4-d]pyrimidine.

[0827] To a solution of pyridin-3-ylmethanol (109 mg, 1 mmol) in tetrahydrofuran (10 mL) was added sodium hydride (60 mg, 1.5 mmol, 60%) at 0 ° C, followed by 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine (264 mg, 1 mmol), and the resulting mixture was stirred at room temperature for 16 hours. The reaction was quenched with water (10 mL) and the mixture was extracted with ethyl acetate (20 mL * 2). The organic layer was dried and concentrated to give 6-chloro-1-phenyl-4-(pyridin-3-ylmethoxy)-1H-pyrazolo[3,4-d]pyrimidine (250 mg, 74%) as a yellow solid. LCMS (ESI) m / z: 338.0 [M + H] +.

[0828] Step 2: Synthesis of 4-(1-phenyl-4-(pyridin-3-ylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)morpholine.

[0829] To a mixture of 6-chloro-1-phenyl-4-(pyridin-3-ylmethoxy)-1H-pyrazolo[3,4-d]pyrimidine (170 mg, 0.5 mmol) in dichloromethane (10 mL) was added morpholine (82 mg, 1 mmol) followed by DIPEA (129 mg, 1 mmol) at 0°C and the resulting mixture was stirred at room temperature for 16 hours. It was then concentrated and the resulting crude product was purified by preparative HPLC (BOSTON pHlex ODS10um 21.2×250mm120A. Mobile phase was acetonitrile / 0.1% ammonium bicarbonate) to give 4-(1-phenyl-4-(pyridin-3-ylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)morpholine (40 mg, 21%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ8.76(d,J=4.6Hz,1H),8.58(dd,J=4.8Hz,1H),8.20-8.18(m,3H),7.95(d,J=8Hz,1H),7.53(t,J=8Hz,2H),7.45 (dd, J=7.6, 4.8hz, 1H), 7.30 (t, J=6.8Hz, 1H), 5.63 (s, 2H), 3.83 (t, J=4.4Hz, 4H), 3.70 (t, J=4.8Hz, 4H); LCMS (ESI) m / z: 389.1[M+H]+.

[0830] Synthesis of 4-(3-phenyl-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)morpholine (Compound 133):

[0831]

[0832] Step 1: Synthesis of 2-chloro-4-methyl-6-(pyridin-4-yl)pyrimidin-5-amine.

[0833] A mixture of 2,4-dichloro-6-methylpyrimidin-5-amine (9 g, 51 mmol), pyridin-4-ylboronic acid (6.21 g, 51 mmol), potassium carbonate (17.5 g, 126 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (3.7 g, 5.1 mmol) in dioxane / water (150 mL / 25 mL) was stirred at 80 ° C for 4 hours under a nitrogen atmosphere. The reaction mixture was concentrated and the crude product was purified by silica gel column chromatography (dichloromethane: methanol = 20: 1) to give the target product (6.4 g, 57%) as a yellow solid. LCMS (ESI) m / z: 221.0 [M+H] + .

[0834] Step 2: Synthesis of 5-chloro-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine.

[0835] To a mixture of 2-chloro-4-methyl-6-(pyridin-4-yl)pyrimidin-5-amine (4.55 g, 20.6 mmol), acetic anhydride (4.42 g, 43.3 mmol), potassium acetate (4.05 g, 41.2 mmol) and acetic acid (4.33 g, 72.2 mmol) in toluene (100 mL) was added tert-butyl nitrite (2.66 g, 25.8 mmol) at room temperature and the reaction was stirred at 120° C. for 2 hours. It was concentrated and the crude product was purified by silica gel column chromatography (dichloromethane: methanol = 15: 1) to give the target product (2.3 g, 48%) as a yellow solid. LCMS (ESI) m / z: 232.0 [M+H] + .

[0836] Step 3: Synthesis of 3-bromo-5-chloro-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine.

[0837] A mixture of 5-chloro-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine (2.1 g, 9.07 mmol) and N-bromosuccinimide (2.3 g, 9.97 mmol) in N,N-dimethylformamide (25 mL) was stirred at 25 ° C for 2 hours. The mixture was diluted with water and extracted with ethyl acetate (100m*3). The organic layers were combined and concentrated, and the residue was subjected to silica gel column chromatography (dichloromethane: methanol = 10: 1) to give the target product (1.6 g, 57%) as a yellow solid. LCMS (ESI) m / z: 310.0 [M+H] + .

[0838] Step 4: Synthesis of 4-(3-bromo-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)morpholine.

[0839] A mixture of 3-bromo-5-chloro-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine (1.6 g, 5.15 mmol) and morpholine (4.49 g, 51.52 mmol) in 1-methyl-2-pyrrolidone (20 mL) was stirred at 100°C for 8 hours. Water (100 mL) was added to the mixture, and the resulting precipitate was collected by filtration and dried to give the desired product as a yellow solid (1.1 g, 59.11%). LCMS (ESI) m / z: 361.0 [M+H] + .

[0840] Step 5: Synthesis of 4-(3-phenyl-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)morpholine.

[0841] A mixture of 4-(3-bromo-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)morpholine (0.08 g, 0.22 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.016 g, 0.022 mmol), cesium carbonate (0.217 g, 0.66 mmol) and phenylboronic acid (0.054 g, 0.44 mmol) in dioxane / water (3 mL / 0.5 mL) was stirred at 90° C. for 4 hours. It was then concentrated and the residue was subjected to preparative HPLC (SunFire C18, 4.6*50 mm, 3.5 um column Xbridge C18 3.5 μm 4.6×50 mm column. The mobile phase was acetonitrile / 10 mM formic acid aqueous solution) to give the desired product (11.8 mg, 14.87%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ14.11(s,1H),8.88(s,2H),8.44(d,J=7.3Hz,2H),8.26(s,2H),7.53 (d,J=7.4Hz,2H),7.40(d,J=6.2Hz,1H),3.87(s,4H),3.78(s,4H); LCMS(ESI)m / z:358.8[M] + .

[0842] Synthesis of 4-(3-(3-(1H-pyrazol-1-yl)phenyl)-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)morpholine (Compound 134):

[0843]

[0844] A mixture of 4-(3-bromo-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)morpholine (100 mg, 0.28 mmol), 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (48 mg, 0.32 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg, 0.0028 mmol) and cesium carbonate (209 mg, 0.84 mmol) in dioxane (5 mL) and water (0.5 mL) was stirred at 110° C. for 16 hours under a nitrogen atmosphere. Water was then added and the mixture was extracted with ethyl acetate (50 mL×3). The organic layer was dried and concentrated, and the resulting crude product was purified by preparative TLC (petroleum ether:ethyl acetate=50:1 to 10:1) to give 4-(3-(3-(1H-pyrazol-1-yl)phenyl)-7-(pyridin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)morpholine (14.8 mg, 24%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ14.00(s,1H),9.00(s,1H),8.88(dd,J=4.5,1.6Hz,2H),8.56(s,1H),8.41(s,1H),8.17(s,1H),7.88 -7.76(m,2H),7.66(t,J=8.1Hz,1H),6.60(s,1H),3.91(s,4H),3.86-3.68(m,4H); LCMS(ESI)m / z:425.1[M+H] + .

[0845] Synthesis of 4-(7-phenyl-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (Compound 135):

[0846]

[0847] Step 1: Synthesis of 2-chloro-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine.

[0848] To a solution of 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine (15 g, 77 mmol) in dioxane / water (200 mL / 40 mL) was added pyridin-4-ylboronic acid (5.8 g, 77 mmol), potassium carbonate (21.3 g, 154 mmol) and [1,1'bis(diphenylphosphino)ferrocene]dichloropalladium(II) (5.6 g, 7.7 mmol) at 25°C and the resulting mixture was stirred at 85°C for 2 hours under argon protection. The mixture was then filtered and the filtrate was concentrated to give the target product (15 g, 84%) as a dark solid. LCMS (ESI) m / z: 231.1 [M+H]+.

[0849] Step 2: Synthesis of 7-bromo-2-chloro-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine.

[0850] A mixture of 2-chloro-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine (3.0 g, 13 mmol) and N-bromosuccinimide (2.3 g, 13 mmol) in N,N-dimethylformamide (30 mL) was stirred at 25 ° C for 2 hours. Methanol (100 mL) was added to the mixture, which was filtered and the filtrate was concentrated. The resulting residue was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 1:2) to give the target product (2 g, 50%) as a yellow solid. LCMS (ESI) m / z: 309.2 [M+H] + .

[0851] Step 3: Synthesis of 4-(7-bromo-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine.

[0852] A mixture of 7-bromo-2-chloro-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine (0.3 g, 0.97 mmol) and morpholine (0.5 g, 5.8 mmol) in NMP (3 mL) was stirred at 110 ° C for 5 hours. It was cooled to room temperature and quenched with water (15 mL). The mixture was extracted with ethyl acetate (15 mL*3), the organic layer was concentrated and preparative TLC (dichloromethane: acetate = 1: 1) was performed to obtain the target product as a yellow solid (0.08 g, 23%). LCMS (ESI) m / z: 360.1 [M+H] + .

[0853] Step 4: Synthesis of 4-(7-phenyl-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine.

[0854] A mixture of 4-(7-bromo-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (0.07 g, 0.19 mmol), [1,1'bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.015 g, 0.02 mmol), cesium carbonate (0.19 g, 0.58 mmol) and phenylboronic acid (0.05 g, 0.39 mmol) in dioxane / water (3 mL / 0.5 mL) was stirred at 90° C. for 2 hours. The mixture was concentrated and the resulting residue was subjected to preparative HPLC (SunFire C18, 4.6*50 mm, 3.5 um column Xbridge C18 3.5 μm 4.6×50 mm column. The mobile phase was acetonitrile / 10 mM formic acid aqueous solution) to give the desired product (0.0198 g, 29%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ11.96(s,1H),8.81(d,J=5.3Hz,2H),8.38(bs,1H),8.32(s,1H),8.26(d,J=7.8Hz,2H),8 .05(d,J=5.1Hz,2H),7.42(t,J=7.6Hz,2H),7.20(t,J=7.3Hz,1H),3.83–3.74(m,8H); LCMS(ESI)m / z:358.2[M+H] + .

[0855] Synthesis of 4-(7-(pyridin-2-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (Compound 136):

[0856]

[0857] A mixture of 4-(7-bromo-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (60 mg, 0.16 mmol), 2-(trimethylstannyl)pyridine (48.2 mg, 0.2 mmol) and tetrakistriphenylphosphine palladium (18 mg, 0.016 mmol) in dioxane (5 mL) was stirred at 100° C. for 16 hours under nitrogen protection. The resulting crude product was purified by flash chromatography (petroleum ether / ethyl acetate 20:1→10:1→5:1) to give 4-(7-(pyridin-2-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (4.4 mg, 8%) as a white solid. 1H NMR (400MHz, DMSO-d6) δ12.08(s,1H),8.82(d,J=5.9Hz,2H),8.66(d,J=7.9Hz,1H),8.56(d,J=4.6Hz,1H),8.38(d,J=3.2Hz,1H), 8.04(d,J=6.0Hz,2H),7.87(s,1H),7.27–7.12(m,1H),3.83(d,J=5.1Hz,4H),3.78(d,J=4.8Hz,4H); LCMS(ESI)m / z:358.8[M+H]+

[0858] Synthesis of 4-(4-(pyridin-4-yl)-7-(pyrimidin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (Compound 137):

[0859]

[0860] To a solution of 4-(7-bromo-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (100 mg, 0.28 mmol) in dioxane (10 mL) were added 4-(tributylstannyl)pyrimidine (121 mg, 0.33 mmol), lithium chloride (35 mg, 0.84 mmol) and bis(tri-tert-butylphosphine)palladium (15 mg, 0.028 mmol) at 25 °C, and the resulting mixture was stirred at 110 °C for 3 hours under argon protection. The mixture was then concentrated and the residue was purified by preparative HPLC (SunFire C18, 4.6*50 mm, 3.5 um column Xbridge C18 3.5 μm 4.6×50 mm column. The mobile phase was acetonitrile / 10 mM trifluoroacetic acid aqueous solution) to give 4-(4-(pyridin-4-yl)-7-(pyrimidin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (23 mg, 23.1%) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ9.04(s,1H),8.80(d,J=5.9Hz,2H),8.74(d,J=5.4Hz,1H),8.60(d,J= 5.4Hz, 1H), 8.53 (s, 1H), 8.11 (d, J = 5.6Hz, 2H), 3.84 (d, J = 5.2Hz, 4H), 3.78 (d, J = 4.5Hz, 4H).

[0861] Synthesis of 4-(7-(4-cyclopropylpyrimidin-2-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (Compound 138):

[0862]

[0863] Step 1: Synthesis of 2-chloro-4-cyclopropylpyrimidine.

[0864] Cyclopropylboronic acid (722 mg, 8.4 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (511.7 mg, 0.7 mmol) and potassium carbonate (2.9 g, 21.0 mmol) were added to a solution of 2,4-dichloropyrimidine (1.03 g, 6.92 mmol) in dioxane (15 mL) and water (3 mL) at 25 °C and the mixture was stirred at 90 °C for 2 hours under nitrogen protection. It was then extracted with ethyl acetate (20 mL*2) and washed with water (10 mL*2). The organic layer was dried over sodium sulfate and concentrated. The residue was subjected to silica gel column chromatography (35% ethyl acetate / petroleum ether) to give 2-chloro-4-cyclopropylpyrimidine (900 mg, 83.5%) as a colorless oil. LCMS (ESI) m / z: 154.9 [M+H] + .

[0865] Step 2: Synthesis of 4-cyclopropyl-2-(trimethylstannyl)pyrimidine.

[0866] 1,1,1,2,2,2-hexamethyldistanane (1.31 mg, 4.0 mmol) and bis(triphenylphosphine)palladium(II) chloride (140.2 mg, 0.2 mmol) were added to a solution of 2-chloro-4-cyclopropylpyrimidine (308 mg, 2.0 mmol) in dioxane (10 mL) at 25 °C and the reaction was stirred at 100 °C for 2 hours under nitrogen protection. Aqueous potassium fluoride solution (50 mL) was added to the mixture and filtered. The filtrate was extracted with dichloromethane (30 mL*3) and the organic matter was concentrated to give 4-cyclopropyl-2-(trimethylstannyl)pyrimidine (500 mg, 88.0%) as a yellow oil; LCMS (ESI) m / z: 285.0 [M+H] + .

[0867] Step 3: Synthesis of 4-(7-(4-cyclopropylpyrimidin-2-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine.

[0868] 4-(7-bromo-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (150 mg, 0.4 mmol) was added to a solution of dioxane (10 mL) at 25° C. 4-cyclopropyl-2-(trimethylstannyl)pyrimidine (255 mg, 0.8 mmol) and bis(triphenylphosphine)palladium(II) chloride (52 mg, 0.04 mmol), and the resulting mixture was stirred at 100° C. for 2 hours under nitrogen protection. The mixture was then extracted with dichloromethane (20 mL*2), the organic layers were combined, washed with water (10 mL*2), dried over sodium sulfate, and concentrated. The residue was subjected to preparative HPLC (BOSTON pHlex ODS 10um 21.2×250mm 120A. Mobile phase was DMSO / 0.1% ammonium bicarbonate) to give 4-(7-(4-cyclopropylpyrimidin-2-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (9.0 mg, 5.6%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ12.11(s,1H),8.81(d,J=5.9Hz,2H),8.55(d,J=5.1 Hz,1H),8.36(s,1H),8.29(s,1H),8.01(d,J=6.0Hz,2H),7.19(d,J=5.1Hz,1 H), 3.84 (d, J = 4.9Hz, 4H), 3.75 (d, J = 4.7Hz, 4H), 2.10 (pent, J = 4.2Hz, 1H), 1.24 (d, J = 4.0Hz, 2H), 1.07 (dd, J = 7.8, 3.2Hz, 2H); LCMS (ESI) m / z: 399.9[M] + .

[0869] Synthesis of 4-(7-(6-methoxypyridin-2-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (Compound 139):

[0870]

[0871] To a solution of 4-(7-bromo-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (100 mg, 0.28 mmol) in dioxane / water (10 mL / 1 mL) at 25 °C were added (6-methoxypyridin-2-yl)boronic acid (51 mg, 0.33 mmol), cesium carbonate (273 mg, 0.84 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (23 mg, 0.028 mmol) and the resulting mixture was stirred at 110 °C for 3 hours under argon protection. The mixture was then concentrated and the residue was purified by preparative HPLC (SunFire C18, 4.6*50 mm, 3.5 um column Xbridge C18 3.5 μm 4.6×50 mm column. The mobile phase was acetonitrile / 10 mM trifluoroacetic acid aqueous solution) to give 4-(7-(6-methoxypyridin-2-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (21 mg, 19.5%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ12.04(s,1H),8.83(d,J=5.7Hz,2H),8.34(d,J=3.3Hz,1H),8.23(d,J=7.0Hz,1H),8.04(d,J=5.8Hz,2H), 7.76 (t, J = 8Hz, 1H), 6.62 (d, J = 7.8Hz, 1H), 3.96 (s, 3H), 3.82 (d, J = 5.0Hz, 4H), 3.77 (d, J = 5.0Hz, 4H); LCMS (ESI) m / z: 388.8[M]+.

[0872] The following compounds were synthesized according to the scheme described above:

[0873]

[0874]

[0875]

[0876] Synthesis of 4-(7-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (Compound 146):

[0877]

[0878] Step 1: Synthesis of tert-butyl 7-bromo-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate.

[0879] A mixture of 4-(7-bromo-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (400 mg, 1.1 mmol), di-tert-butyl dicarbonate (285 mg, 1.32 mmol) and N,N-dimethylpyridin-4-amine (14 mg, 0.11 mmol) in tetrahydrofuran (20 mL) was stirred at 15 °C for 2 hours. The resulting precipitate was collected by filtration to give tert-butyl 7-bromo-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (460 mg, 91.1%) as a light yellow solid. LCMS (ESI) m / z: 459.8 / 461.8 [M+H] + .

[0880] Step 2: Synthesis of 5-(tert-butoxycarbonyl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-7-ylboronic acid.

[0881] A mixture of tert-butyl 7-bromo-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (400 mg, 0.84 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (426 mg, 1.68 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (32 mg, 0.04 mmol) and cesium carbonate (546 mg, 1.68 mmol) in dioxane (10 mL) and water (1.5 mL) was stirred at 100° C. for 16 hours under a nitrogen atmosphere. The mixture was poured into water and extracted with ethyl acetate (150 mL*2). The organic phases were combined and concentrated to give 5-(tert-butoxycarbonyl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-7-ylboronic acid (1.8 g, crude) as a brown oil, which was used in the next step without further purification. LCMS (ESI) m / z: 425.9 [M+H] + .

[0882] Step 3: Synthesis of tert-butyl 7-(5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate.

[0883] A mixture of tert-butyl 2-morpholino-4-(pyridin-4-yl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (1.8 g, crude, from the previous step), tert-butyl 3-bromo-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate (100 mg, 0.33 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (27 mg, 0.033 mmol) and cesium carbonate (214 mg, 0.66 mmol) in dioxane (10 mL) and water (2 mL) was stirred at 100° C. for 2 hours under a nitrogen atmosphere. The mixture was poured into water and extracted with ethyl acetate (150 mL*2). The organic phases were combined and concentrated, and the residue was subjected to silica gel column chromatography (10% dichloromethane / methanol) and preparative HPLC (column Xbridge 21.2*250mm C18, 10um, mobile phase A: water (10mmol / L ammonium bicarbonate) B: acetonitrile) to obtain tert-butyl 7-(5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (150 mg, 75%) as a yellow solid. LCMS (ESI) m / z: 603.2 [M+H] + .

[0884] Step 4: Synthesis of 4-(4-(pyridin-4-yl)-7-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine.

[0885] A mixture of tert-butyl 7-(5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (70 mg, 0.11 mmol) and hydrochloric acid (4 M in dioxane, 2 mL) in dichloromethane (10 mL) was stirred at 30° C. for 2 hours. The mixture was neutralized with ammonia (7.0 M in methanol, 20 mL) and concentrated. The residue was subjected to silica gel column chromatography (30% dichloromethane / methanol) to give 4-(4-(pyridin-4-yl)-7-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (30 mg, 67%) as a light yellow solid. LCMS (ESI) m / z: 402.9 [M+H] + .

[0886] Step 5: Synthesis of 4-(7-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine.

[0887] A mixture of 4-(4-(pyridin-4-yl)-7-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (25 mg, 0.062), formaldehyde (40% in water, 2 mL), acetic acid (0.05 mL) and methanol (5 mL) was stirred at 20° C. for 0.5 h, followed by the addition of sodium cyanoborohydride (20 mg, 0.31 mmol). The mixture was stirred at 20° C. for another 0.5 h and concentrated. The residue was subjected to preparative HPLC (column Xbridge 21.2*250mm C18, 10um, mobile phase A: water (10mmol / L ammonium bicarbonate) B: acetonitrile) to give 4-(7-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (17.9 mg, 69.3%) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ8.82(d,J=6.0Hz,2H),8.45(s,1H),8.05(s,1H),7.86(dd,J=4.5,1.4Hz,2H),7.43(d,J=2.8Hz,1H),4.30(t,J =5.5Hz,2H),3.95(s,2H),3.91(t,J=4.0Hz,4H),3.86(t,J=4.0Hz,4H),2.96(t,J=5.5Hz,2H),2.55(s,3H); LCMS(ESI)m / z:416.9[M] + .

[0888] Synthesis of 4-(7-(5-(cyclopropylmethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-3-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (Compound 147):

[0889]

[0890] A mixture of 4-(4-(pyridin-4-yl)-7-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (15 mg, 0.037 mmol), cyclopropanecarboxaldehyde (13 mg, 0.18 mmol), acetic acid (0.05 mL) and methanol (5 mL) was stirred at 20° C. for 30 minutes, followed by the addition of sodium cyanoborohydride (20 mg, 0.31 mmol). The mixture was stirred at 20° C. for another 30 minutes and concentrated. The obtained crude product was subjected to preparative HPLC (column Xbridge 21.2*250mmC18, 10um, mobile phase A: water (10mmol / L ammonium bicarbonate) B: acetonitrile) to give 4-(7-(5-(cyclopropylmethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (12.1 mg, 69.3%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ11.52(s,1H),8.63(d,J=4Hz,2H),7.86(dd,J=6.7,5.2Hz,3H),7.58(d,J=2.5Hz,1H),3.98(t,J=5.2Hz,2H),3.81(s,2H) ,3.58(s,8H),2.83(t,J=5.3Hz,2H),2.31(d,J=6.6Hz,2H),0.77(s,1H),0.34(q,J=5.4Hz,2H),-0.01(d,J=4.3Hz,2H); LCMS(ESI)m / z:456.8[M] + .

[0891] Synthesis of 4-(7-(6-methoxypyridazin-3-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (Compound 148):

[0892]

[0893] Step 1: Synthesis of tert-butyl 7-(6-methoxypyridazin-3-yl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate.

[0894] Tert-butyl (2-morpholino-4-(pyridin-4-yl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (100 mg, 0.28 mmol), 3-bromo-6-methoxypyridazine (31 mg, 0.34 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg, 0.028 mmol) and cesium carbonate (270 mg, 0.84 mmol) were dissolved in dioxane (5 mL) and water. The mixture in (0.5mL) was stirred at 120 ° C for 16 hours under a nitrogen atmosphere. The mixture was extracted with ethyl acetate (50mL×3), and the organic layer was dried and concentrated. The resulting crude product was purified by preparative TLC (petroleum ether: ethyl acetate from 50:1 to 10:1) to give tert-butyl 7-(6-methoxypyridazine-3-yl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (54 mg, 42%) as a yellow solid; LCMS (ESI) m / z: 489.7 [M+H] + .

[0895] Step 2: Synthesis of 4-(7-(6-methoxypyridazin-3-yl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine.

[0896] To a solution of tert-butyl 7-(6-methoxypyridazine-3-yl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (54 mg, 0.11 mmol) in acetonitrile (10 mL) was added hydrochloric acid (3 mol / L in methanol, 5 mL). The mixture was stirred at 25°C for 2 hours and concentrated. The residue was purified by preparative HPLC (SunFire C18, 4.6*50 mm, 3.5 um column Xbridge C18 3.5 μm 4.6×50 mm column. The mobile phase was acetonitrile / 10 mM formic acid aqueous solution) to give the desired product (13.1 mg, 30%) as a yellow solid. 1HNMR(400MHz,DMSO-d6)δ12.21(s,1H),8.83-8.80(m,3H),8.46(s,1H),8.05( d,J=5.7Hz,2H),7.33(d,J=9.1Hz,1H),4.05(s,3H),3.82(s,4H),3.77(s,4H). LCMS(ESI)m / z:389.8[M+H] + .

[0897] Synthesis of 2-(7-(3-(1H-pyrazol-1-yl)phenyl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethan-1-ol (Compound 149):

[0898]

[0899] Step 1: Synthesis of 4-(7-(3-(1H-pyrazol-1-yl)phenyl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine.

[0900] A mixture of 4-(7-bromo-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (100 mg, 0.28 mmol), 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (31 mg, 0.34 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg, 0.028 mmol) and cesium carbonate (270 mg, 0.84 mmol) in dioxane (5 mL) and water (0.5 mL) was stirred at 120° C. under a nitrogen atmosphere for 16 hours. The mixture was extracted with ethyl acetate (50 mL x 3), the organic layers were combined, dried, concentrated, and purified by preparative TLC (50:1 to 5:1 petroleum ether:ethyl acetate) to give 4-(7-(3-(1H-pyrazol-1-yl)phenyl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (94 mg, 72%) as a yellow solid. LCMS (ESI) m / z: 424.8 [M+H]+

[0901] Step 2: Synthesis of 2-(7-(3-(1H-pyrazol-1-yl)phenyl)-2-morpholino-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethan-1-ol.

[0902] To a solution of 4-(7-(3-(1H-pyrazol-1-yl)phenyl)-4-(pyridin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (94 mg, 0.21 mmol) and 2-bromoethanol (0.31 mmol) in dimethyl sulfoxide (10 mL) was added potassium hydroxide (31 mg, 0.63 mmol) at 25°C and the mixture was stirred at 70°C for 16 hours. The reaction was quenched with water and extracted with ethyl acetate (50 mL×3). The organic layer was dried, concentrated and purified by preparative HPLC (SunFire C18, 4.6*50 mm, 3.5 um column Xbridge C18 3.5 μm 4.6×50 mm column. The mobile phase was acetonitrile / 10 mM formic acid aqueous solution) to give the target product (9.2 mg, 10%) as a brown solid. 1H NMR(400MHz, DMSO-d6)δ9.58(s,2H),8.99(d,J=6.4Hz,2H),8.73(s,1H),8.47–8.45(m,2H),8.14(s,1H),7.75(s,1H), 7.41 (d, J = 4.6Hz, 2H), 6.56 (s, 1H), 5.30 (s, 1H), 4.66 (s, 2H), 3.90 (s, 2H), 3.82 (s, 8H); LCMS (ESI) m / z: 467.7[M+H]+.

[0903] Synthesis of 4-(7-(3-(1H-pyrazol-1-yl)phenyl)-4-(pyridazin-3-ylmethoxy)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (Compound 150):

[0904]

[0905] Step 1: Synthesis of tert-butyl 7-bromo-2-morpholino-4-(pyridazin-3-ylmethoxy)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate.

[0906] A solution of (4-(7-bromo-4-(pyridazin-3-ylmethoxy)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine (100 mg, 0.26 mmol), di-tert-butyl dicarbonate (67 mg, 0.31 mmol) and 4-dimethylaminopyridine (10 mg, 0.05 mmol) in tetrahydrofuran (5 mL) was stirred at room temperature for 4 hours under a nitrogen atmosphere. The resulting mixture was extracted with ethyl acetate (50 mL×3), and the organic layers were combined, dried and concentrated. The residue was subjected to preparative TLC (petroleum ether:ethyl acetate from 50:1 to 10:1) to give tert-butyl 7-bromo-2-morpholino-4-(pyridazin-3-ylmethoxy)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (110 mg, 92%) as a yellow oil. LCMS (ESI) m / z: 491.0 [M+H] +

[0907] Step 2: Synthesis of tert-butyl 7-(3-(1H-pyrazol-1-yl)phenyl)-2-morpholino-4-(pyridazin-3-ylmethoxy)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate.

[0908] A mixture of tert-butyl 7-bromo-2-morpholino-4-(pyridazin-3-ylmethoxy)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (100 mg, 0.2 mmol), 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole (66 mg, 0.22 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg, 0.02 mmol) and cesium carbonate (195 mg, 0.6 mmol) in dioxane (5 mL) and water (0.5 mL) was stirred at 100° C. for 16 hours under a nitrogen atmosphere. The mixture was extracted with ethyl acetate (50 mL×3), and the organic phases were combined, dried and concentrated. The residue was purified by preparative TLC (petroleum ether:ethyl acetate 50:1 to 10:1) to give tert-butyl 7-(3-(1H-pyrazol-1-yl)phenyl)-2-morpholino-4-(pyridazin-3-ylmethoxy)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (100 mg, 82%) as a yellow solid. LCMS (ESI) m / z: 555.1 [M+H] +

[0909] Step 3: Synthesis of 4-(7-(3-(1H-pyrazol-1-yl)phenyl)-4-(pyridazin-3-ylmethoxy)-5H-pyrrolo[3,2-d]pyrimidin-2-yl)morpholine.

[0910] To a solution of tert-butyl 7-(3-(1H-pyrazol-1-yl)phenyl)-2-morpholino-4-(pyridazin-3-ylmethoxy)-5H-pyrrolo[3,2-d]pyrimidine-5-carboxylate (100 mg, 0.11 mmol) in acetonitrile (10 mL) was added hydrochloric acid (3 mol / L in methanol, 5 mL). The resulting mixture was stirred at 25°C for 2 hours and concentrated. The residue was subjected to preparative HPLC (SunFireC18, 4.6*50 mm, 3.5um column Xbridge C18 3.5μm 4.6×50 mm column. The mobile phase was acetonitrile / 10 mM formic acid aqueous solution) to give the desired product (40.6 mg, 50%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.22(dd,J=4.9,1.6Hz,1H),8.75(s,1H),8.51(d,J=2.5Hz,1H),8.19(s,1H),8.15(d,J=7.8Hz,1H),7.90(dd,J=8.5,1.6Hz ,1H),7.79–7.74(m,2H),7.61(dd,J=8.0,1.4Hz,1H),7.47(t,J=7.9Hz,1 H),6.59–6.55(m,1H),5.85(s,2H),3.68(s,8H); LCMS(ESI)m / z:454.8[M] + .

[0911] Synthesis of 4-{4-[(oxan-4-yl)methoxy]-7-(pyridin-3-yl)-5H,6H,7H-pyrrolo[2,3-d]pyrimidin-2-yl}morpholine (Compound 151)

[0912] Compound 151 was synthesized according to procedures known to those skilled in the art.

[0913]

[0914]

[0915] Example 2. PIKfyve Inhibitory Activity

[0916] PIKfyve Biochemical Assay. The biochemical PIKFyve inhibition assay was performed by Carna Biosciences according to a proprietary method based on Promega ADP-Glo TMKinase assays were performed. Full-length human PIKFYVE [amino acids 1-2098 (terminal) and S696N, L932S, Q995L, T998S, S1033A and Q1183K of a protein having a sequence set forth in NCBI reference sequence number NP_055855.2] was expressed as an N-terminal GST fusion protein (265 kDa) using a baculovirus expression system. GST-PIKFYVE was purified using glutathione agarose chromatography and used for ADP-Glo TM Kinase assay (Promega). Set up the reaction by adding test compound solution, substrate solution, ATP solution, and kinase solution (each at 4x final concentration). Prepare the reaction with assay buffer (50 mM MOPS, 1 mM DTT, pH 7.2), mix, and incubate for 1 hour at room temperature in a black 384-well polystyrene plate. Then add ADP-Glo TM Reagent, keep for 40 minutes, then add kinase detection reagent, keep for another 40 minutes. Kinase activity is evaluated by detecting relative light units on a luminescent plate reader. Samples are repeated at a concentration of 10 μM to 3 nM. Data are analyzed by setting the control well (+PIKfyve, no compound) to 0% inhibition and setting the readout value of the background (no PIKfyve) to 100% inhibition, and then calculating the inhibition % of each test solution. IC50 values ​​are calculated from the concentration to inhibition % curve by fitting to a four-parameter logistic curve.

[0917] NanoBRET TM TE Intracellular Kinase Assay K-8 (Promega) Cell-based assay. Promega's NanoBRET TM Intracellular inhibition of PIKfyve was determined using the TE Intracellular Kinase Assay K-8. A series of dilutions of the test compounds were added to HEK293 cells for 2 h, which were plated in 96-well plates using the PIKFYVE-containing full-length PIKfyve according to the manufacturer's instructions. The fusion vector (Promega) was transfected for at least 20 hours. TM Kinase activity was detected using a tracer reagent, which was a proprietary PIKfyve inhibitor attached to a fluorescent probe (BRET, bioluminescence resonance energy transfer). Test compounds were tested at concentrations of 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003 μM. An integration time of 0.3 sec / well, a 450BP donor filter and a 600LP acceptor filter were used. The BRET signal was measured using a Discover multi-mode microplate reader (Promega). Active test compounds that bind to PIKfyve and displace the tracer reduce the BRET signal. IC50 values ​​were then calculated by fitting the data to the normalized BRET ratio.

[0918] The results of the PIKfyve inhibition assay are summarized in the table below.

[0919]

[0920]

[0921]

[0922]

[0923]

[0924]

[0925]

[0926] a ++++ represents <10 nM, +++ represents 10-100 nM, ++ represents 100-1000 nM, + represents 1-10 μM, and – represents >10 μM.

[0927] Example 3. Viability assay to assess TDP-43 toxicity in FAB1 TDP-43 and PIKfyve TDP-43 yeast cells.

[0928] Generation of a TDP-43 yeast model expressing human PIKfyve. Human PIKFYVE ("entry clone") was cloned into pAG416GPDccdB ("destination vector") according to the standard Gateway cloning protocol (Invitrogen, Life Technologies). The resulting pAG416GPD-PIKFYVE plasmid was amplified in E. coli and the plasmid identity was confirmed by restriction digestion and Sanger sequencing. The above PIKFYVE plasmid was introduced into the BY4741 yeast strain that is auxotrophic for the ura3 gene and lacks two transcription factors that regulate the xenobiotic efflux pump: the major efflux pump and FAB1, i.e., the yeast orthologs of PIKFYVE (MATa, snq2::KlLeu2; pdr3::Klura3; pdr1::NATMX; fab1::G418 R ,his3;leu2;ura3;met15;LYS2+)( Figure 2). The transformed yeast were plated on solid agar plates with complete synthetic medium lacking uracil (CSM-ura) and containing 2% glucose. Single colonies carrying control or PIKFYVE TDP-43 plasmids were recovered. A plasmid containing wild-type TDP-43 under the transcriptional control of the GAL1 promoter and containing the hygromycin resistance gene as a selectable marker was transformed into fab1::G418 R pAG416GPD-PIKFYVE yeast strain ( Figure 1 ). The transformed yeast were recovered overnight in medium lacking antibiotics and then plated on CSM-ura containing 2% glucose and 200 μg / mL G418. The cytotoxicity and TDP-43 expression levels of multiple independent isolates were also evaluated.

[0929] Viability assay. The toxicity of a control yeast strain ("FAB1 TDP-43", carrying an empty pAG416 plasmid) and a "PIKFYVE TDP-43" yeast strain with a wild-type yeast FAB1 gene and TDP-43 was evaluated using a propidium iodide viability assay. The two yeast strains were transferred from a solid CSM-ura / 2% glucose agar plate to 3 mL of liquid CSM-ura / 2% glucose medium and cultured at 30°C under aeration for 6-8 hours. The yeast culture was then diluted to an optical density at 600 nm (OD 0.005) in 3 mL of CSM-ura / 2% raffinose. 600 ) and grown overnight at 30°C with aeration to an OD of 0.3-0.8 600 Log phase overnight cultures were diluted to an OD of 0.005 in CSM-ura containing 2% raffinose or galactose. 600 And 150 μL is distributed to each well of a flat-bottom 96-well plate. The compound prepared in 100% dimethyl sulfoxide (DMSO) is serially diluted in DMSO and 1.5 μL of the diluted compound is transferred to a 96-well plate using a multichannel pipette. The wells containing only DMSO are also evaluated as controls for the effects of the compounds. The concentrations tested are in the range of 15 μM to 0.11 μM. The cultures are mixed immediately to ensure compound distribution, and the covered plates are incubated at 30 ° C for 24 hours in a fixed humidified incubator.

[0930] After the incubation is complete, propidium iodide (PI) is used to stain dead / dying cells to determine the viability of the culture. A working solution of PI is prepared, wherein for each plate, 1 μL 10mM PI is added to 10mL CSM-ura (raffinose or galactose). The final PI solution (50 μL / well) is dispensed into each well of a new round-bottom 96-well plate. The 96-well assay plate overnight is then mixed with a multichannel pipette and 50 μL is transferred to the plate containing PI. The plate is then incubated at 30°C in the dark for 30 minutes. Red fluorescence (B2 channel), forward scattering and side scattering (using the following settings: gentle mixing, high flow rate, rapid measurement, 10,000 events) are then evaluated using a desktop flow cytometer (Miltenyi MACSquant). The raffinose and galactose cultures treated with DMSO are then used as controls, and "PI-positive" or "PI-negative" gates are performed on the intensity histogram. DMSO controls of cultures containing raffinose or galactose were used to determine the window of increased cell death and this difference was set to 100. All compounds were similarly gated and then compared to this maximum window to determine the percent reduction in PI-positive cells. IC50 values ​​for compounds that exhibited concentration-dependent enhancement of viability were then calculated by fitting logistic regression curves.

[0931] After induction of TDP-43 in both strains, nonviable cells (rightmost population) increased significantly in both FAB1 TDP-43 and PIKFYVE TDP-43, with the effect being more pronounced in PIKFYVE TDP-43 ( Figure 3 and 4 ).

[0932] PIKfyve inhibition suppresses PIKfyve toxicity in the TDP-43 model. The biochemical PIKfyve inhibition assay was performed by Carna Biosciences according to a proprietary method based on Promega ADP-Glo TMKinase assay was performed. Full-length human PIKFYVE [1-2098 (terminal) amino acids and S696N, L932S, Q995L, T998S, S1033A and Q1183K of accession number NP_055855.2] was expressed as an N-terminal GST fusion protein (265kDa) using a baculovirus expression system. GST-PIKFYVE was purified using glutathione agarose chromatography and used in the ADP-GloTM kinase assay (Promega). The reaction was set up by adding a test compound solution, a substrate solution, an ATP solution, and a kinase solution (each at 4x final concentration). The reaction was prepared with an assay buffer (50mM MOPS, 1mM DTT, pH 7.2), mixed, and incubated in a black 384-well polystyrene plate for 1 hour at room temperature. ADP-GloTM reagent was then added and kept for 40 minutes, followed by a kinase detection reagent and kept for another 40 minutes. Kinase activity was evaluated by detecting relative light units on a luminescent plate reader. Samples were tested in duplicate at concentrations of 10 uM to 3 nM. Data were analyzed by setting the control well (+PIKfyve, no compound) to 0% inhibition and setting the readout of the background (no PIKfyve) to 100% inhibition, and then calculating the inhibition % of each test solution. IC50 values ​​were calculated from the concentration to inhibition % curve by fitting to a four-parameter logistic curve.

[0933] APY0201 (a known PIKFYVE inhibitor) in FAB1 TDP-43 ( Figure 5 ) and PIKFYVE TDP-43( Figure 6 ). There was no increase in viable cells in FAB1 TDP-43 over a range of compound concentrations, as evidenced by a reduction in the rightmost propidium iodide-positive cell population (only 0.23 μM is shown). In the PIKFYVE TDP-43 model, 0.23 μM reduced the propidium iodide-positive dead cell population, indicating that PIKFYVE inhibition improves TDP-43 toxicity. Concentrations ranging from 0.5 mM to less than 100 nM provided increased viability.

[0934]

[0935] In the biochemical PIKFYVE assay (ADP-Glo TMA panel of compounds was tested in FAB1 and PIKFYVE TDP-43 yeast models and IC50 (nM) was determined (see table below). The same compounds were also tested in FAB1 and PIKFYVE TDP-43 yeast models. Their activity is reported here as "active" or "inactive". Compounds with low nanomoles / liter potency in biochemical assays are active in the PIKFYVE TDP-43 yeast model. Compounds with lower potency or inactivity in biochemical assays are inactive in the PIKFYVE TDP-43 model. Compounds inactive in biochemical or PIKFYVE TDP-43 assays are plotted together with the highest concentration tested in the assay.

[0936]

[0937] Biochemistry and efficacy assays. A large panel of PIKfyve inhibitors was evaluated in the PIKfyve kinase domain binding assay (nanobret) and in the PIKFYVETDP-43 yeast strain. IC50 values ​​(μM) are plotted. The format of the data points is based on the binding potency (binned potency) from the nanobret assay, as indicated in the legend ( Figure 7 ). Below is Figure 7 Table of compounds and their biochemical and PIKFYVE TDP-43 IC50 values ​​plotted in Figure 2.

[0938]

[0939]

[0940]

[0941]

[0942] Other Implementations

[0943] Various modifications and variations of the described invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in conjunction with specific embodiments, it should be understood that the claimed invention should not be unduly limited to such specific embodiments. In fact, various modifications of the described modes for carrying out the invention that are apparent to those skilled in the art are intended to be within the scope of the invention.

[0944] Other embodiments are within the claims.

Claims

1. A compound of formula (I): or a pharmaceutically acceptable salt thereof, in is a single bond, X 1 (C(R A )2) m or –OC(R A )2–R X , and X 2 C(R A )2 or CO; or is a double bond, and X 1 and X 2 Each of the CR A or N, where R X For X 2 Keys; R 1 for – (L) n –R B ; halogen, cyano, hydrogen, optionally substituted C 1-6 Alkoxy, optionally substituted C 1-9 heterocyclyl, optionally substituted C1-C6 alkyl, optionally substituted piperazin-1-yl, optionally substituted pyrrolidin-3-yl, pyrimidinyl optionally substituted by cyclopropyl, or optionally substituted C6-C 10 aryl, optionally substituted pyridazinyl, optionally substituted oxazolyl, pyridin-2-on-1-yl, optionally substituted isoindolinyl, unsubstituted pyridin-4-yl, unsubstituted pyridin-2-yl, optionally substituted furan-3-yl, unsubstituted pyridin-3-yl or optionally substituted pyrazol-1-yl; R 2 is an optionally substituted C1-C6 alkyl, an optionally substituted C 6- C 10 aryl, optionally substituted piperidin-4-yl, optionally substituted tetrahydropyran-4-yl, optionally substituted pyrimidin-5-yl, optionally substituted pyrimidin-4-yl, optionally substituted pyridin-3-yl, optionally substituted pyridazin-4-yl, optionally substituted pyrazol-1-yl, optionally substituted pyrazol-4-yl, optionally substituted pyrazol-3-yl, optionally substituted pyridin-2-yl, optionally substituted triazolyl, optionally substituted benzodioxol-2-yl, optionally substituted benzodioxol-2-yl, optionally substituted C6-C 10 Aryl C1-C 10 alkyl or optionally substituted acyl; R 3 A group of the following structure: Each R A are independently H, optionally substituted C 1-6 Alkyl or optionally substituted C 6- C 10 Aryl, or two R A Together with the atoms to which they are attached, they form an oxo group; A When combined with the atoms to which they are attached to form an oxo group, is a single bond; R B is an optionally substituted C 6-10 aryl, optionally substituted C1-C9 heteroaryl, optionally substituted C 3-8 Cycloalkyl, -N=CH-R D , or optionally substituted C1-C9 heterocyclyl, optionally substituted C2-C9 heteroarylC1-C6 alkyl, optionally substituted C2-C9 heterocyclylC1-C6 alkyl; R C is H or optionally substituted C 1- C6 alkyl; R D is an optionally substituted C 6- C 10 aryl; or Each L is independently an optionally substituted C 1-6 alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C3-C8 cycloalkylene, optionally substituted C2-C6 alkynylene, O or NR C ; n is 1, 2 or 3; and m is 0, 1 or 2.

2. The compound of claim 1, wherein For a single key.

3. The compound according to claim 1 or 2, wherein X 1 (C(R A )2) m .

4. The compound of claim 3, wherein m is 1.

5. The compound according to any one of claims 1 to 4, wherein X 2 C(R A )2.

6. The compound of any one of claims 1 to 5, wherein each R A For hydrogen.

7. The compound of claim 1, wherein the compound is of formula (1a): or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, wherein the compound is of formula (1a'): or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, wherein the compound is of formula (1b): or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, wherein the compound is of formula (1c): or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, wherein the compound is of formula (1d): or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, wherein the compound is of formula (1e): or a pharmaceutically acceptable salt thereof.

13. The compound of any one of claims 1 to 12, wherein R 1 for –O–(L) (n-1) –R B .

14. The compound of any one of claims 1 to 13, wherein n is 2.

15. The compound of any one of claims 1 to 13, wherein n is 1.

16. The compound of any one of claims 1 to 15, wherein at least one L is an optionally substituted C 1-6 Alkylene.

17. The compound of claim 16, wherein L is methylene.

18. The compound of claim 16, wherein L is ethylene.

19. The compound of any one of claims 1 to 18, wherein R B is an optionally substituted C 1-9 Heterocyclic group.

20. The compound of any one of claims 1 to 18, wherein R B is an optionally substituted C 1-9 Heteroaryl.

21. The compound of any one of claims 1 to 18, wherein R B is an optionally substituted C 1-6 alkyl.

22. The compound of any one of claims 1 to 21, wherein R A is an optionally substituted C 1-6 alkyl.

23. The compound of claim 22, wherein R A It is methyl.

24. The compound of any one of claims 1 to 21, wherein R 1 is an optionally substituted C1-C6 alkyl group.

25. The compound of claim 24, wherein R 1 is an optionally substituted C4 alkyl group.

26. The compound of claim 24 or 25, wherein R 1 Replaced by hydroxyl groups.

27. The compound of any one of claims 1 to 21, wherein R 1 is an optionally substituted piperazin-1-yl group.

28. The compound of claim 27, wherein R 1 Replaced by methyl.

29. The compound of any one of claims 1 to 28, wherein R 2 is an optionally substituted C6-C 10 Aryl C1-C6 alkyl.

30. The compound of claim 29, wherein R 2 is an optionally substituted C6-C 10 Aryl C1-C2 alkyl.

31. The compound of claim 29 or 30, wherein R 2 Replaced by oxygen.

32. The compound of any one of claims 1 to 28, wherein R 2 is an optionally substituted C1-C6 alkyl group.

33. The compound of claim 32, wherein R 2 is an optionally substituted C4 alkyl group.

34. The compound of claim 32 or 33, wherein R 2 Replaced by hydroxyl groups.

35. The compound of any one of claims 1 to 28, wherein R 2 is an optionally substituted C6-C 10 Aryl.

36. The compound of claim 35, wherein R 2 is an optionally substituted phenyl group.

37. The compound of claim 35 or 36, wherein R 2 Substituted by fluorine, cyano or methoxy.

38. A compound as described in any one of claims 1 to 12 or 29 to 37, wherein R 1 for: Methyl or methoxy.

39. The compound of claim 38, wherein R 1 for or methoxy.

40. The compound of any one of claims 1 to 28 or 38, wherein R 2 for:

41. The compound of claim 40, wherein R 2 for:

42. The compound of any one of claims 1 to 41, wherein R 3 for:

43. The compound of claim 1, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof, Where R 2 is optionally substituted pyrimidin-3-yl or optionally substituted pyrimidin-4-yl; and R 4 is hydrogen or optionally substituted C 6- C 10 Aryl.

44. The compound of claim 43, wherein R 4 For hydrogen.

45. The compound of claim 44, wherein R 4 is an optionally substituted C6-C 10 Aryl.

46. ​​The compound of claim 45, wherein R 4 It is phenyl.

47. The compound of claim 45 or 46, wherein R 4 Replaced by fluorine.

48. The compound of claim 45 or 46, wherein R 4 Replaced by methoxy.

49. The compound of any one of claims 43 to 48, wherein R 2 is optionally substituted pyridin-3-yl.

50. The compound of any one of claims 43 to 48, wherein R 2 It is pyridin-4-yl.

51. The compound of claim 1 or 29, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof, Where R 5 is hydrogen or optionally substituted C 6- C 10 aryl; and R 2 is optionally substituted triazolyl, optionally substituted pyrazol-4-yl, optionally substituted pyrazol-3-yl, optionally substituted pyrimidin-4-yl or optionally substituted C6-C 10 Aryl C1-C6 alkyl.

52. The compound of claim 51, wherein R 5 For hydrogen.

53. The compound of claim 51, wherein R 5 It is phenyl.

54. The compound of any one of claims 51 to 53, wherein R 2 Substituted with phenyl.

55. The compound of any one of claims 51 to 54, wherein R 2 for 56. The compound of claim 51, wherein R 2 for 57. The compound of claim 1, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof, Where R 2 is optionally substituted pyridin-3-yl.

58. The compound of claim 1, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof, Where R 2 is an optionally substituted C6-C 10 aryl; or optionally substituted pyridazin-4-yl.

59. The compound of claim 58, wherein R 2 is 3-fluoro-phenyl.

60. The compound of claim 58, wherein R 2 It is pyridazin-4-yl.

61. The compound of claim 1, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof, Where R 2 is optionally substituted pyridin-3-yl.

62. The compound of claim 1, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof, wherein L is an optionally substituted C3-C8 cycloalkylene or C2-C6 alkynylene; and R B is an optionally substituted C 6- C 10 Aryl.

63. The compound of claim 62, wherein L is 64. The compound of claim 63, wherein L is 65. The compound of any one of claims 62 to 64, wherein R B is 3-methoxy-phenyl.

66. The compound of claim 1, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof, Among them LR B -NHN=CHR D ; R 2 is optionally substituted pyridin-3-yl; and R D is an optionally substituted C 6- C 10 Aryl.

67. The compound of claim 66, wherein R D It is 3-methyl-phenyl.

68. The compound of claim 66 or 67, wherein R 2 It is pyridin-3-yl.

69. The compound of any one of claims 66 to 68, wherein the compound has the structure or a pharmaceutically acceptable salt thereof.

70. The compound of claim 1, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof, Where R 2 is optionally substituted pyridin-3-yl; and R 6 is an optionally substituted C 6- C 10 Aryl.

71. The compound of claim 70, wherein R 6 is 3-methyl-phenyl or phenyl.

72. A compound or a pharmaceutically acceptable salt thereof having the structure: or a pharmaceutically acceptable salt thereof, Where X 2 N or CH; R A is an optionally substituted C2-C9 heteroaryl; or an optionally substituted C6-C 10 Aryl; R 1 is an optionally substituted C2-C9 heteroaryl or -OR 7 ; R 2 is hydrogen or optionally substituted C1-C6 alkyl; and R 7 It is an optionally substituted C2-C9 heteroarylC1-C6 alkyl.

73. The compound of claim 72, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof.

74. The compound of claim 72 or 73, wherein R 2 It is 2-hydroxy-ethyl.

75. The compound of claim 72 or 73, wherein R 2 For hydrogen.

76. The compound of claim 72, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof.

77. The compound of claim 72, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof.

78. The compound of any one of claims 72 to 77, wherein R A is an optionally substituted phenyl group.

79. The compound of any one of claims 72 to 77, wherein R A is optionally substituted pyridin-2-yl, optionally substituted pyrimidin-4-yl, optionally substituted pyrimidin-2-yl, optionally substituted pyrazol-4-yl, optionally substituted pyridin-3-yl, optionally substituted pyrazol-4-yl, optionally substituted 7-aza-5,6,7,8-tetrahydroindolizin-1-yl, optionally substituted pyridazin-3-yl or optionally substituted pyridin-4-yl.

80. The compound of any one of claims 72 to 77, wherein R A is an optionally substituted C2-C9 heteroaryl group or a C6-C9 heteroaryl group substituted by an optionally substituted C2-C9 heteroaryl group 10 Aryl.

81. The compound of any one of claims 72 to 80, wherein R A Cyclopropyl, methyl, methoxy or replaced.

82. The compound of claim 80, wherein R A It is phenyl substituted by pyrazol-1-yl.

83. The compound of any one of claims 72 to 77, wherein R A for 84. The compound of any one of claims 72 to 83, wherein R 1 is pyridin-3-yl, pyridin-4-yl or 85. The compound of claim 76, wherein the compound has the structure or a pharmaceutically acceptable salt thereof.

86. The compound of claim 77, wherein the compound has the structure: or a pharmaceutically acceptable salt thereof.

87. A compound of the following structure: or a pharmaceutically acceptable salt thereof.

88. A compound of the following structure: or a pharmaceutically acceptable salt thereof.

89. A pharmaceutical composition comprising a compound according to any one of claims 1 to 88 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

90. A method of treating a neurological disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of any one of claims 1 to 88 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 89.

91. The method of claim 90, wherein the neurological disorder is FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.

92. The method of claim 91, wherein the neurological disorder is ALS.

93. A method of inhibiting protein-associated toxicity in a cell, the method comprising contacting the cell with a compound of any one of claims 1 to 88, or a pharmaceutically acceptable salt thereof.

94. The method of claim 93, wherein the toxicity is TDP-43-related toxicity.

95. The method of claim 93, wherein the toxicity is C9orf72-related toxicity.

96. A method of inhibiting PIKfyve in a cell expressing a PIKfyve protein, the method comprising contacting the cell with a compound of any one of claims 1 to 88, or a pharmaceutically acceptable salt thereof.

97. The method of any one of claims 93 to 96, wherein the cell is a mammalian neural cell.

98. The method of any one of claims 93 to 97, wherein the cell is in a subject.

99. The method of claim 98, wherein the subject suffers from a neurological disorder.

100. A method of treating a TDP-43-related disorder in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (14): or a pharmaceutically acceptable salt thereof, in is a single bond, X 1 (C(R A )2) m or –OC(R A )2–R X , and X 2 C(R A )2 or CO; or is a double bond, and X 1 and X 2 Each of the CR A or N, where R X For X 2 Keys; R 1 for – (L) n –R B , hydrogen, halogen, cyano, optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Heteroalkyl, optionally substituted C 1-6 Alkoxy, optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heterocyclic or optionally substituted C 1-9 heteroaryl; R 2 is hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heterocyclic group, optionally substituted C 1-9 heteroaryl or optionally substituted C6-C 10 Aryl C1-C6 alkyl; R 3 A group of the following structure: Each R A are independently H, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl, or two twin R A The groups, together with the atoms to which they are attached, combine to form an oxo group; R B is an optionally substituted C 6-10 Aryl, optionally substituted C 1-9 Heteroaryl, optionally substituted C 3-8 Cycloalkyl, -N=CH-R D or optionally substituted C 1-9 Heterocyclyl, optionally substituted C2-C9 heteroarylC1-C6 alkyl, optionally substituted C2-C9 heterocyclylC1-C6 alkyl; R C is H or optionally substituted C 1- C6 alkyl; R D is an optionally substituted C 6- C 10 Aryl; Each L is independently optionally substituted alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C3-C8 cycloalkylene, optionally substituted C2-C6 alkynylene, O or NR C ;and n is 1, 2 or 3; and m is 0, 1 or 2.